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Abstract
This thesis examines the effects of ageing on the use and on
the behavioural impact of hypnotic drugs. Within this context,
experiments reported here further examined the proposition that
elimination half-life reliably predicts the occurrence and the
magnitude of daytime behavioural impairment in older individuals
following the repeated use of hypnotic drugs.
Evidence considered in Chapters 1 and 2 indicates that, while
age is recognized as an influential subject variable in the drug-
performance relationship, it has received little experimental
attention.
Experiment 1 (Chapters 2, 3 and 4) evaluates the effects of
repeated doses of two short acting hypnotics, triazolam 0.5mg and
lormetazepam l.Omg, and placebo both within, and between sub¬
groups of, middle-aged subjects.
Chapter 5 examines the clinical and experimental evidence
which indicates that the elderly (65y+) are more susceptible to
the behavioural side-effects of hypnotic drugs. The epidemio¬
logical literature reviewed in Chapter 6 shows that the elderly
are more likely to be prescribed and to use sedative-hypnotic
drugs relative to younger age groups.
Two surveys of hypnotic drug usage in residential homes for
the elderly, conducted six months apart, are reported in Chapter
7. The drugs and dosages used, and the age, sex, and health
status of users are examined. Prospective trends in hypnotic drug
prescribing and usage are also considered.
Experiment 2 (Chapter 8) tests the hypothesis that repeated
doses of nitrazepam, when used in low (5mg) doses, effectively
reduces the probability of daytime performance deficits occurring
in the elderly. Experiment 3 (Chapter 9) compares the effects of
repeated doses of nitrazepam 5mg and lormetazepam l.Omg in elderly
subjects. An experimental methodology for assessing the pharmaco¬
logical effects of hypnotic drugs in the elderly is presented.
The results and conclusions are summarized in Chapter 10.
Overall, the experimental findings indicate that: 1) in
combination, drug elimination half-life and the continuity of
drug usage are reliable predictors of daytime behavioural
disruption in older age groups; and 2) age related changes
increase an individuals vulnerability to such effects. These
results are considered in relation to the data from Surveys 1
and 2, and some of the implications are discussed.
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Chapter 1
Introduction
Hypnotics, while being among the most widely prescribed of all
drugs (Skegg et al. 1977), are clinically distinct in at least
one other important respect. Unlike most other commonly used
pharmacological substances, hypnotics are required to act only
for a strictly limited period within the 24h cycle.
Pharmacological activity which continues to influence behaviour
after this period may be considered as a Type A adverse reaction
according to the logical schema proposed by Rawlins and Thompson
(1977), i.e. a reaction which results from "qualitatively normal,
but quantitatively abnormal" pharmacological effects (Rawlins,
1981). Thus, just as sleep cannot be considered apart from
wakefulness (a point recently re-emphasized by Dement et al.
1982), so too the actions of hypnotic drugs cannot be considered
apart from their implications for daytime behaviour. It is now
widely recognized, in both the United Kingdom (Committee on the
Review of Medicines, 1980) and the United States (Solomon, 1979:
Institute of Medicine Report), that studies of the behavioural
consequences of hypnotic drug usage should augment the more
traditional clinical attention paid to the efficacy, toxicity,
abuse potential, and withdrawal of these products.
The task of detecting and evaluating the daytime
consequences of hypnotic drug usage can be approached from
several different directions. Controlled clinical observations
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of overt CNS depression (e.g. Greenblatt et al. 1977) or an
individual's own ratings of daytime drowsiness (see Oswald, 1980)
have been successfully employed where sedation is apparent to the
clinician, or to the subject, or to both. However, from the
earliest laboratory studies of the residual effects of hypnotics
(e.g. Walters and Lader, 1971; Bond and Lader, 1972) it is clear
that impaired efficiency can be objectively measured in subjects
who do not rate themselves as sedated, and \«ho are not overtly
drowsy. The objective assessment of performance [performance is
defined here as the goal-directed organization of cognitive and
motor activities; after Fitts and Posner, 1973], frequently
combined with subjective appraisals of mood and feelings, has now
become established as the method of choice for evaluating residual
sequelae to hypnotic drugs. Such experiments have the potential,
not only to indicate the probability of residual side effects
occurring following a given hypnotic, but also to specify those
skills and aspects of performance most likely to be affected.
Unfortunately, while there now exists a considerable literature
concerning both the acute and the residual effects of sedative-
hypnotic drugs on human performance (for reviews see McNair, 1973;
Bixler et al. 1975; Kleinknecht and Donaldson, 1975; Wittenborn,
1979; Hindmarch, 1981; Johnson and Chernik, 1982), in many
experiments this potential is far from fully realised.
Successive reviews have pointed out that much of the
available experimental data concerning sedative-hypnotic drugs and
human performance lack both generality and direct clinical
relevance. McNair (1973), for example, reviewing over 100
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studies which had investigated the effects of anti-anxiety drugs
on performance observed that: "Almost two decades of laissez-faire
research in the area have yielded no adequate, systematic data
base for meaningful inferences. About all one can safely and
tritely conclude is that all these drugs affect performance under
some conditions... In view of the widespread use of these drugs
and the evidence that impairment and facilitation of performance
are often associated with their use, it should be rather startling
that we have so little directly relevant clinical information".
A feature of many psychopharmacological studies which
particularly limits the generality of data reported (and thus
diminishes their clinical relevance) is the unrepresentativeness
of subjects. Relatively few studies have employed subjects who
typify, in characteristics of age, sex, or health status, the
target populations of sedative-hypnotic drugs. McNair (1973), for
example, reports that subjects were predominantly healthy male
college students; only 12% of all drug-placebo comparisons
examined in this review included patient groups. Similarly, in a
review of the effects of diazepam on human performance Kleinknecht
and Donaldson (1975) found that 79% of all subjects were young
healthy males. More recently, Johnson and Chernik (1982) , in a
detailed review of the effects of sedative-hypnotic drugs on
daytime skills have commented: "We note that there are still
little data as to the effects of age, sex differences and, as
decried in previous reviews, there are far too few performance
studies using the medications on the population for which they are
intended".
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The relevant literature, then, reflects an overall lack of
experimental interest in subject-variables which may significantly
influence the drug-performance relationship. With particular
reference to age, this is a serious omission. A growing body of
evidence indicates that metabolic, pharmacokinetic, and
pharmacodynamic processes can be greatly affected by
physiological changes associated with ageing (James, 1978; Crooks
and Stevenson, 1979; Vestal, 1982). With increasing age the
response to a given drug may become more profound (Crooks and
Stevenson, 1981), and the occurrence of major side effects more
frequent (Hurwitz, 1969; Hurwitz and Wade, 1969) . Surveys of
hospital inpatients, for example, have shown that the frequency of
"clinically significant" daytime drowsiness associated with the
use of flurazepam (Greenblatt et al. 1977) and nitrazepam
(Greenblatt and Allen, 1978) consistently increases with age.
Thus, information concerning the daytime behavioural consequences
of hypnotic drug usage derived largely frcm healthy young
individuals does not necessarily generalize to older age groups.
Clearly, the need exists for detailed, systematic investigations
which both acknowledge, and elucidate, the influence of ageing on
post- hypnotic behavioural impairments. This need is further
emphasized when the prevalence of dissatisfaction with sleep and
the consequent use of sedative-hypnotic drugs are also considered
in relation to age.
Subjectively estimated sleep quality shows a decline with
increasing age (McGhie and Russel, 1962; Kales et al. 1974;
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Karacan et al. 1976). Electroencephalographic sleep variables
also show age-related trends consonant with these subjective
estimates. Total sleep time, and the duration of stages 4 (slow
wave sleep) and REM (rapid eye movannent) decrease with advancing
age, while arousals intervening during sleep become more frequent
(Williams et al. 1974; Feinberg, 1976). Thus, sleep beccmes
progressively less "deep" and more broken. It would also appear
that the duration of each intra-sleep arousal tends to be longer
in older individuals (Brezinova, 1975) . Certainly, estimates of
sleep efficiency (as measured by the sleep efficiency index of
Total Sleep Time/Total Time in Bed) show a rapid decline between
the ages 50y and 79y (e.g. 0.925 for the age group 50-59y, and
0.795 for the age group 70-79y; after Williams et al. 1974).
These age-related changes in both subjectively assessed and
objectively measured sleep have been shown to be correlated with
an increase in the use of sedative-hypnotic medications. For
example, in a survey of 1654 individuals randomly sampled from an
urban comriunity in Florida, USA, Karacan et al. (1976) found that
the prevalence of hypnotic drug usage, on at least an occasional
basis, increased rapidly during early (40-49y) and late (50-59y)
middle age, and continued to increase across the age groups 60-69y
and 70y+.
Increasing age, therefore, is associated not only with an
increased susceptibility to drug side effects, but also with an
increased likelihood of receiving certain drugs vAiich produce
such reactions. In combination, these clinical and epidemio¬
logical findings stress the need for psychopharmacological studies
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which recognize age as important, and influential, characteristic
of subjects.
The characteristics of experimental subjects are not the only
neglected aspects of research concerned with hypnotic drugs and
daytime performance. The psychological characteristics of the
performance deficit itself have also received scant attention.
Broadly, many studies have been concerned only with reporting the
presence or absence of residual sequelae to hypnotic drugs. Tests
employed for such evaluations tend to be selected, not on the
basis of psychological merit or relevance, but are selected rather
on the basis of demonstrated or presumed sensitivity to drug
effects. Thus, results are frequently reported from test
procedures which are not predictive of clinically or
psychologically relevant behavioural changes which may follow the
use of some hypnotics. Hindmarch (1981), for example, lists over
50 different test procedures which have been used to assess the
effects of psychoactive drugs on performance, and has recently
concluded that many of these tasks cannot be regarded as "serious
attempts at measuring sedation" (Hindmarch, 1982). Statistical
analyses, too, infrequently proceed beyond the point at which post-
drug behavioural change is established. This approach to the
evaluation of residual drug effects has, as McNair (1973) has
pointed out, produced an excess of non-cumulative, atheoretical
research. Consequently, and despite the sheer volume of reported
studies concerned with the residual effects of hypnotics, there
exists no comprehensive model which attempts to explain how these
drugs may disrupt the organization of human performance. Such a
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model can be constructed only from evaluative studies which
progress beyond the simple goal of establishing that a given drug,
at a given dose, does or does not impair performance on a given
task. In both the design and the analysis of the experiments
described in this thesis, the need for detailed information on the
characteristics of post-drug behavioural change has been
recognized.
Organization of Thesis
In the following chapters the residual effects of sedative
hypnotics on performance, and the therapeutic usage of these
drugs, are considered in relation to age. The intention
throughout has been to identify, and respond to, areas of the
drug-performance literature vhere clinically relevant information
is particularly lacking. The organization of this thesis reflects
these intentions. Several aspects of hypnotic drug use, each
pertinent to the issue of daytime behavioural impairment, are
individually reviewed and analyzed. Appropriate experimental or
epidemiological studies have then been undertaken with the
specific aim of testing hypotheses and clarifying assumptions
which have direct clinical relevance.
Before presenting the outline of this thesis, brief
consideration will be given terminology.
The terms "hypnotic" and "sedative-hypnotic" are used
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interchangeably throughout. Where necessary (e.g. Chapter 7),
"hypnotic" is operationally defined.
Similarly, the terms "psychotropic", "psychoactive",
"behaviourally active", and "psychotherapeutic" (as used in the
literature) are treated as synonymous, and refer generically to
drugs used to modify mood and behaviour. Hypnotics are subsumed
within these categories.
For simplicity, age groups are frequently referred to
nominally, rather than numerically. The following classification
has been arbitrarily adopted: early middle-age = 40-49y; late
middle-age = 50-64y; and "elderly" refers to those aged 65y or
more. Numerical categories are used viien the age group
"elderly" is further sub-divided (e.g. Chapter 7).
Outline of Thesis
Chapter 2 introduces the first experimental study.
Information concerning the pharmacology, efficacy, clinical use,
and behavioural side effects of two benzodiazepine hypnotics
(loprazolam and triazolam) is reviewed, and the age factor is
considered. The rationale, design, and execution of the study is
then described.
Chapter 3 describes and discusses the effects of loprazolam
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and triazolam on the daytime performance efficiency of early and
late middle-aged individuals. Characteristics of performance,
and of performance-change in the two groups are compared.
Chapter 4 examines the effects of loprazolam and triazolam on
subjectively rated mood and daytime feelings, and presents the
conclusion to, and implications of, Experiment 1.
Chapter 5 reviews the clinical and experimental data
concerning the daytime behavioural consequences of hypnotic drug
use in the elderly. Theoretical and practical issues relevant to
the cause, and the measurement, of impaired performance in this
age group are also considered.
Chapter 6 critically reviews the epidemiological literature
concerning hypnotic drug use, and specifically examines the
prevalence of hypnotic drug prescribing for the elderly since
the early 1960s.
Chapter 7 describes the design and execution of two surveys
of hypnotic drug usage in a large elderly population. The
information thus provided complements that reviewed in the
previous chapter.
Chapter 8 combines information from Chapters 5 and 7 in the
design of Experiment 2, which investigates the effects of low-dose
nitrazepam on performance in the elderly. This experiment is
presented as a pilot study.
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Chapter 9 describes Experiment 3, which investigates the
effects of nitrazepan and lormetazepam on performance in the
elderly. The experimental rationale and testing procedures are
derived from both the previous experiment, and from Experiment 1.
Chapter 10 concludes the thesis and considers the clinical,




Experiment 1: A comparison of the effects of two benzodiazepine
hypnotics, triazolam and loprazolam, on the daytime performance
of middle-aged subjects. Background and Methodology.
Experimental studies indicate that elimination half-life may be a
useful predictor of both the occurrence, and the magnitude, of
residual sequelae to hypnotic drugs. Nicholson (1981) notes that
performance deficits are much less likely to be associated with
hypnotics in which the individual elimination half-life does not
exceed 24h. Conversely, single clinically-recommended doses of
longer acting compounds like nitrazepam and flurazepam have been
shown to impair the performance of young volunteers up to 12h
after ingestion (Bond and Lader, 1972; Bond and Lader, 1973).
While, on experimental grounds, short half-life hypnotics may
appear to be devoid of, or associated with lesser residual
effects, than seme longer acting drugs, the clinical relevance of
this conclusion may be limited. A growing literature indicates
that both physiological (see Hicks et al. 1981) and behavioural
(see Swift, 1982) responses to hypnotic drugs change with
advancing age. However, as pointed out in the previous chapter,
knowledge of the residual effects of these drugs is derived
largely frcm experiments using young volunteers. Johnson and
Chernik (1982), in a review of 52 studies concerned with sedative
hypnotics and human performance, found that the bulk of
experiments employed subjects aged 18-40y. In contrast, a recent
survey of psychotropic drug usage in London (Murray et al. 1981)
found that 83% of all hypnotic users were aged 44y or more.
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Clearly, the age-range of subject volunteers emerges as an
important factor in determining the immediate clinical relevance
of experiments measuring the effects of hypnotics on daytime
performance.
Impaired performance may arise not only from persistent sedation
following single doses of hypnotic drugs, but may also arise from
accumulation, either of the drug itself, or of its active
metabolites, with repeated doses. Such effects are more likely to
be observed under multiple dose experimental conditions which
closely simulate the pattern of drug usage encountered in clinical
practice. Borland and Nicholson (1975) , for example, report that
performance impaired lOh after a single (30mg) dose of flurazepam
gradually returned to placebo baseline levels by the 19th post-
ingestion hour. However, in 10 day (Church and Johnson, 1979) and
16 day (Oswald et al. 1979) periods of repeated daily doses,
flurazepam (30mg) has been reported to show a build-up effect,
progressively increasing decrements on some tasks. Further,
Oswald et al. (1979) report that after three weeks of flurazepam
ingestion, significant performance decrements persisted throughout
morning, midday, and evening testing sessions. This sustained
performance decrement was attributed, in part, to the use of older
age-group subjects (mean age = 53y). However, no specific
treatment by age interaction analysis was reported.
Multiple dose trials which include periodic besting sessions
throughout the day can, then, produce a more realistic profile of a
drugs residual influence on behaviour. With particular regard to
the timing of test sessions, it is also relevant to note that
residual drug effects occur against a background of circadian
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variations in the efficiency of human performance. The possibility
that drug effects interact with, and may exacerbate, normally
occurring troughs in both cognitive (Baddeley et al. 1970) and
psychomotor (Colquhoun, 1971) performance efficiency has received
little experimental attention. Thus, post-drug testing schedules
which include morning, early afternoon, ard evening periods can
provide information on the time-course of drug effects in relation
to known circadian variations in performance. The present
experiment is concerned with the effects of two relatively short
half-life hypnotics, triazolam, ard loprazolam, on daytime
performance. The experimental design, subjects, and testing
schedule were all selected to optimise both the clinical and
psychological relevance of test results.
Triazolam, a benzodiazepine derivative with an elimination half-
life estimated to be within the range 2-4h (see Cook, 1980) has been
shown to be an effective hypnotic in clinical trials with normal
(Wang and Stockdale, 1973) and insomniac (Vogel et al. 1975)
volunteers. Over a 28 day period, Reeves (1977) reports continuing
hypnotic efficacy for triazolam 0.25mg nightly as subjectively
rated by geriatric outpatients (mean age = 68.6y). Experimental
studies concerned with the residual effects of single doses of
triazolam on daytime performance report equivocal results. In a
group of male volunteers aged 21-40y Veldkamp et al. (1974) report
that triazolam 0.5 and 1.0mg impaired performance 10h, but not 13h
and 16h after ingestion on tests of digit symbol substitution,
card-sorting, ard occular convergence. Roth et al. (1977), on the
other hand, report that performance 10h after triazolam 0.25 and
- 13 -
0.5mg did not differ significantly from that 10h after placebo on
a test battery which included the digit symbol substitution, and
card-sorting tasks. Roth et al.'s (1977) experimental group also
comprised male adults (n = 12), with ages ranging from 25-35y. In
this latter experiment, however, subjects were awakened at 2 a.m.
to complete the full test battery (pursuit rotor, Purdue pegboard,
continuous arithmetic, digit symbol substitution, and card-
sorting) , and also to rate their mood on visual analogue scales.
As the test battery alone is reported to have taken at least lhr
15min to complete, then it is likely that placebo scores recorded
10h after ingestion (at 08.30) were confounded with the effects of
grossly disturbed sleep, and do not reflect accurate baseline
performance levels. Thking this consideration into account, it
cannot be concluded from Roth et al.'s (1977) data that low dose
triazolam does not impair early morning performance.
The effects of repeated doses of triazolam on the performance
of older subjects has not been experimentally evaluated. Clinical
observations, however, have suggested that chronic use of triazolam
in doses of 0.5mg or more can produce a variety of behavioural
dysfunctions, including sleep disturbance, acute and chronic
anxiety, and paranoid symptoms (van der Kroef, 1979). The
mergence of these symptoms, which are reported to subside on
withdrawal of the drug, may reflect cumulative drug effects.
Loprazolam (HR 158, Roussel) is a 1-4 benzodiazepine derivative
having a mean elimination half-life of 15h (Jochemsen, 1982). In
doses of l-2mg loprazolam has been shown to be an effective
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hypnotic in single dose EEG laboratory studies (Oswald et al.
1977), and in repeated dose clinical trials (Petite, 1978).
Hindmarch and Clyde (1980) report that two and four consecutive
nightly doses of loprazolam (as HR 158) 0.5mg, 1.0rag, and 2.0mg
produced no significant residual impairment the following morning
on measures of critical flicker fusion, letter cancellation, short
term msnory, and choice reaction time in 10 healthy young
volunteers (mean age = 21.8y). CP visual analogue scales,
however, these subjects did rate their general performance as
impaired following loprazolam 0.5 and 1.0mg, but not following
loprazolam 2.0mg. This apparently paradoxical response to the
2.0mg dose is explained by Hindmarch and Clyde (1980) in terms of
particularly low placebo baseline scores achieved by subjects in
the 2.0mg condition. As with triazolam, loprazolam has not been
assessed in multiple dose performance studies using subjects of a
clinically representative age group.
A common, and relevant, feature of all the tests cited above
showing no residual effects for triazolam and loprazolam is their
relatively short duration, most taking less than 10 minutes to
complete. Several researchers (Hart et al. 1976; Oswald, 1978;
Hinchiarch, 1981) have anphasised the advantages of using
protracted, low interest tasks to detect residual hypnotic drug
effects on behaviour. Hindmarch and Clyde (1980), for example,
report a non-significant tendency for loprazolam 2.0mg to increase
response latencies in serial subtraction, and attribute this to
the low-interest, habitual nature of this task. Insofar as they
affect arousal, similarities have been suggested between the
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effects of sleep deprivation, and the effects of hypnotic drugs
(Hart et al. 1976). According to this rationale, impaired
performance following hypnotics may become apparent only after
considerable time-on-task, as Wilkinson (1965; 1968) has shown to
be the case following sleep deprivation. In experimental
practice, tests of vigilance have proved particularly useful in
detecting the acute (Hart et al. 1976) and residual (Oswald et al.
1979) effects of benzodiazepine derivatives. Thus, the overall
sensitivity of a test battery to residual drugs effects may be
enhanced by including measures of the efficiency of sustained
attention.
In the present experiment, the effects on daytime performance
of triazolam, and loprazolam (as HR 158), were further evaluated,
and compared. Specifically, the experimental design required a
period of drug taking which would reasonably allow for cumulative
effects to emerge and, further, permitted:-
1) the development of such effects, if present, to be assessed
throughout the drug taking period; and
2) the time-course of such effects, if present, to be assessed
throughout days within the drug taking period.
Also considered in the present study were the effects of drug
withdrawal, after sustained usage, on the efficiency of daytime
performance. Performance efficiency impaired by hypnotic drug
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usage may reasonably be expected to return to normal (baseline)
levels on withdrawal of the drug. However, in the short term,
drug withdrawal itself can precipitate events which can, in turn,
disrupt daytime behaviour. Rebound insomnia, and reduced sleep
efficiency (as measured by total sleep time/total time in bed) are
well documented features of EEG sleep recordings made immediately
after the withdrawal of some hypnotic drugs. Mam et al. (1976),
for example, report that following 10 weeks of nitrazepam 5.0mg
nightly, intervening wakefulness increased rapidly on withdrawal
of the drug, being maximal on the second withdrawal night in a
group of 10 middle-aged subjects (mean age = 57y). Similarly,
Oswald et al. (1979) report that after three weeks administration
of lmg and 2.5mg doses of the shorter acting benzodiazepine
lormetazepam, withdrawal was associated with rebound sleep
disturbances which included increases in sleep onset latency
(2.5mg) and increased duration of REM periods during the first
three hours of sleep (1.0mg) in a group of nine volunteers (mean
age = 61y) .
Daytime performance may also be disrupted by mood changes
produced by drug withdrawal. In particular, subjective feelings of
anxiety modified by the use of benzodiazepine hypnotics have been
reported to increase above baseline values during the withdrawal
period (Allen and Oswald, 1976). The design of the present study,
then, further allowed for a detailed assessment of performance
efficiency to be made during the immediate withdrawal period.
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Methods
Subjects. Twelve volunteers, nine females and three males aged
40-65y (mean age = 52y; median age = 52y), who considered
themselves to be poor sleepers, served as subjects. None was
receiving psychotropic drugs, and each abstained from alcohol
during the experimental periods. Subjects were in good general
health, and took part with the consent of their general
practitioners. Each subject was paid on completion of the study,
and each was reimbursed for travel expenses to and from the
laboratory.
Drugs. Subjects received each of the following preparations in
identical capsules: triazolam 0.5mg; loprazolam (as HR 158) l.Omg;
loprazolam (as HR 158) 0.5mg; and placebo. Each preparation was
taken at the subject's normal bedtime.
Experimental Design. The experimental design is shown
diagramatically in Figure 2:1. The basic sequence of weeks shown
in this figure will be referred to as an 'experimental period'.
Subjects attended the laboratory in groups of six either on
Sundays, or on Thursdays. Drugs were administered in a balanced
order according to three four-sided Latin squares. Each
experimental period lasted six weeks, and was organised as
follows: one practice week; one baseline week; three drug/placebo
weeks; and one withdrawal week (see Fig 2:1). Experimental
periods were separated by four-week washout periods, during which
the subjects took no capsules, and the experimental constraints on
- 18 -








































*beginningofstudyl Treatmentscom encedtbedtiDay1. Theabovesequenc(excl dingthadaptatiowe k)asr pe tedo3fu t rcc sions.
alcohol consumption did not apply. For all subjects, a single
adaptation week, during which they took placebo capsules and
attended the laboratory for testing, preceded, and was continuous
with, their first treatment condition. Thus, each subject
participated for a total of 37 weeks (experimental periods +
washout periods) . Subjects were blind to all conditions,
including the preliminary adaptation week. The experimenter was
blind only to the three drug/placebo weeks in each treatment
condition.
Test Schedule
All testing procedures were conducted in the performance
laboratory. Subjects attended the laboratory on the morning
following the second night of capsule ingestion, and thereafter on
the same day at weekly intervals (see Figure 2:1). Thus, for the
first experimental period subjects attended the laboratory on
seven testing days, and for each of the remaining three
experimental periods, subjects attended on six testing days. For
each of these days of attendance the test procedures, which took
approximately 2h to complete, were administered at three times
throughout the day commencing at 08.30, 12.30, and 16.30. The
tests, in their order of administration, were as follows:
1) the Wilkinson Auditory Vigilance Test (Wilkinson, 1970). For lh
the subjects listened through headphones to a series of standard
1000Hz tones of 0.5sec duration which were presented every 2sec.
Tones were of 60dB intensity, and each occurred against a background
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of 70dB continuous white noise. Target signals were tones of 0.4sec
instead of the 0.5sec standard. The ratio of target signals to
standard tones was 1-48. Target signals were presented according
to six 10min semi-random distributions which ran continuously during
the one hour period. The order in which these 10min distributions
were presented was varied on each testing occasion. Subjects sat in
individual cubicles and were required to register their detection of
a target signal by pushing a button. Watches were left outside
the cubicle. For each of the six continuously running target
signal distributions, both correct detections and false reports
(i.e. registering a detection after a standard tone) were
recorded. No feedback to subjects (i.e. no knowledge of results)
was given.
2) Manual Dexterity. Subjects were required to place cylindrical
pellets 5.5mm in diameter into an upright tube of slightly larger
bore. The tube, mounted on a collecting chamber, was placed
directly in front of each seated subject within the testing
cubicles. Pellets would enter in only one orientation, viz.
perpendicular to the tube. Subjects were required to place into
the tube as many pellets as possible, using the preferred hand,
picking up only one pellet at a time. A single trial lasted one
minute, and was followed by a one minute inter-trial interval.
Six trials were repeated in identical manner. During the inter-
trial interval, subjects emptied the collecting chamber and
recorded the number of pellets placed in that trial. The results
from trials 2-5 only were recorded for subsequent analysis.
Trial 1 was considered a practice or 'adaptation' trial, and
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final trials in a series, in this case, trial 6, are known to be
influenced by "end spurt" accelerations in performance (Catalano,
1973) .
3) The Digit Symbol Substitution Test. Using a modified version of
the Wechsler Mult Intelligence Scale coding sub-test (Wechsler,
1958), subjects were required to enter digits below corresponding
symbols according to a given code. Eight different symbols were
randomly arranged in printed blocks of 200. Two such blocks were
provided, the code being printed above the first block (see
appendix 1:1). TWo minutes were allowed for coding, the subject
being asked to work as quickly and as accurately as possible. Nine
different translation codes were randomly varied throughout the
experiment to offset possible learning effects. The total number
of items correctly coded, and the total number of items
incorrectly coded, were recorded for each session.
4) The Crossman Card-Sorting Task (Crossman, 1953) . Packs of 32
ordinary playing cards were sorted on a specially constructed tray
(55cm x 48cm) divided into two rows of four 1cm deep compartments
(15cm x 10cm). The pack was placed in a three-sided compartment,
also 1cm deep, which was centrally situated on the side of the tray
nearest the subject, and from which single cards could be drawn
from the top of the pack with one hand. Three packs of 32 cards
were used for sorting: a two-category pack containing equal
numbers of 2s and 3s; a four-category pack containing equal
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numbers of 2s, 3s, 4s, and 5s, and an eight-category pack
containing equal numbers of 2s, 3s, 4s, 5s, 6s, 7s, 8s and 9s.
Fixed face-up to the bottom of each of the eight sorting
compartments was an example of each of these denominations, a 2,
3, 4, and 5, from left to right across the top row, and a 6, 7, 8,
and 9, frcm left to right across the bottom row. A further pack of
32 cards, the movement-time pack, contained only 10s. For each
subject, the four packs, and the eight example cards, were of the
same colour.
Trials commenced with the movenent-time pack of cards being
placed face-down in the open ended compartment. The subject was
first asked to place, one at a time, cards from this pack into the
"2" and "3" compartments, sharing the pack equally between the
two. This procedure was then repeated for compartments 2-5, and
2-9. The sequence was then reversed, and the subject shared the
pack equally between compartments 2-9, then 2-5, and finally 2-3.
The subject was then presented with the two-category pack, and
asked to sort each card into its matching compartment. This was
repeated for the four-category pack, and then the eight-category
pack. The order was then reversed, and the subject then sorted
the eight-, four-, and two-category packs. For each movement-time
and sorting trial, the subject was asked to work as quickly, and
as accurately as possible. Each sorting pack was shuffled before
use. The timing of each trial commenced with the verbal cue "go",
and stopped when the final card from the pack was placed. The
mean of each pair of two-, four-, and eight-category movement
times, and two-, four-, and eight-category sorting times were
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recorded. The movement time was then deducted from the approprate
sorting time (e.g. two-category sorting time minus the two-
category movement time) and the resulting Choice Reaction Time
(Crossman, 1953) was also recorded for analysis.
Subjective Ratings
Throughout each of the experimental periods subjects rated
their mood and behaviour using visual analogue scales. These
instruments, their analysis, and the results, are fully described
in Chapter 4.
Analysis of Data
Test scores from the baseline weeks, the drug/placebo weeks,
and the withdrawal weeks only were used in the analysis. To
reduce the impact of initial baseline group differences on the
subsequent analyses of performance change, unweighted deviation
scores were calculated. For a full discussion of the statistical
reliability of such indices of change, see Overall (1977). Within
each of the four experimental periods, deviation scores were
calculated by deducting each of a given subject's drug/placebo
week scores, and withdrawal week scores, from that subject's
appropriate baseline week score (e.g. 08.30 baseline score minus
- 24 -
08.30 week 1 score, etc.). Deviation scores were derived for
each occasion of testing throughout the drug/placebo and
withdrawal weeks for each drug treatment. Scores from the
drug/placebo weeks, and scores frcm the withdrawal week, were
analyzed separately.
For each test measurement, deviation scores from the
drug/placebo weeks were analyzed using a repeated measures
analysis of variance model (Jenrich and Sampson, 1979) with three
trial factors (drug, week, and time), and one grouping factor
(age). Levels for each of the trial factors were as follows.
Drug: (1) triazolam 0.5mg; (2) loprazolam 1.0mg; (3) loprazolam
0.5mg; (4) placebo. Week: (1) week 1 testing sessions; (2) week 2
testing sessions; (3) week 3 testing sessions. Time (1) 08.30
testing sessions; (2) 12.30 testing sessions; (3) 16.30 testing
sessions. The grouping factor, age, which was crossed with each
of the trial factors had two levels: (1) those subjects above the
group median age at the start of the experiment; (2) those
subjects below the group median age at the start of the
experiment.
The main effects of, and interactions between these factors
were computed. Where significant main effects of the drug factor
were found, within-factor means were compared using correlated t-
tests. Significant interactions between the drug factor and the
'test occasions' factors (i.e. week, time, or week x time) were
further evaluated by repeating the analysis of variance for each
separate week, or each separate time as appropriate to determine
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the influence of drug on these occasions of testing. Where
significant four-way interactions were found (i.e. drug x week x
time x age) the analysis was repeated for each separate time of
day to determine the combined influence of drug and age on weekly
test performance. Where appropriate, treatment means from
significant drug x age interactions were compared using correlated
t-tests. Similarly, and where appropriate, treatment means from
significant drug x test occasions factors were also compared using
correlated t-tests. These latter comparisons were undertaken only
where they assisted in the interpretation of significant
interactions.
Scores from the withdrawal period v«re separately analyzed by
repeated measures analysis of variance with two trial factors
(drug and time) and one grouping factor (age). Levels for these
factors were as described above. Main effects of, and
interactions between these factors were also similarly evaluated.
Two-tailed tests of significance were used throughout. The




Experiment 1: Effects of triazolam and lormetazepam on the
daytime performance of middle-aged subjects.
The effects of the four experimental treatments (viz.
placebo, loprazolam l.Omg, triazolam 0.5mg, and loprazolam 0.5mg)
on performance in veeks 1, 2, and 3 (the drug/placebo weeks) are
summarized in Table 3:1. Complete analysis of variance tables for
each variable are shown in Appendix 2. These results, and the
results of further analyses, will be considered for each test in
turn. With the single exception of false positive reports on the
auditory vigilance test, all results refer to deviation scores,
calculated as described above. In both the figures and tables
presented in this chapter, the following abbreviations have been
adopted: P (placebo); T (triazolam 0.5mg); Ll.O (loprazolam
l.Omg); and L0.5 (loprazolam 0.5mg). Also, the two groups created
by the age factor in the analyses of variance will be referred to
as the older sub-group, and the younger sub-group (i.e. older and
younger than the group median age) .
Results
This section describes the results from the main analyses,
and indicates where further analyses were undertaken; it also
provides a guide to the Figures and Tables. All the results are
fully discussed in the next section.
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D=rug(treatment) A=ge(grouping) W=eek(oftesting) T=ime(ofday) * p<0.05 **p<O.Ol
Auditory Vigilance
Correct detections were converted to percentages of the total
number of target signals presented prior to the computation of
deviation scores. Percent correct detections over lh showed no main
effect of drug, and no significant interaction effects between
drug and age, or between drug and either of the test occasions
factors (Table 3:1). Percent correct detections for the final
40min of the test, however, showed a significant main drug effect
(F = 3.30, df = 3,30, p<0.05), and also showed a significant drug
x week x time x age interaction (F = 2.13, df = 12,120, p<0.05).
The significant main effect of drug was further evaluated by
multiple comparisons of the cell means for each drug condition
using correlated t-tests. The results from these comparisons,
together with the drug treatment means, are shown in Table 3:2.
To further evaluate the significant 4-way interaction, the
analysis of variance was repeated for each time of day (i.e. the
analysis was repeated with time held constant). The results of
these further analyses of the 08.30, 12.30, and 16.30 testing
sessions are shown in Figures 3:2a, 3:2b, and 3:2c respectively.
Separate analyses of the 12.30 (Figure 3:2b) and 16.30 (Figure
3:2c) times of testing showed no significant main effects of
drug, and no significant interaction effects between drug and age,
or between drug and weeks. However, separate analysis of percent
correct detections for the final 40min of the auditory vigilance
test recorded at the 08.30 test sessions (Figure 3:2a) showed a
significant drug x week x age interaction (F = 3.11, df = 6.60,
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Table 3:2 Auditory vigilance: paired comparisons between treatment
means for correct detections (final 40min)
Drug Treatment Placebo Loprazolam 1.0 Triazolam 0.5
(Mean; SD) (2.0%; 8.47)
Loprazolam 1.0 t = 1.11
(-3.6%; 10.10)
Triazolam 0.5 t = 0.27 t = 1.29
(1.39%; 7.19)




Values are shown for t (correlated)
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Figure 3;2a Effects of two hypnotics on auditory
vigilance performance at 08.30
time. 12 30


























Figure 3:2b Effects of two hypnotics on auditory
vigilance performance at 12.30
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Figure 3:2c Effects of two hypnotics on auditory








Older sub- Younger sub- Older sub- Younger sub- Older sub- Younger sub-
Group Group Group Group Group Group
DRUG * AGE F = 0«33,d f =3,30. pNS DRUG * AGE F= >91. d f =3.30.p<0 5 DRUG * AGE Fr2*81,df =3.30.pN S
Figure 3:3 Effects of two hypnotics on false positive
reporting in two age groups
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Table 3:3 Paired comparisons between treatment conditions for correct
detections (final 40min) on the auditory vigilance task
Older Sub-group Younger Sub-group
Drug P L1.0 T P L1.0 T Time
Wteek 1
LI. 0 0.42 2.13 _ _
T 0.47 0.03 - 1.85 0.61 - 08.30
L0.5 1.67 0.95 1.21 2.19 0.64 1.42
L1.0 0.69 _ _ 0.00 — _
T 0.57 0.29 - 0.17 0.20 - 12.30
L0.5 0.77 1.32 1.18 0.04 0.05 0.17
L1.0 0.29 1.03 _
T 1.75 1.05 - 0.42 1.05 - 16.30
L0.5 0.41 0.19 1.49 0.06 1.16 0.91
Week 2
LI. 0 1.40 _ _ 1.21 _ _
T 1.73 0.41 - 0.84 1.67 - 08.30
L0.5 1.24 0.56 0.02 1.54 0.15 0.79
L1.0 1.88 _ 1.19 _ _
T 0.28 1.01 - 2.22 0.82 - 12.30
L0.5 1.69 0.94 1.90 0.69 1.32 2.64*
LI. 0 0.49 _ _ 0.32 — _
T 0.16 0.40 - 0.52 0.53 - 16.30
L0.5 0.76 0.91 0.51 0.28 0.08 2.77*
Week 3
L1.0 0.91 _ _ 0.14 — _
T 1.82 0.21 - 0.33 0.61 - 08.30
L0.5 1.40 0.29 0.21 1.32 0.92 0.33
LI. 0 1.15 _ _ 1.14 _
T 0.94 0.83 - 1.03 0.25 - 12.30
L0.5 2.19 1.96 2.05 0.02 1.15 0.71
LI. 0 1.82 _ _ 1.95 _ _
T 1.25 0.27 - 0.53 2.31 - 16.30
L0.5 0.63 0.80 0.54 1.41 0.24 1.39
* p<0.05
** p<0.01
Values shown are for t (correlated), df = 5, two-tailed probablities
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p<0.01). Within each sub-group, and for each week of testing,
paired comparisons between the drug conditions for the 08.30,
12.30, and 16.30 test sessions are shown in Table 3:3.
Analysis of the absolute number of false reports over Ih showed
no significant main effect of drug, but did show significant drug x
time x age (F = 2.28, df = 6,60, P<0.05) and drug x week x time x
age (F = 2.24, df =l2,i2o, p<0.01) interactions. Both of these
significant interactions were further evaluated by repeating the
analysis of variance for the 08.30, 12.30, and 16.30 testing
sessions. The combined influence of drug and age on false
positive reports is shown in Figure 3:3. The combined influence
of drug, age, and week on false positive reports is shown in
Figures 3:4a, 3:4b, and 3:4c for the 08.30, 12.30 and 16.30 test
sessions respectively. At the 08.30 (figure 3:4a) test sessions,
false reports showed no sigificant main effect of drug, and no
significant interaction effects between drug and age, or between
drug and weeks. Separate analysis of the 12.30 test sessions
(Figure 3:4b) showed a significant drug x age interaction (F =
3.91, df = 3,30, p<0.05). For the 16.30 test sessions (Figure
3:4b) a highly significant interaction was found between drug,
week, and age (F = 3.38, df = 6,60, p<0.01). Within each sub¬
group, and for each week of testing paired comparisons between the
drug conditions for the 08.30, 12.30, and 16.30 test sessions are
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Figure 3:4a Effects of two hypnotics on false
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Figure 3;4b Effects of two hypnotics on false
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Figure 3:4c Effects of two hypnotics on false
positive reporting by time and age
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TIME : 08 30 TIME 12 30 TIME: 16 30
W1 W2 W3
WEEK (w) OF TESTING
CARD SORTING: MOVEMENT TIME
(2 CATEGORIES)
~W1 W2 W3
WEEK (w) OF TESTING
Figure 3:5 Effects of two hypnotics on movement
time (card sorting) by time of day
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Table 3:4 Paired comparisons between treatment conditions for
false positive reports on the auditory vigilance task
Older sub-group Younger sub-group
Drug P L1.0 T P LI. 0 T Time
Vfeek 1
LI. 0 0.67 _ _ 0.82 _ _
T 1.11 0.35 - 0.19 1.46 - 08.30
L0.5 0.50 1.41 2.39 0.53 0.21 0.43
L1.0 0.61 _ _ 0.33 _ _
T 1.43 0.32 - 0.93 0.93 - 12.30
L0.5 0.19 0.57 1.41 1.35 1.10 0.20
LI. 0 1.42 _ _ 0.79 _ _
T 1.87 0.49 - 1.63 1.94 - 16.30
L0.5 1.69 0.47 1.49 1.73 1.57 0.79
Week 2
LI. 0 1.26 _ _ 0.15 _ _
T 1.19 0.16 - 0.47 0.25 - 08.30
L0.5 1.38 0.45 0.40 1.05 0.71 1.77
L1.0 1.66 _ _ 2.87* _ _
T 0.44 0.91 - 2.13 0.19 - 12.30
L0.5 0.47 1.15 0.08 2.49* 0.18 0.31
L1.0 3.13* _ _ 0.70 _ _
T 1.94 0.66 - 1.09 2.15 - 16.30
L0.5 0.54 1.96 3.05* 1.35 2.99* 2.24
Week 3
L1.0 1.30 __ — 0.50 _ _
T 1.43 0.74 - 1.36 1.31 - 08.30
L0.5 0.72 0.21 0.81 0.92 0.68 2.24
L1.0 2.22 _ _ 0.64 _ _
T 1.53 0.74 - 2.09 2.24 - 12.30
L0.5 0.89 1.90 1.24 1.87 0.81 0.65
L1.0 0.45 _ 1.45 _
T 1.63 1.58 - 0.60 1.19 - 16.30
L0.5 2.45* 1.68 4.66** 0.75 1.08 0.54
* p<0.05
** p<0.01
Values shown are for t (correlated), df = 5, two-tailed probablities
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Digit Symbol Substitution
Analysis of variance of the digit symbol substitution test
data (items correctly coded) showed no significant main effect of
drug, and no significant interaction effects between drug and age,
or between drug and either of the test occasions factors (Table
3:1). Errors (i.e. items incorrectly coded) occurred with an
extremely low frequency throughout the experiment under all
treatment conditions, providing insufficient data for analysis.
Card Sorting
Movement time from the two-category condition of the card
sorting task showed no significant main effect of drug, but did show
a significant drug x week x time interaction effect (F = 2.03,
df = 12,120, p<0.05). The analysis of these data was, therefore,
repeated for each time of testing separately to determine the
influence of drug treatment and week at the 08.30, 12.30, and
16.30 times of testing. The results of these analyses are shown
in Figure 3:5. None of these further analyses showed significant
main effects of drug, or showed significant interaction effects
between drug and week. For each week of testing, paired
comparisons between the drug conditions for the 08.30, 12.30, and
16.30 test sessions are shown in Table 3:5.
The four-category movement times showed no significant main
effect of drug, and no significant interactions between drug and
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Table 3; 5 Movorient time (two category) from the card sorting task:
paired comparisons between drug conditions for each week, and for
each time of testing
Week 1 Testing Sessions














































Week 2 Testing Sessions
















































Vfeek 3 Testing Sessions
P( 0.93; 1.74) LI.0 T 08.30
LI.0 ( 0.56; 1.77) 0.60
T ( 1.11; 2.26) 0.18 0.68
L0.5 ( 1.50; 2.14) 0.91 1.06 0.41
P( 0.66; 2.35) L1.0 T 12.30
L1.0 ( 0.30; 2.22) 0.39
T (-0.40; 1.66) 0.75 0.49
L0.5 ( 0.80; 2.31) 0.13 0.58 1.03
P(-0.17; 1.91) LI.0 T 16.30
LI.0 ( 0.11; 1.99) 0.46
T ( 0.32; 1.70) 0.73 0.30
L0.5 ( 0.98; 1.55) 1.68 1.45 1.00
Values shown between conditions are for t (correlated)
Table 3:6a Movement time (eight category) from the card sorting
task: paired comparisons between the drug treatment means within the
older, and the younger sub-groups
Older sub-group
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L1.0 (-0.38; 0.92) P (-0.17; 1.06) 0.41
T ( 1.07; 1.62) P (-0.17; 1.06) 1.66
L0.5 ( 0.52; 0.58) P (-0.17; 1.06) 1.60
LI. 0 (-0.38; 0.92) T ( 1.07; 1.62) 1.97
LI. 0 (-0.38; 0.92) L0.5 ( 0.52; 0.58) 1.98
T ( 1.07; 1.62) L0.5 ( 0.52; 0.58) 1.35
Younger sub-group
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
LI. 0 (-0.34 1.50) P ( 0.84 0.55) 1.91
T (-0.25 0.71) P ( 0.84 0.55) 3.05*
L0.5 (-0.03 0.94) P ( 0.84 0.55) 2.28
LI. 0 (-0.34 1.50) T (-0.25 0.71) 0.18
L1.0 (-0.34 1.50) L0.5 (-0.03 0.94) 0.44
T (-0.25 0.71) L0.5 (-0.03 0.94) 0.48
* p<0.05 ** p<0.01
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age, or between drug and either of the test occasions factors (Table
3:1) .
Analysis of variance of the eight-category movanent times also
showed no significant main effect of drug, but did show significant
interaction effects between drug treatment and age (F = 3.20, df =
3,30, p<0.05), and between drug treatment and time of testing (F =
2.78, df = 6,60, p<0.05). These two-way interactions are shown in
Figures 3:6 and 3:7 respectively. Paired comparisons between the
drug treatment means within each sub-group, and also between the
drug condition means for each time of testing, are shown in Table
3:6a and 3:6b respectively.
Choice reaction time in the two-category condition showed no
main effect of drug, but did show a significant interaction effect
between drug condition and time of testing (F = 2.51, df = 6,60,
p<0.05). This two-way interaction is shown in Figure 3:8, and the
cell means for each drug condition, at each of the three times of
testing, are compared in Table 3:7.
In the four-category condition of the choice reaction time
task, analysis of variance showed no significant main effect of
drug, but did show a significant reaction between drug, week, time,
and age (F = 2.23, df = 11,120, p<0.01). The analysis of these data
was then repeated for each separate time of testing, and these
results are shown in Figures 3:9a, 3:9b, and 3:9c for the 08.30,
12.30, and 16.30 times of testing respectively. Separate analysis
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Figure 3:7 Effects of two hypnotics on movement
time (card sorting) by time of day
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Table 3:6b Mavorient time (eight category) from the card sorting
task: paired comparisons between the drug treatment means for each
time of testing
08.30 Testing Sessions
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L1.0 ( 0.02; 1.83) P ( 1.00; 1.70) 1.36
T ( 0.93; 1.33) P ( 1.00; 1.70) 0.09
L0.5 (-0.54; 1.18) P ( 1.00; 1.70) 2.25*
LI. 0 ( 0.02; 1.83) T ( 0.93; 1.33) 1.17
L1.0 ( 0.02; 1.83) L0.5 (-0.54; 1.18) 0.75
T ( 0.93; 1.33) L0.5 (-0.54; 1.18) 4.19**
12.30 Testing Sessions
LI. 0 ( -0.21; 1.58) P ( 0.16; 1.78) 0.86
T ( -0.36; 1.64) P ( 0.16; 1.78) 0.67
L0.5 ( 0.73; 1.47) P ( 0.16; 1.78) 0.91
LI. 0 ( -0.21; 1.58) T (-0.36; 1.64) 0.24
LI. 0 ( -0.21; 1.58) L0.5 ( 0.73; 1.47) 1.85
T ( 0.36; 1.64) L0.5 ( 0.73; 1.47) 1.89
16.30 Testing Sessions
LI. 0 ( -0.90; 1.31) P (-0.15; 1.27) 1.59
T ( 0.67; 1.61) P (-0.15; 1.27) 1.12
L0.5 ( 0.56; 1.74) P (-0.15; 1.27) 1.20
L1.0 ( -0.90; 1.31) T ( 0.67; 1.61) 2.57*
LI. 0 ( -0.90; 1.31) L0.5 ( 0.56; 1.74) 2.42*
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Figure 3:8 Effects of two hypnotics on choice
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Figure 3:9a Effects of two hypnotics on choice
reaction time by age group: 08.30
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Figure 3:9c Effects of two hypnotics on choice
reaction time by age group: 16.30
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Table 3:7 Choice reaction time (two category) from the card
sorting task: paired comparisons between drug treatment means for
each time of testing
08.30 Testing Sessions
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L1.0 -0.59; 1.57) P ( 0.88 1.49) 2.24*
T -0.19; 2.68) P ( 0.88 1.49) 1.85
L0.5 0.12; 1.76) P ( 0.88 1.49) 1.22
LI. 0 -0.59; 1.57) T (-1.19 2.68) 0.67
L1.0 -0.59; 1.57) L0.5 ( 0.12 1.76) 0.83
T -1.19; 2.68) L0.5 ( 0.12 1.76) 1.38
12.30 Testing Sessions
LI. 0 ( 0.02; 1.76) P ( 0.32; 1.34) 0.46
T ( 0.01; 2.20) P ( 0.32; 1.34) 0.39
L0.5 (-1.26; 2.74) P ( 0.32; 1.34) 1.53
L1.0 ( 0.02; 1.76) T ( 0.01; 2.20) 0.01
LI. 0 ( 0.02; 1.76) L0.5 (-1.26; 2.74) 1.32
T 0.01; 2.20) L0.5 (-1.26; 2.74) 1.19
16.30 Testing Sessions
LI. 0 (-0.83; 1.56) P ( 0.70; 1.90) 1.96
T ( 0.69; 1.44) P ( 0.70; 1.90) 0.01
L0.5 (-1.03; 2.16) P ( 0.70; 1.90) 1.72
LI. 0 ( -0.83; 1.56) T ( 0.69; 1.44) 2.17*
LI. 0 (-0.83; 1.56) L0.5 (-1.03; 2.16) 0.22




Table 3:8 Paired comparisons between treatment conditions for
card sorting into four categories (choice reaction time)
Older sub-group Younger sub-group
Drug P LI. 0 T P L1.0 T Time
Week 1
LI. 0 0.22 _ _ 0.62 _ _
T 0.47 0.11 - 0.21 1.04 - 08.30
L0.5 1.80 0.58 0.57 0.51 0.31 0.44
L1.0 0.34 _ _ 0.15 _ _
T 0.60 0.10 - 0.12 0.61 - 12.30
L0.5 2.02 3.23* 2.12 1.24 1.23 1.13
LI. 0 1.98 _ _ 1.78 _ _
T 1.64 0.45 - 1.86 0.46 - 16.30
L0.5 1.49 0.09 0.19 3.24* 1.53 3.51**
Week 2
LI. 0 0.04 _ _ 0.97 _ _
T 1.85 2.74* - 1.77 0.49 - 08.30
L0.5 2.18 1.10 0.07 1.96 0.00 0.70
LI. 0 0.01 _ _ 2.83* _ _
T 0.33 0.68 - 1.59 2.93* - 12.30
L0.5 0.50 0.67 0.32 7.36** 0.17 1.72
LI. 0 0.98 _ _ 0.42 _ _
T 0.35 0.07 - 0.01 0.60 - 16.30
L0.5 0.31 0.14 0.22 1.88 1.85 6.67**
Week 3
L1.0 0.07 _ _ 1.63 _ _
T 0.48 0.59 - 1.52 0.40 - 08.30
L0.5 0.03 0.09 0.57 2.05 0.50 2.12
L1.0 0.63 _ _ 2.58* _ —
T 0.00 0.89 - 0.66 1.50 - 12.30
L0.5 2.18 3.26* 2.76* 3.22* 1.17 2.12
LI. 0 0.62 _ _ 0.26 _ _
T 1.18 0.55 - 2.24 0.71 - 16.30
L0.5 0.20 0.67 0.93 2.58* 0.87 0.76
* p<0.05
** p<0.01
Values shown are for t (correlated), df = 5, two-tailed probabilities
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significant main effect of drug, and no significant interaction
effects between drug and age, or between drug and week at these
times of testing. However, separate analysis of the 12.30 test
session data showed a significant drug main effect (F = 4.06, df =
3,30, p<0.05) which was independent of both the age, and the weeks
factors. Within each sub-group, and for each week of testing,
paired comparisons between the drug conditions for the 08.30,
12.30, and 16.30 test sessions are shown in Table 3:8. For the
12.30 test sessions, the cell means for each drug condition are
compared in Table 3:9.
In the eight-category condition choice reaction time showed no
significant main effect of drug, and no significant interaction
effects between drug and age, or between drug and either of the
test occasions factors.
Manual Dexterity
Analysis of the data from the manual dexterity test showed no
significant main effect of drug, but did show a significant
interaction effect between drug treatment and time of testing (F =
2.28, df = 6,60, p<0.05), and also showed a significant
interaction between the drug, week, time and age factors (F =
2.13, df = 12,120, p<0.05). The drug x time interaction is shown
in Figure 3:10, and paired comparisons between the drug means at
each time of testing are shown in Table 3:10. The analysis of
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Table 3:9 Card sorting into four categories (choice reaction time):
paired comparisons between treatment means for the 12.30 testing
Drug Treatment Placebo Loprazolam 1.0 Triazolam 0.5
(Mean; SD) (0.57; 1.76)
Loprazolam 1.0 t = 1.06
(-0.52; 2.49)
Triazolam 0.5 t = 0.41 t = 1.22
(0.22; 1.98)
Loprazolam 0.5 t = 3.31** t = 2.00 t = 2.55*
(-2.11; 2.19)
Values shown are for t (correlated)
Table 3;10 Manual dexterity: paired comparisons between treatment
means for each time of testing
08.30 Testing Sessions
Drug Treatment (mean; SD) v Drug Treatment (mean ; SD) t-value
L1.0 ( 0.31; 2.95) P (-2.48; 3.67) 2.41*
T (-0.10; 1.54) P (-2.48; 3.67) 2.37*
L0.5 (-0.91; 1.89) P (-2.48; 3.67) 1.24
LI. 0 ( 0.31; 2.95) T (-0.10; 1.54) 0.40
LI. 0 ( 0.31; 2.95) L0.5 ( 0.31; 2.95) 1.50
T (-0.10; 1.54) L0.5 ( 0.31; 2.95) 1.17
12.30 Testing Sessions
LI. 0 (-0.30; 2.67) P (-0.68; 3.06) 0.39
T (-0.34; 1.93) P (-0.68; 3.06) 0.30
L0.5 ( 0.25; 1.41) P (-0.68; 3.06) 1.21
L1.0 (-0.30; 2.67) T (-0.34; 1.93) 0.04
LI. 0 (-0.30; 2.67) L0.5 ( 0.25; 1.41) 0.65
T (-0.34; 1.93) L0.5 ( 0.25; 1.41) 0.71
16.30 Testing Sessions
LI. 0 ( 0.36; 2.19) P (-0.25, 2.45) 0.79
T (-0.51; 2.81) P (-0.25; 2.45) 0.27
L0.5 (-0.24; 2.43) P (-0.25; 2.45) 0.00
LI. 0 ( 0.36; 2.19) T (-0.51; 2.81) 1.06
LI. 0 ( 0.36; 2.19) L0.5 (-0.24; 2.43) 0.69
T (-0.51; 2.91) L0.5 (-0.24; 2.43) 0.31
* p<0.05 ** p<0.01











































































































































* p<0.05 ** p<0.01
Values are shown for t (correlated), df = 5, two-tailed probabilities
Table3:12Withdrawaleek:
summaryofresultsfr
Test/Variable AuditoryVigilance: %detections(1hour) %detections(final40m ) falsereports DigitSymbolubst tuti n CardSorting: movementti(2category)
l movementti(4category) uimovementti e(8category) W 1ChoiceReactionTime (2category) (4category) (8category) ManualDexterity
MainEffects Drug 0.93 0.14 0.13 1.39 1.30 2.20 0.80 1.89 1.70 0.67 0.26
D=rug(treatment) A=ge(grouping) T=ime(ofday)
































of testing. The results of these further analyses are shown in
Figures 3:11a, 3:11b, and 3:11c respectively. At the 08.30 and
12.30 times of testing, separate analyses of variance showed no
main effects of drug, and no significant interaction effects
between drug and age, or between drug and week, At the 16.30
time of testing, however, a significant interaction was found
between drug and age (F = 3.37, df = 3,30, p<0.05). Within each
sub-group, and for each week of testing, paired comparisons
between the drug conditions for the 08.30, 12.30 and 16.30 test
sessions are shown in Table 3:11.
Withdrawal Data
The effects of withdrawal on performance for each of the
treatment conditions are summarized in Table 3:12. None of the
test measurements analyzed showed a significant main effect of
drug condition, and none showed significant interactions between
drug and age, or between drug and time of testing.
Discussion
Results will be discussed in the order presented in the
previous section. A summary of conclusions is presented at the end of
this chapter.
Auditory Vigilance (correct detections)
- 54 -
Efficiency on vigilance tasks declines progressively as time-
on- task increases (Mackworth, 1969). Several researchers have
reported that both sedative and stimulant drug influences on
vigilance performance are greatest during the latter portions of
the task, when vigilance is normally lowest (e.g. Loeb et al.
1965). Hart et al.( 1976), assessing the acute influence of
amylobarbitone and diazepam on performance in a one-hour auditory
vigilance task, analyzed correct detections for each successive
quarter-hour period. These researchers found that the progressive
decrement, typical of sustained vigilance performance, was
greatest between the first and second quarter-hour periods
irrespective of drug treatment. Thus, for a one hour auditory
vigilance task, it is likely that the latter three quarter-hour
periods are more sensitive to residual drug influences. As the
data from the present task were collected in 10min units, the
latter 40min of the task were analyzed in addition to the data
collected for the full one hour.
The differential sensitivity to residual drug effects of
early and late portions of the auditory vigilance task is
reflected in Table 3:1. While correct detections for the full
one hour show no significant main or interaction effects, correct
detections for the final 40min of the task show a significant
influence of drug which interacts with age, time and week. Table
3:2 shows that, across all times and weeks of testing, and across
both sub-groups, only one drug treatment, loprazolam 0.5mg,
differed significantly from placebo. Triazolam 0.5mg and
loprazolam 1.0mg show no significant departure from placebo
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levels of performance. However, performance associated with
loprazolam 0.5mg was significantly inferior to that which
obtained under the placebo condition.
This main drug effect was not independent of the age, week,
or time factors. Figures 3:2a, 3:2b, and 3:2c show that
loprazolam 0.5mg was consistently associated with the lowest
levels of performance in the older sub-group for all times of
testing. This is particularly the case for the 12.30 sessions
(Figure 3:2b), where loprazolam 0.5mg is associated with the
lowest percentage of correct detections for all three weekly
testing sessions. For the younger sub-group, performance during
the loprazolam 0.5mg condition is, nevertheless, low when compared
with the loprazolam 1.0mg, and the triazolam condition. An
interesting feature of Figures 3:2a, 3:2b and 3:2c is the tendency
shown, particularly in the younger sub-group, for test scores to
improve over the three weekly testing sessions. Pre drug-
treatment practice sessions, and a further baseline week (see
Figure 2:1), should have minimized the impact of practice on the
drug treatment data. Nevertheless, week 3 scores among the younger
sub-group for the active drug conditions are generally higher than
week 1 scores, the only exception to this being the loprazolam
0.5mg values at 16.30 (Figure 3:2c). These data, then, do not
suggest cumulative drug effects arising from repeated ingestion of
the experimental treatments.
Whether this improvement in performance over weeks represents
a genuine practice effect, or whether it reflects the ability of
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subjects to compensate for the residual effects of drugs is not
entirely clear. However, considering only the 08.30 testing
sessions (Figure 3:2a) the latter conclusion, that of
compensating for residual drug effects, gains credibility. Re-
analysis of the 08.30 testing session data showed a further
significant drug x week x age interaction. If practice effects
per se were responsible for the improvements shown over weeks,
then placebo scores ought equally to be affected. This is clearly
not the case for the younger sub-group. While placebo scores are
associated with the highest level of performance relative to the
baseline mean, this condition shows similar levels of performance
maintained over the three weekly testing sessions. Scores for the
three active drug treatments, however, begin at low levels, and
only exceed baseline mean values in v*eek 3. If we reasonably
assume that residual drug effects will be maximal in the early
morning, then, for the younger sub-group, this pattern of
performance is consistent with compensation for drug effects over
time. Within the older sub-group, such improvements are less
evident, and placebo values more labile. Individual comparisons
between drug conditions within each sub-group, and for each week
and time of testing, yielded few significant differenes (Table
3:3). Comparisons which did produce significant t-values occurred
with a frequency no greater than that to be expected by chance
alone (with alpha at the 5% level). Such results caution against
over interpretation.
In general, then, the effects of loprazolam 1.0mg and 0.5mg,
and triazolam 0.5mg on correct detections present an apparently
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paradoxical result. While the higher dose of loprazolam, and
triazolam 0.5mg appear not to impair performance, the lover dose
of loprazolam produces significant performance decrements relative
both to placebo (p<0.05) and to triazolam (p<0.05; Table 3:2).
Such a result, however, is not entirely inconsistent with previous
research concerning either vigilance performance alone, or drug
effects on vigilance performance. Hart et al. (1976) tested
subjects for one hour on the Wilkinson auditory vigilance task
45min after the administration of diazepam 2.5mg and 5mg, and
amylobarbitone 50mg and 100mg, and placebo. While both doses of
diazepam, and the lower dose of amylobarbitone significantly
impaired performance (as measured by the number of correct
detections), the higher dose of amylobarbitone did not.
Furthermore, the decrsnent produced by the diazepam condition was
greatest for the lower (2.5mg) dose.
With regard to the present data, at least two hypotheses may
be advanced to account for the pattern of drug effects on auditory
vigilance performance. Firstly, given that all the subjects
considered thanselves to be poor sleepers, improved sleep quality
following loprazolam 1.0mg and triazolam 0.5mg, but not following
loprazolam 0.5mg, may have differentially affected subsequent
vigilance performance. If, for example, subjects were ordinarily
below optimal vigilance levels due to poor sleep, thai an
effective hypnotic, or an effective dose of an hypnotic, by
improving sleep quality, may enhance performance on the auditory
vigilance task. It is evident from Table 3:2, however, that the
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highest mean level of performance is associated with placebo, and
from Figures 3:2a, 3:2b, and 3:2c, that performance levels for the
three hypnotics, more often than not, fail to exceed original
baseline values. Such a pattern is inconsistent with improved
performance under the active drug treatments.
A second hypothesis concerns the motivation of subjects.
Mackworth (1970) has reviewed a series of studies concerning
auditory vigilance performance in which the motivation of
subjects, and subsequent performance on the vigilance task, has
been improved. Thus, vigilance performance can improve if the
subject's motivation (or effort) is increased through, for
example, the use of rewards, providing knowledge of results, etc.
In the present context, the subject's own perception of atypical
drowsiness or reduced attention may have 'cued' changes in his or
her motivational state, increasing the effort to remain alert, and
thus compensating for the deleterious effects of sedation. This
hypothesis would predict that, if feelings of drowsiness were
greatest for loprazolam 1.0mg and triazolam 0.5mg, and least for
loprazolam 0.5mg, then any adjustments in motivation would follow
a similar pattern, being least for loprazolam 0.5mg. Support for
this hypothesis is provided by the daily subjective ratings of
morning vigilance completed by each subject throughout the study,
and fully described in the next chapter. Suffice it to point out
here that, irrespective of age sub-group, subjects consistently
rated thanselves as less vigilant during the loprazolam 1.0mg and
triazolam conditions than during the loprazolam 0.5mg condition
(p<0.05 for both comparisons; Table 4:4a). Indeed, mean
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subjective ratings of vigilance during the three weeks of
loprazolam 0.5rag consumption deviated little from placebo values.
Similar motivational influences have been reported in the
literature concerning alcohol and performance. Williams et al.
(1978) used a balanced placebo design to assess the effects of
zero, 0.03, and 0.06 percent blood alcohol levels on cognitive and
motor tasks which included a letter cancellation test, the WAIS
digit span, and Raven's Progressive Matrices. According to
this design, half the subjects receiving alcohol are told they are
receiving placebo, while half the subjects receiving placebo are
told they are receiving alcohol. The remaining halves are
correctly informed as to the nature of the experimental treatment.
The results showed that, among those expecting and receiving
alcohol, performance improved as the dose of alcohol increased.
When the subjective experience of an individual can reliably
distinguish between one drug condition and another, (as appears to
be the case in the present study) , then the advantages of a double-
blind procedure are greatly reduced, and the data may become
systematically influenced by motivational changes in the
individuals concerned. It is also probable that such compensatory
strategies are learned progressively, and are subject to
improvement over time. With reference to the 08.30 testing
sessions (Figure 3:2a), the relative stability of the placebo
scores for the younger sub-group, and the overall improvement
between weeks 1 and 3 shown for the active drug conditions accord
with this view, and further suggest that such strategies were
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better learned by the younger, than by the older sub-group.
Auditory Vigilance (False Positive Reports)
False positive responses occurred with a low frequency
throughout the experiment, with scores of zero, or one per hour
not infrequently recorded. Binford and Loeb (1966), analyzing the
effects of repeated sessions on auditory vigilance performance,
found that false positives began at high levels in the early
sessions, and rapidly declined in later sessions as the subject
apparently learns about the distribution of signals, and also
learns to distinguish more efficiently between signal and noise.
A similar trend was apparent in the present data. False positive
reports were highest during the practice and baseline weeks, and
lowest during the subsequent drug and withdrawal weeks. To
maintain comparability with previous studies, the mean absolute
number of false positive reports were analysed.
While the number of false positive reports showed no
significant main effect of drug (Table 3:1), the age factor did
emerge as a significant main effect (F = 5.11; df = 1,10; p<0.05;
for analysis of variance table see Appendix 2:3). With the single
exception of placebo scores at 12.30 (Figure 3:3), the younger sub¬
group invariably made fewer false positve reports for each drug
condition at each time of testing. It is also apparent from
Figure 3:3 that the relative position of the drug condition values
for the older sub-group remained fairly constant for each time of
testing, though again, with the 12.30 testing sessions being the
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only exception. Thus, for the older sub group, the highest
frequency of false positive reporting was associated with
triazolam, followed by loprazolam 1.0mg, and placebo. For both
sub-groups, however, loprazolam 0.5mg was associated with the
lowest levels of false positive reporting.
Interestingly, while triazolam 0.5mg was associated with the
highest levels of false positive reporting in the older sub-group,
the converse applied to the younger sub-group, particularly at
the 08.30 and 16.30 testing sessions (Figure 3:3). This
difference in the response of the two sub-groups to the same drug
condition is better illustrated in Figures 3:4a, 3:4b, and 3:4c.
For the older sub-group, triazolam is consistently associated with
high levels of false positive reporting in week 3 for all times of
testing. On the other hand, triazolam values for the younger sub¬
group are both lower, and show more stability, over the three
weeks of testing.
False positive reports reflect, to some extent, the degree of
caution exercised by the subject. When caution is high, false
reports are correspondingly low; as caution decreases, false
positive reports increase. Typically, sedative drugs are reported
to increase the frequency of false positive reports on vigilance
tasks (Loeb et al. 1965; Neal and Pearson, 1966). Hart et al.
(1976) also found that amylobarbitone 100mg was associated with an
increase in false positive reports on auditory vigilance, an
effect which wore off after 4h. In the present study, none of the
active drug conditions significantly influenced the degree of
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caution shown by the younger sub-group. In the older sub-group,
however, differences between the triazolam and loprazolam 0.5mg
conditions (see Table 3:4) suggest a selective effect of the
active drugs. Specifically, among the older sub-group, triazolam
is associated with a progressive lowering of caution, relative to
loprazolam 0.5mg, between the first and the third testing weeks.
Considered in relation to the correct detections data, this
reduction in caution among the older subjects during the triazolam
condition is not associated with any increase in the efficiency
of target detections. The low levels of false positive reports
for the loprazolam 0.5mg condition, however, _is associated with
a similarly low level of correct detections (particularly among
the older sub-group), suggesting a rather generalized suppression
of responding during this drug condition.
Card Sorting (movsnent times)
Both the two-, and eight-category movsnent times from the
card sorting task showed significant drug influences on
performance. For the two-category condition, the drug factor
interacted with the week and time factors, and for the eight-
category condition the drug factor interacted independently with
age, and with time (see Table 3:1). The movement time component
of the card sorting task has been interpreted as a measure of
motor speed and coordination (e.g. Malpas and Joyce, 1969).
Results from the two- and eight-category conditions will be
considered together.
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For the two-category condition Figure 3:5 shows few distinct
differences between the drug treatments. Relative to placebo,
movement times ware significantly slower following loprazolam
1.0mg at the 08.30 testing session on week 1 (Table 3:5). Table
3:5 also shows that, for the 16.30 testing sessions, sorting times
following loprazolam 0.5mg were significantly faster than placebo
in week 1, and significantly faster than loprazolam 1.0mg in
week 2. Again, considering the number of paired comparisons made,
the occurrence of significant t-values with a frequency no greater
than would be expected by chance alone cautions against over-
interpretation. Re-analysis of each time of testing separately
revealed no further significant main effects of, nor interaction
effects with the drug factor. It is interesting to note, however,
that both the 08.30 and 16.30 testing sessions showed significant
main effects of week, indicating strong practice effects (see
Appendix 2:5). The 12.30 testing sessions showed no significant
improvement over the three weekly test sessions.
For the eight-category sorting times, Figure 3:6 clearly
indicates the tendency (also seen in the manual dexterity test)
for the younger subjects to show greater improvements with
practice under placebo conditions. Indeed, the placebo treatment
mean for the older sub-group does not exceed the original
baseline mean movement time. While it might appear from the
figure that both loprazolam and triazolam improved performance in
the older sub-group, paired comparisons between these mean values
(Table 3:6a) showed no significant differences. Conversely,
Table 3:6a shows that, for the younger sub-group, triazolam 0.5mg
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was associated with significantly impaired performance relative
to placebo.
The significant interaction between drug condition and time
of testing for the eight-category movement times is shown in
Figure 3:7. It can be seen from the figure that the interaction
arises from the consistent decline in the speed of performance
between 08.30 and 16.30 shown for the placebo and loprazolam 1.0mg
conditions. It is not possible to conclude frctn these results
that any of the drug conditions exerted a systematic influence on
performance throughout the day. Paired comparisons between the
treatment means for each of these times of testing (Table 3:6)
show that for the 08.30 testing sessions, movement times for the
loprazolam 0.5mg condition were significantly slower than those
for placebo, or triazolam. At the 16.30 times of testing,
performance associated withg loprazolam 0.5mg was significantly
faster that for loprazolam 1.0mg. These few, and rather erratic,
significant differences might plausibly be attributed to randan
fluctuations in performance throughout the day.
Card Sorting (choice reaction time): two-category
By deducting movorient time from the actual time taken to
sort the playing cards into their appropriate categories, a
measure of central processing time is derived (Crossman, 1953).
This measurement, the choice reaction time, represents only the
time taken to process the information on 32 cards (i.e. to
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recognize the value, and decide upon the destination of 32 cards).
Thus, choice reaction time is independent of motor speed, and
relatively inrnune frcm somatic drug influences (e.g. drug-induced
reductions in muscle tone, etc.).
The significant drug x time of testing interaction for the
two-category choice reaction time is shown in Figure 3:8. Placebo
mean values show a clear superiority over the active drug
conditions, with a peak in speed at 08.30, an increase in reaction
time at 12.30, and some recovery of speed shown at 16.30. Such a
pattern is consistent with the circadian variations in performance
reported by Kleitman (1963) and Colquhoun (1971), the 12.30
results (see Figure 3:8) corresponding to the so called "post-
lunch dip" (Colquhoun, 1971) .
Table 3:7 shows that at the 08.30 times of testing, the mean
choice reaction time following loprazolam 1.0mg was signigicantly
slower than under placebo conditions. However, while Figure 3:8
suggests particularly poor performance under the triazolam
condition at 08.30, this effect is more apparent than real.
Triazolam scores did not differ from placebo at this time, a
finding that can be accounted for by wide scatter in the triazolam
data at this time. None of the paired comparisons showed
significant differences at 12.30, but triazolam reaction times
were significantly faster than both loprazolam 0.5mg and 1.0mg
at 16.30.
Given that the mean placebo condition reaction times show
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typical time of day variations, the drug x time interaction found
in this task is not particularly surprising. If performance is
impaired by residual drug effects in the early morning (in this
case, by loprazolam 1.0mg) some recovery in performance efficiency
would be expected as drug effects subside later in the day. That
reaction times following loprazolam recovered to placebo levels by
the 12.30 testing sessions suggests that, in this case, the
residual effects of a relatively short-life hypnotic did not
exacerbate normally-occurring troughs in early afternoon
performance.
Choice reaction time (four-category)
The significant drug x week x time x age interaction for the
four-category choice reaction times (Figures 3:9a, 3:9b, and 3:9c)
again illustrates differences in performance efficiency between
the two sub-groups. These differences show features similar to
the 4-way interaction frcm the auditory vigilance task. In
particular, under placebo conditions, the younger sub-group show a
tendency to improve over baseline levels of performance, while the
mean performance scores for the older sub-group rarely exceed the
baseline mean. None of the drug treatment versus placebo
treatment comparisons showed significant differences at the 08.30
times of testing (Table 3:8). At the 12.30 testing sessions,
choice reacton times for the younger sub-group under the
loprazolam 0.5mg and 1.0mg conditions are significantly slower
than under the placebo condition for both week 1 and week 2, while
for the 16.30 testing sessions, loprazolam 0.5mg scores differed
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significantly from placebo values in weeks 1 and 3. Within the
older sub-group, none of the active drug treatment versus placebo
comparisons yielded significant t-values (Table 3:8).
In general, then, loprazolam in both 1.0mg and 0.5mg doses
was associated with some degree of performance impairment,
particularly at the 12.30 times of testing, ard particularly among
the younger subjects. The analyses of variance for each separate
time of testing, however, do not support a view that loprazolam
1.0mg consistently impaired performance, or that loprazolam 0.5mg
differentially affected the two sub-groups. The main effect of
drug found for the 12.30 testing session was independent of both
week and age (Appendix 2:9). Table 3:9 shows that this main
effect is principally due to the loprazolam 0.5mg condition; none
of the other active drug conditions differed significantly from
placebo.
The pattern of impaired performance on choice reaction time
is raniniscent of the results obtained from final 40min of the
auditory vigilance task. It is particularly relevant to note
that, with regards the present test, the significantly lower
levels of performance associated with loprazolam 0.5mg are not
entirely confined to the 12.30 testing sessions, and can be found,
within the younger sub-group, at the 16.30 sessions (Figure
3:9c). Furthermore, among the younger subjects, the 0.5mg dose of
loprazolam was consistently associated with the lowest levels of
performance at all three times of testing, while among the older
subjects, this dose of loprazolam was associated with the lowest
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levels of performance for all three weeks at the 12.30 testing
sessions. It is unlikely, therefore, that these results reflect
randan variations in performance leading to spuriously significant
differences. This being the case, it is not unreasonable to
suggest that the effects of loprazolam 0.5mg on choice reaction
time, at a given level of task complexity, are mediated by
processes similar to those already proposed in relation to the
results from the auditory vigilance task (final 40min). That, in
the present case, this effect is more pronounced in the early
afternoon, a time associated with a decline in performance
efficiency, is suggestive of an interaction between residual drug
effects, ard circadian variations in performance.
Manual Dexterity
No significant main effect of drug was found in the principal
analysis of variance of the manual dexterity data (Table 3:1).
Again, however, interaction effects clearly indicate differences
between the four drug conditions, such differences depending upon
age, and the time and week of testing. For the placebo scores,
manual dexterity shows a marked time of day effect (Figure 3:10),
with performance declining sharply after the peak levels shown at
08.30 (drug x time interaction: p<0.05; Table 3:1). This early
morning peak appears to be modified by the active drug treatments,
resulting in fairly uniform levels of performance for each
time of day. For the 08.30 testing sessions, paired conparisons
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between the drug treatment means (Table 3:5) show that loprazolam
1.0mg, and triazolam 0.5mg are associated with significantly-
impaired performance relative to placebo (p<0.05 in both cases).
Thus, unlike the performance decrements seen for the more complex
vigilance task, simple motor coordination shows a more
conventional pattern of drug effects, the larger dose of
loprazolam, and triazolam 0.5mg impair performance, but only
during the early morning testing sessions.
The results from these paired comparisons should, however, be
interpreted with some caution. In the re-analysis of the 08.30
testing sessions using repeated measures analysis of variance
(Figure 3.11a), the drug main effect failed to reach the criterion
level of significance (F = 2.73; df = 3,30; p = 0.061). For this
time of testing, paired comparisons between treatment means within
the two sub-groups (Table 3:5b) show only sporadic treatment
versus treatment differences (older sub-group week 1: T v L0.5,
p<0.05; younger sub-group week 3: P v T, p<0.05).
For the 12.30 and 16.30 times of testing (Figures 3:11b and
3:11c) the apparent superiority of the placebo scores is maintained
only for the younger sub-group. Scores for the older sub-group
again show much greater variability. In general, performance on
this task was characterized by a marked tendency to improve between
week 1 and week 3, evidenced in the main analysis of variance by a
significant main effect of week (F = 9.50; df = 2,20; p<0.001; see
Appendix 2:11). The pattern of performance shown in Figures
3:11a, 3:11b, and 3:11c also suggests that the younger sub-group,
under placebo conditions, showed a greater tendency to improve
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over time. Once again, however, it is not possible to interpret
these improvenents as simple practice effects under each drug
condition.
At all times of testing, particularly for the younger sub¬
group, improvanent over weeks for placebo values might reasonably be
interpreted as a practice effect per se, with week 1 scores
being equivalent to, or exceeding, the original baseline mean.
This interpretation is not appropriate in the case of the active
drug condition scores. Active drug scores for week 1, especially
those for loprazolam 1.0mg and triazolam 0.5mg, are generally
below baseline, exceeding this value only in week 3. Thus, as was
the case for correct detections (final 40min) on the auditory
vigilance task, the pattern of results for the active drug
conditions shown in Figures 3:11a, 3:11b, and 3:11c is not
entirely consistent with a true practice effect, but rather, may
reflect a complex interaction between drug condition and
practice effects. That such an interaction appears to be more
pronounced in the younger subjects may be attributable to the
greater variability in performance shown by the older sub-group.
In conclusion, loprazolam 1.0mg and triazolam 0.5mg were
associated with performance decranents relative to placebo on the
manual dexterity test. This decrement was confined to the early
morning (08.30) testing sessions. There is no evidence of a
cumulative drug effect on performance.
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Summary of Results and Conclusions
In a multiple dose trial which allowed reasonable time for
the development of culmulative effects, short-life hypnotics of
the type used in the present experiment were not associated with
the profound performance decrements reported for longer acting
hypnotics like nitrazepam (e.g. Bond and Lader, 1972) or
flurazepam (e.g. Oswald et al. 1979). Nevertheless, the present
results do indicate that both triazolam and loprazolam, in
clinically recommended doses, can impair performance on a variety
of tasks. Overall, such impairment as there was did not emerge
as a general and easily recognized reduction in performance
efficiency, but emerged, rather, as a subtle and often complex
interaction with age, time of day, and week of testing. Drug
influences also appeared to be selective with regard to both the
dose used, ard the tasks affected. Impairment clearly associated
with loprazolam 1.0mg and triazolam 0.5mg was confined to the
manual dexterity task (08.30 testing sessions), ard the card-
sorting movement times (two- and eight-category). Both tasks are
primarily measures of motor speed, ard perceptual motor
coordination. In contrast, impairment associated with loprazolam
0.5mg is evident in those tasks requiring attention and
information processing skills (viz. auditory vigilance and choice
reaction time [four-category]).
Considered in functional terms, the higher dose of
loprazolam, ard triazolam 0.5mg were detrimental to performance
only on those tasks which showed a significant degree of
improvement over the three week experimental period. CP the other
hand, neither the auditory vigilance task, nor the choice reaction
time task, showed a significant main effect of week in the main
analyses of variance. Thus, the performance decrements seen on
seme of the motor tasks in the present experiment may have
occurred, not because of a deterioration in the level of
performance as such, but rather because the tendency to improve
with practice, or the effects of earlier pre-drug practice
sessions, was attenuated. The performance curves shown in Figure
3:11a for the manual dexterity task certainly accord with this
view.
Differences between the drug treatments, especially
differences between loprazolam l.Gfmg and triazolam 0.5mg (both
relatively high doses), are not particularly distinct in the
present study. One such effect, the progressive increase in false
positive reports associated with triazolam on the auditory
vigilance task for the older sub-group, will be discussed in the
next chapter.
The results will now be summarized in relation to the three
non-drug factors of particular interest in this experiment, i.e.
the duration of drug usage, the time of performance testing, and
the age of the subj ects.
Duration of drug usage
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Overall, the effects on performance of loprazolam 0.5mg and
1.0mg, and triazolam 0.5mg reported here are not consistent with
drug accumulation over the 16 day treatment periods. None of the
performance measures showed a progressive decrement over time,
and, in some cases, performance is actually shown to improve under
the active drug conditions, though at an apparently slower rate
than performance associated with placebo.
Time of day
None of the experimental treatments was associated with
sustained performance decrements throughout the day. With regards
the larger dose of loprazolam, and triazolam 0.5mg, the early
morning testing sessions appeared to be most sensitive to drug
effects. In this respect, the present results accord with those
previous acute studies which report an absence of drug impairment
10h after the ingestion of loprazolam 0.5mg, 1.0mg, and 2.0mg
(Hindmarch and Clyde, 1980) , and 16h after triazolam 0.5mg or
1.0mg (Veldkamp et al. 1974).
Three of the performance measures showed significant drug x
time interactions: card sorting movement times (eight-category);
choice reaction time (two-category); and manual dexterity. For
all three tasks, the performance curves (Figures 3:7, 3:8, and
3:10 respectively) show a peak in efficiency at the 08.30 testing
sessions, and a decline in performance efficiency at 12.30.
Considered in relation to "post-lunch" effects, it should be
remembered that the 12.30 testing sessions commenced at 12.30;
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all the above three tasks folloved the one hour auditory vigilance
task, and were conducted, therefore, between 13.30 and 14.30.
None of these interactions provides convincing evidence that any
of the experimental treatments significantly exacerbated normally
occurring "dips" in diurnal performance efficiency. Results from
the four-category choice reaction time task, however, clearly show
selective impairment for the loprazolam 0.5mg condition at the
12.30 testing session (Figure 3:9b). While, in context, this
single result appears to be an isolated finding, it nevertheless
does not allow the conclusion that the active drugs did not
interact with circadian variations in performance efficiency.
Age of subjects
The pervasive influence of age on the present results clearly
justifies the attention paid to this factor. Of the ten
significant interactions shown in Table 3:1, six include the age
factor. In general, the older subjects did not show a greater
sensitivity to the drug treatments. Any such differential
response to the active drugs, however, may have been masked by the
broad, and consistent, inter-group differences in the overall
pattern of performance. Under placebo conditions, mean scores for
the older sub-group tended to be lower, more labile, and less
likely to improve with practice, than those of the younger sub¬
group. Indeed, these characteristics in the performance of the
older sub-group suggest that, in many cases, these subjects were
not performing at peak levels throughout the experiment,
particularly in those tasks which loaded heavily on motor skills.
- 75 -
If this was the case, then such performance would be less likely
to show drug-induced decranents than would be the performance of
subjects working closer to the 'ceiling' of their abilities. This
would certainly explain vfay, on some of the tasks, (see, for
example, Figure 3:9a) performance in the younger sub-group appears
to be more consistently affected by the active drug treatments.
Nevertheless, in sane of the tasks showing impairment for both sub¬
groups (e.g. correct detections on auditory vigilance) there is a
clear tendency for the effect to be more profound in the older
subj ects.
Differences between the sub-groups are present in the false-
alarm data from the auditory vigilance task. While triazolam
decreased caution in the older subjects, this drug was associated
with an increase in caution among the younger subjects. This
result also represents one of the few differences observed between
the effects of loprazolam, and the effects of triazolam on
performance. In the older sub-group, false alarms associated
with loprazolam tended to decrease. As this difference between
the two drug conditions is also reflected in the daily subjective
ratings of anxiety, the drug and age differences present in the
false alarm data will be discussed in the next chapter. Suffice
it to point out now that the false alarm data does admit the
possibility of differential responses to short-life hypnotic drugs
between the early and late middle-aged.
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Any attempt to identify, or to interpret, the effects on
performance of sedative-hypnotic drugs must take into account
variables affecting the drug-performance relationship. On
theoretical grounds, drugs vAiich improve the sleep quality of
otherwise poor sleepers, but which are nevertheless devoid of
residual activity, may be expected actually to improve performance
by reducing sleepiness and fatigue. Motivational changes arising
from, for example, improved sleep quality, reduced daytime
fatigue, or reductions in daytime anxiety following the use of
sedative-hypnotic drugs, may all contribute to the resulting
pattern of measured performance. It is clear from previous
experiments, however, that the detrimental sedative effects of
potent long-acting hypnotics may supersede many of these possible
advantages, producing a generalized, and consistent, reduction in
performance efficiency which affects motor and cognitive tasks
alike (e.g. the results reported by Oswald et al. [1979] for
flurazepam). Results frcm the present experiment danonstrate
that this is not the case for either loprazolam or
triazolam. Behavioural advantages arising from the use of
hypnotic drugs compete with the behavioural disadvantages. Where
these disadvantages are clearly dominant (as with high-dose
flurazepam), the effects on performance appear relatively
straightforward. Where, however, residual daytime sedation is
not a dominant characteristic of a particular drug, then it is
reasonable to suppose that any disadvantage arising from its use,
(reductions in vigilance for example), is more likely to be
modified by appropriate changes in the individuals general
'motivation', leading in turn to a more complex pattern of effects
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on performance (as seen in the present study). This ability to
compensate for drug effects which appears to mediate several of
the results reported here does, however, represents a major




Experiment 1: Effects of triazolam and loprazolam on daily ratings
of mood and subjective feelings.
Throughout each of the experimental periods described in Chapter 2
(see Figure 2:1) subjects completed daily subjective ratings of
sleep quality, morning vigilance, concentration, and anxiety using
lOcrn line visual analogue scales. These rating forms are
reproduced in Appendix 3. Ttoo scales were completed in the
morning (Sleep Quality and Morning Vigilance) and twD in the
evening (Concentration and Anxiety) . Subjects were required to
make a mark on a 10cm line separating semantically opposed
statements. A mark in the centre of the line would indicate no
subjectively assessed change from normal. Daily ratings commenced
on the morning following the first capsules, and continued until
the morning following the last capsules for that period. Thus,
for each of the four subjectively rated variables, seven ratings
were completed during the placebo (baseline) week, 21 (3 x 7) were
completed during the drug/placebo treatment weeks, and seven were
completed during the withdrawal week by each subject.
Analysis of data
Rating forms were scored according to a method fully described
by Oswald (1980). Raw scores were calculated as the distance in mm
of each mark from the left-hand margin of the 10cm line. Each
subject's baseline week ratings were then averaged, and the standard
deviation for this period was calculated. Each subsequent daily
rating was then deducted from the baseline mean score, and then
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expressed as a percentage of the baseline standard deviation.
Thus, for the three drug treatments weeks, and for the withdrawal
week, rating scores were calculated as:
Baseline Week Mean Score - Subsequent Raw Score
X 100
Baseline Week Standard Deviation
Using these transformed scores, the mean ratings for each of
the three drug treatment weeks, and for the withdrawal week, were
computed for each subject. These data were then analyzed using
repeated measures analysis of variance with two trial factors, viz.
drug (placebo; loprazolam l.Omg; triazolam 0.5mg; and loprazolam
0.5mg) and week (week 1; week 2; week 3; and withdrawal), and one
grouping factor, viz. age (those above the median age at the start
of the experiment versus those below the median age at the start
of the experiment). The main effects of, and interaction effects
between these factors were computed. Where significant main
effects of the drug factor, or significant interaction effects
between the drug factor and the weeks factor were found, relevant
within factor means were compared using correlated t-tests.
Additional analyses of Anxiety Ratings
Throughout the course of the study, nine further subjects
participated in a separate, though similarly designed, sleep-
laboratory investigation of the three experimental treatments
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(loprazolam l.Omg and 0.5mg, and triazolam 0.5mg). Each of these
nine subjects completed daily ratings on visual analogue scales
identical to those used in the present experiment. Drug
treatments were taken for a period of three weeks, preceded by 14
nights, and followed by seven nights of placebo capsules. It was
therefore possible to process, and to combine, subjective rating
scores from the two experiments in a post-hoc analysis of data.
In a further analysis of the subjective ratings of anxiety, the
data were pooled from the two studies, and the effects of
loprazolam l.Omg and triazolam 0.5mg compared using a repeated
measure analysis of variance with two trial factors, viz. drug and
week, and one grouping factor, age. In order to maintain
comparability with previous analyses, the nine further subjects
were grouped above and below the median age of the 12 performance-
study subjects, (i.e. 52y). For the combined 21 subjects, this
grouping resulted in an older sub-group with n = 13, and a younger
sub-group with n = 9.
Results
Sleep Quality. Results from the analysis of variance of subjective
ratings of sleep quality are shown in Table 4:1. Ratings of sleep
quality showed no main effect of drug, but did show a highly
significant drug x week interaction effect (F = 5.28; df = 3,30;
p<0.001). The drug treatment means for each week are shown
graphically in Figure 4:1, and the results of paired comparisons
between drug treatments for each week are shown in Table 4:2.
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MEAN WEEKLY RATINGS OF SLEEP QUALITY
Figure 4:1 Effects of two hypnotics on subjective




















MEAN WEEKLY RATINGS OF VIGILANCE
Figure 4:2 Effects of two hypnotics on subjective
ratings of morning vigilance
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Table 4:2 Mean weekly subjective ratings of sleep quality paired
comparisons between drug treatments for each week
Week 1
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L0.1 (-132.21; 141.19) P ( -47.94; 107.65) 1.43
T (-128.11; 122.38) P ( -47.94; 107.65) 1.85
L0.5 (-140.02; 205.94) P ( -47.94; 107.65) 1.21
L1.0 (-132.21; 141.19) T (-128.11; 122.38) 0.09
LI. 0 (-132.21; 141.19) L0.5 (-140.02; 205.94) 0.14
T (-128.11; 122.38) L0.5 (-140.02; 205.94) 0.16
Week 2
LI. 0 (-191.72; 240.91) P (-125.39; 191.76) 0.68
T (-153.39; 190.35) P (-125.39; 191.76) 0.35
L0.5 (-139.64; 151.79) P (-125.39; 191.76) 0.18
L1.0 (-191.72; 240.91) T (-153.39; 190.35) 0.48
LI. 0 (-191.72; 240.91) L0.5 (-139.64; 151.79) 0.74
T (-153.39; 190.35) L0.5 (-139.64; 151.79) 0.17
Week 3
L1.0 (-209.75; 195.38) P (-180.97; 275.49) 0.34
T ( -90.92; 217.65) P (-180.97; 275.49) 0.97
L0.5 ( -86.89; 184.40) P (-180.97; 275.49) 0.85
LI. 0 (-209.75; 195.38) T ( -90.92; 217.65) 1.88
LI. 0 (-209.75; 195.38) L0.5 ( -86.89; 184.40) 2.01
T ( -90.92; 217.65) L0.5 ( -86.89; 184.40) 0.05
Withdrawal (x 2 nights)
LI. 0 ( 125.36; 150.24) P (-127.93; 345.02) 2.49*
T ( 79.49; 148.43) P (-127.93; 345.02) 2.41
L0.5 ( 49.64; 102.07) P (-127.93; 345.02) 1.63
L1.0 ( 125.36; 150.24) T ( 79.49; 148.43) 1.05
L1.0 ( 125.36; 150.24) L0.5 ( 49.64; 102.07) 1.12
T ( 79.49; 148.43) L0.5 ( 49.64; 102.07) 0.51
* p<0.05
** p<0.01
t-values are for t (correlated), df = 11
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Morning Vigilance. Results from the analysis of variance of
subjective ratings of morning vigilance are shown in Table 4:3.
Ratings of morning vigilance showed a significant main effect of
drug (F = 2.88; df = 3,30; p<0.05) which was independent of both
the week, and the age factors. The drug treatment means for each
week are shown graphically in Figure 4:2. The results from paired
comparisons of the overall drug treatment means are shown in Table
4:4a; the results from paired comparisons between the treatment
means for each week are shown in table 4:4b.
Concentration. Results from the analysis of variance of
subjective ratings of concentration are shown in Table 4:5.
Ratings of concentration showed no significant main effects of
drug, and no significant interaction effects between the drug and
week, or between the drug and age factors. The drug treatment
means are shown graphically in Figure 4:3.
Anxiety. Results from the analysis of variance of subjective
ratings of anxiety are shown in Table 4:6. Ratings of anxiety
showed a significant main effect of drug (F = 3.49; df = 3,30;
p<0.05) which was independent of both the week, and the age
factors. The drug treatment means for each week are shown
graphically in Figure 4:4, and the results of paired comparisons
between the overall drug treatment means are shown in Table 4:7a.
Results from paired comparisons between the treatment means for
each week are shown in Table 4:7b. It can be seen from Figure
4:4, and also from the paired comparisons shown in Table 4:7a,
that the most extreme changes from baseline mean ratings were
associated with triazolam 0.5mg, and loprazolam 1.0mg.
Interestingly, while subjectively rated anxiety appeared to
decrease during the loprazolam 1.0mg condition, triazolam 0.5mg
was associated with a mean increase. To further investigate this
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Table 4:3 Analysis of variance for subjective ratings of
morning vigilance
Source Degrees of Sum of Mean sum of F-ratio
freedcm squares squares
Age (A) 1 27028.72 27028.72 0.15
Error 10 1863352.43 186335.24
Drug (D) 3 1273817.39 424605.80 2.88*
D x A 3 394424.15 131474.72 0.89
Error 30 4423012.44 147433.75
Week (W) 3 88646.16 29548.72 0.75
W x A 3 75203.74 25067.91 0.64
Error 30 1182445.99 39414.87
D x W 9 172485.90 19165.10 0.75
D x W x A 9 384380.08 42708.90 1.68
Error 90 2291384.07 25459.82
* p<0.05
** p<0.01
Table 4:4a Subjective ratings of morning vigilance: paired comparisons
between the drug treatment means
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L0.1 (-197.99; 302.34) P ( -15.10; 122.77) 1.77
T (-122.93; 166.88) P ( -15.10; 122.77) 1.92
L0.5 ( 1.32; 134.61) P ( -15.10; 122.77) 0.25
LI. 0 (-197.99; 302.34) T (-122.93; 166.88) 0.82
LI. 0 (-197.99; 302.34) L0.5 ( 1-32; 134.61) 2.42*
T (-122.93; 166.88) L0.5 ( 1.32; 134.61) 2.19*
* p<0.05
** p<0.01
t-values are for t (correlated), df = 11
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Table 4;4b Mean weekly subjective ratings of morning vigilance:
paired comparisons between the drug treatments for each week
Week 1
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t value
LI. 0 (-239.26; 338.68) P ( -25.49 78.91) 2.15*
T (-115.19; 239.74) P ( -25.49 78.91) 1.20
L0.5 ( -1.15; 176.44) P ( -25.49 78.91) 0.43
LI. 0 (-239.26; 338.68) T (-115.19 239.74) 1.29
LI. 0 (-239.26; 338.68) L0.5 ( -1.15 176.44) 2.59*
T (-115.19; 239.74) L0.5 ( -1.15 176.44) 1.23
Week 2
L0.1 (-229.42; 465.18) P ( 25.65; 95.11) 1.74
T (-108.26; 254.01) P ( 25.65' 95.11) 1.91
L0.5 ( -14.79; 221.72) P ( 25.65; 95.11) 0.58
LI. 0 (-229.42; 465.18) T (-108.26; 254.01) 0.82
LI. 0 (-229.42; 465.18) L0.5 ( -14.79; 221.72) 1.69
T (-108.26; 254.01) L0.5 ( -14.79; 221.72) 1.23
Week 3
L1.0 (-230.02; 388.15) P ( -41.50; 235.25) 1.37
T (-176.26; 250.31) P ( -41.50; 235.25) 1.31
L0.5 ( 17.04; 190.19) P ( -41.50; 235.25) 0.50
L1.0 (-230.02; 388.15) T (-176.26; 250.31) 0.43
LI. 0 (-230.02; 388.15) L0.5 ( 17.04; 190.19) 2.12*
T (-176.26; 250.31) L0.5 ( 17.04; 190.19) 2.29*
Withdrawal (x 2 nights)
L1.0 -93.27; 140.45) P -19.06; 155.20) 1.07
T -92.02; 165.20) P ( -19.06; 155.20) 1.50
L0.5 4.22; 206.88) P -19.06; 155.20) 0.27
L1.0 -93.27; 140.45) T ( -92.02; 165.20) 0.02
L1.0 -93.27; 140.45) L0.5 4.22; 206.88) 1.47
T -92.02; 165.20) L0.5 ( 4.22; 206.88) 1.25
* p<0.05
** p<0.01
t-values are for t (correlated), df = 11
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MEAN WEEKLY RATINGS OF CONCENTRATION


















WEEK (w) OF STUDY
MEAN WEEKLY RATINGS OF ANXIETY
Figure 4:4 Effects of two hypnotics on subjective
ratings of anxiety
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Table 4.7a Subjective ratings of anxiety: paired comparisons between
the drug treatment means
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L1.0 (-86.93; 163.70) P ( -1.81; 93.91) 1.40
T ( 70.89; 165.90) P ( -1.81; 93.91) 1.21
L0.5 (-56.35; 94.55) P ( -1.81; 93.91) 1.15
LI. 0 (-86.93; 163.70) T ( 70.89; 165.90) 4.83**
L1.0 (-86.93; 163.70) L0.5 (-56.35; 94.55) 0.65
T ( 70.89; 165.90) L0.5 (-56.35; 94.55) 2.32*
* p<0.05
** p<0.01
values are for t (correlated), df = 11
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Table 4:7b Mean weekly subjective ratings of anxiety; paired
comparisons between the drug treatments for each week
Week 1
Drug Treatment (mean; SD) v Drug Treatment (mean; SD) t-value
L1.0 ( -77.76; 185.84) P ( 15.36 90.02) 1.70
T ( 20.22; 136.74) P ( 15.36 90.02) 0.10
L0.5 ( -51.80; 126.34) P ( 15.36 90.02) 1.52
L0.5 ( -77.76; 185.84) T ( 20.22 136.74) 1.74
LI. 0 ( -77.76; 185.84) L0.5 (-51.80 126.34) 0.43
T ( 20.22; 136.74) L0.5 (-51.80 126.34) 1.03
Week 2
L1.0 (-125.00 170.55) P (-17.45; 156.03) 1.36
T ( 35.20 140.00) P (-17.45; 156.03) 0.83
L0.5 ( -90.01 77.05) P (-17.45; 156.03) 1.31
L1.0 (-125.00 170.55) T ( 35.20; 140.00) 4.02**
LI. 0 (-125.00 170.55) L0.5 (-90.01; 77.05) 0.62
T ( 35.20 140.00) L0.5 (-90.01; 77.05) 2.54*
Week 3
L1.0 (-172.45; 278.81) P (-21.50; 129.64) 1.51
T ( 155.24; 368.03) P (-21.50; 129.64) 1.42
L0.5 ( -68.09; 225.87) P (-21.50; 129.64) 0.50
LI. 0 (-172.45; 278.81) T (155.24; 368.03) 3.87**
LI. 0 (-172.45; 278.81) L0.5 (-68.09; 225.87) 1.12
T ( 155.24; 368.03) L0.5 (-68.09; 225.87) 2.02
Withdrawal (x 2 nights)
LI. 0 ( 27.48; 109.08) P ( 16.33; 135.70) 0.22
T ( 72.89; 146.30) P ( 16.33; 135.70) 0.99
L0.5 ( -15.49; 187.17) P ( 16.33; 135.70) 0.45
LI.0 ( 27.48; 109.08) T ( 72.89; 146.30) 2.62*
LI. 0 ( 27.48; 109.08) L0.5 (--15.49; 187.17) 0.73
T ( 72.89; 146.30) L0.5 (--15.49; 187.19) 1.48
* p<0.05
** p<0.01
t-values are for t (correlated) , df = 11
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finding, anxiety ratings from the sleep laboratory study
(described above) were pooled with the present data, and the
effects of the two drug treatments were compared in a further
analysis. The results from this additional analysis of the
anxiety ratings are shown in Table 4:8. This analysis showed a
significant difference between the two drug treatments (F = 5.79;
df = 1,19; p<0.05), and also showed a significant drug x week
interaction effect (F = 3.81; df = 3,57; p<0.05). The drug
treatment means are shown graphically in Figure 4:5, and the
results of paired comparisons between the two drug treatments for
each week are shown in Table 4:9.
Discussion
Each subjectively rated variable will be considered in turn,
and then discussed in relation to the performance data reported in
the previous chapter.
Sleep Quality. For the three weeks of active drug
consumption, mean weekly subjective ratings of sleep quality
associated with triazolam 0.5mg, loprazolam l.Omg, and loprazolam
0.5irtg, showed no significant departure from placebo ratings (Table
4:2). Figure 4:1 shows a uniform tendency for subjects, on
average, to rate their sleep as improved, even during the placebo
condition. Mean scores for the withdrawal period, however,
clearly distinguish between active drug, and placebo conditions.
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Table 4:8 Analysis of variance for subjective ratings of anxiety.
Data combined from sleep (n = 9) and performance (n = 12) subjects.
Source Degrees of Sum of Mean sum of F-rati(
freedan squares squares
Age (A) 1 8324.14 8324.14 0.04
Error 19 4199323.09 221017.00
Drug (D) 1 1039997.13 1039997.13 5.79*
D x A 1 36368.25 36268.25 0.20
Error 19 3411539.76 179554.72
Week (W) 3 156767.68 52255.89 1.59
W x A 3 15007.49 5002.50 0.15
Error 1867885.33 32769.92
D x W 3 321081.26 107027.08 3.81*
D x W x A 3 9612.89 3204.30 0.11
Error 57 1599986.39 28069.94
* p<0.05
Table 4;9 Mean weekly subjective ratings of anxiety. Data combined
from sleep (n = 9) and performance (n = 12) subjects: paired comparisons
between loprazolam 1.0mg and triazolam 0.5mg
Week 1
Drug Treatment (mean; SD)
LI.0 ( -56.15; 147.09)
Week 2
LI.0 ( -76.21; 152.43) T ( 89.78; 249.59) 2.71*
Week 3
L1.0 (-103.69; 232.45) T (210.80; 474.08) 3.00**
Withdrawal (x 2 nights)
L1.0 ( 15.87; 110.61) T (117.29; 380.03) 1.14
* p<0.05
** p<0.01
t-values are for t (correlated), df = 20
v Drug Treatment (mean; SD) t-value
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Effects of triazolam 0.5mg and
loprazolam l.Omg on subjective
ratings of anxiety:
combined data from sleep study
(n = 9) and performance study
(n = 12)
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Withdrawal of both triazolam 0.5mg, and loprazolam l.Omg was
associated with significantly impaired sleep quality.
The tendency for subjects to rate their sleep as improved,
relative to baseline, during the placebo condition clearly
prevented significant differences emerging when active drug and
placebo means were compared. Subjectively rated improvements in
sleep quality have been reported by Hindmarch and Clyde (1980) for
loprazolam l.Omg, and by Roth et al. (1977) for triazolam 0.5mg.
Reeves (1977) also reports that triazolam 0.5mg significantly
improved subjective sleep quality over a 28 day period in a group
of elderly hospital outpatients. Placebo scores in the present
experiment, however, show no effect of withdrawal, while both
triazolam, and loprazolam l.Omg show withdrawal effects consistent
with rebound insomnia, and typical of effective hypnotics, e.g.
Allen and Oswald (1976); Oswald et al. (1979).
Morning Vigilance. While none of the active drug treatment
means differed significantly from placebo (Table 4:4), ratings of
morning vigilance during the triazolam and loprazolam l.Omg
conditions were significantly lower than those which obtained
during the loprazolam 0.5mg condition. Comparing the mean values
for each drug condition week-by-week (Table 4:4b), it can be seen
that loprazolam l.Omg was associated with reduced vigilance
relative to both loprazolam 0.5mg and placebo in week 1, while
week 3 comparisons again show significantly reduced vigilance for
loprazolam l.Omg and triazolam 0.5mg when compared with loprazolam
0.5mg. That the main drug effect shown in Table 4:3 is
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independent of the Weeks factor confirms the impression given in
Figure 4:2 of a sustained and consistent reduction in morning
vigilance for the triazolam and loprazolam l.Omg conditions
(relative to loprazolam 0.5mg) throughout the drug-taking period.
For the two-day withdrawal period, Figure 4:2 shows a tendency for
ratings to return to baseline values.
Anxiety. Relative to placebo, subjects experienced no significant
change in evening anxiety levels during the active drug
treatments. Nevertheless, as Figure 4:4 shows, while both doses
of loprazolam were associated with a mean decrease in anxiety,
triazolam was associated with a mean increase. These mean
differences between the loprazolam and triazolam conditions
reached significance for both the lower (0.5mg) and higher (l.Omg)
doses of loprazolam (Table 4:7a). Considered week-by-week, Table
4:7b also shows that significant differences between triazolam
and loprazolam l.Omg were sustained throughout the second and
third weeks of consumption, and after two nights following drug
withdrawal. Analysis of the data pooled from 21 subjects shows a
similar pattern of significant differences between these two
conditions, with triazolam consistently associated with
increased anxiety relative to loprazolam l.Omg during each week
of consumption, but not two days after drug withdrawal.
A mean reduction in subjectively assessed anxiety is not a
particularly surprising consequence of hypnotic drug usage.
Oswald (1980) has pointed out that hypnotic drugs are also anti-
anxiety drugs, and that drugs used to modify anxiety states may
also be used as hypnotics. Mean increases in anxiety, however,
are more usually encountered on withdrawal of such medication
after sustained usage (e.g. Allen and Oswald, 1976; Petursson and
Lader, 1981). It would be parsimonious, therefore, to suggest
that the relative increase in anxiety associated with triazolam in
the present study is related to the withdrawal process.
The time-course of rebound phenomena associated with sedative-
hypnotic drug withdrawal (e.g. insomnia, feelings of anxiety)
appears to be closely related to the elimination half-life of the
drug concerned. Allen and Oswald (1976) report that, in a group
of six middle-aged subjects who had been taking fosazepam 60mg
nightly for three weeks, visual analogue ratings of anxiety rose
to a peak 3-4 days after withdrawal. The withdrawal profile
reported by Petursson and Lader (1981) for 16 chronic
benzodiazepine users (most of whom had been taking diazepam for
more than one year) shows that peak anxiety, as measured by the
Hamilton Rating Scale, occurred between 4 and 7 days. While both
drugs produce the active metabolite N-desmethyldiazepam, diazepam
remains active for up to 28h longer than fosazepam. Triazolam, on
the other hand, is both short acting, and devoid of known active
metabolic products. It is reasonable to conclude, therefore, that
the rapid metabolism of triazolam 0.5mg lead, in the present
experiment, to daytime rebound anxiety relative to the more
characteristic reduction in anxiety associated with the longer
acting loprazolam. Such a conclusion is consonant with clinical
observations associating anxiety states with chronic usage of high
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dose triazolam (van der Kroef, 1979).
Conclusions
In relation to the performance data considered in the
previous chapter, it is clear that visual analogue ratings, while
efficient at detecting drug-induced changes in mood and subjective
feelings, are less efficient at predicting the effects of drug
usage on performance. Unlike many of the performance tests, none
of the subjective variables distinguished between the age sub¬
groups. It is relevant to note here that Castleden et al. (1977)
found a similar insensitivity in subjective ratings. These
authors report that, while performance measures differed
significantly between old and young subjects following a single
dose of nitrazepam lOmg, subjective ratings of sleep quality,
daytime alertness, and side effects did not. Conversely, the
effects of drug withdrawal in the present study, while absent fran
the performance data, are clearly visible in the ratings of sleep
quality and morning vigilance; the significant reduction in sleep
quality associated with the withdrawal of loprazolam l.Omg and
triazolam 0.5mg, for example, were not associated with measurable
effects on objective measures of performance.
While the subjective ratings used in the present experiment
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did not predict the outcome of objective performance tests, they
do provide an important aid to the interpretation of performance
test data. This is, perhaps, best illustrated by the
relationship, already discussed, between objective and subjective
measures of daytime vigilance. The subjective ratings of anxiety
might similarly clarify the (rather isolated) differences
betweeen triazolam and loprazolam seen in the performance
results. On the auditory vigilance task, for example, the older
sub-group made significantly more false positive reports during
the triazolam condition than during the loprazolam 0.5mg
condition, at the 16.30 testing session on week three (see Table
3:4). If relative increases in anxiety occurred as a daytime
rebound phenomenon, then it is likely that the evening (16.30)
testing sessions would have been most sensitive to these changes
in mood and motivation. Figures 3:4a, 3:4b, and 3:4c show that,
for the older sub-group, while false reports increased under
triazolam at all times of testing on week three, the greatest
increase occurred in the evening. The differential effects of
triazolam and loprazolam on subjective feelings of anxiety,
therefore, may have contributed to the significant drug x week x




Increased susceptibility to the adverse behavioural consequences
of hypnotic drug use in the elderly: A review of the clinical,
epidemiological and experimental literature.
The experimental data presented in the previous two chapters
showed little evidence of differential drug effects on performance
between early and late middle-aged subjects. Evidence that the
elderly (defined here as the age group 65y+) are more susceptible
to the adverse behavioural effects of hypnotic drugs canes from a
variety of sources, which include clinical observations,
epidemiological surveys, and laboratory investigations. The
present chapter examines this evidence and, in particular,
focusses upon: 1) the testing strategies used to assess post
hypnotic performance deficits in older subjects; and 2) relevant
factors which appear greatly to affect the drug-performance
relationship in the elderly. The latter part of this review
provides the rationale for Experiment 2 (Chapter 8) and has two
specific objectives. First, to identify aspects, and parameters,
of performance in the elderly most consistently reported to be
affected by hypnotic drugs. And second, to consider, with regard
to the present literature, appropriate testing procedures to
detect post-hypnotic performance decrements in the elderly. In
many of the experimental studies considered, both pharmacokinetic
and objective performance data have been reported. Greater
emphasis will be placed here on performance data. Reviews of the
pharmacokinetics in the elderly of psychotropic drugs in general,
and hypnotic drugs in particular, have been compiled by Hicks et
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al. (1981) and Swift (1982) respectively.
Clinical Observations
Over the last decade both clinical observations and
experimental studies have identified behavioural problems arising
from hypnotic drug usage which appear to be specific to the
elderly. Evans and Jarvis (1972) report a confusional state in
elderly patients associated with the chronic use of nitrazepam.
This syndrome, which diminished rapidly on withdrawal of the drug,
presented a clinical profile similar to dementia. Similar pseudo-
dementias have been attributed to long term bromide and
barbiturate use in the elderly (Rudd, 1972), with equally rapid
reversal of symptoms on withdrawal.
Further evidence of benzodiazepine toxicity specific to the
elderly is provided by information frcm the Boston Collaborative
Drug Surveillance Program (BCDSP), an extensive, multi-national
survey of hospital admissions sampled from 1969 onwards. Reports
originating from this source show the frequency, and the severity,
of residual "central nervous system depression" (i.e. clinically
assessed drowsiness, ataxia, and hangover) to be consistently and
significantly greater in the age group 70y+ following diazepam
(BCDSP, 1973), chlordiazepoxide (BCDSP, 1973), flurazepam
(Greenblatt, Allen and Shader, 1977) , and nitrazepam (Greenblatt
and Allen, 1978). As regards nitrazepam and flurazepam, the
probability of drug-age interactions were reported to increase
with the dose of the drug (Greenblatt, Allen and Shader, 1977;
Greenblatt and Allen, 1978).
- 101 -
Controlled clinical evaluations of hypnotic drug effects also
emphasize the susceptibility of elderly hospital inpatients to
adverse behavioural reactions, particularly in those individuals
with pre-existing mental impairment. Harenko (1975) compared the
hypnotic efficacy of chlormethiazole 500mg and nitrazepam lOmg in
68 demented psychogeriatric patients (mean age = 77y). Only 44
patients completed the seven-day crossover study. Of the
remaining 24, 16 discontinued because of "severe 'hang-over'
effects" (mostly associated with nitrazepam), and in a further
five patients who did complete the study, observers reported a
"worsening of the patients' mental condition" (associated
exclusively with nitrazepam). Similar drug comparisons in
psychogeriatric populations have reported equally profound
behavioural disturbances. Linnoila and Viukari (1976), comparing
14 consecutive nightly doses of nitrazepam lOmg and thioridazine
25mg in a crossover study with 20 such patients report that
"ability to move declined drastically in 8 patients, and slightly
in 2 during the nitrazepam condition". General "ability to
conduct daily activities" was also reported to be impaired in 9
patients during the nitrazepam condition, compared with only 3
following thioridazine. The authors concluded that nitrazepam
should "probably be avoided in the treatment of psychogeriatric
patients". Elderly hypnotic users in the community have received
relatively less clinical attention, and evidence of drug-
associated behavioural impairment in this population is largely
indirect. Macdonald and Macdonald (1977a), for example, report
that, of 390 patients admitted to a geriatric-orthopaedic unit
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following nocturnal femoral fractures (due to falls), over 90%
were receiving barbiturate hypnotics at the time of the accident.
A significant proportion of these barbiturate users were
subsequently described as having "a clinically important degree of
mental confusion" (Macdonald and Macdonald, 1977b). In a survey
of 1998 patients consecutively admitted to geriatric medical
units, Williamson and Chopin (1980) list adverse reactions to
"hypnotics, sedatives, and anticonvulsants" as the main factor
contributing to admission in a minority of cases.
These clinical, and controlled, observations indicate that
hypnotic drugs can produce behavioural deficits in the elderly
which are not apparent, or do not occur, in younger age groups.
Considerably less emphasis, however, has been placed on
systematically evaluating these deficits. Controlled clinical
trials of hypnotic drugs using elderly hospital patients have
relied heavily on nurse ratings of both hypnotic efficacy, and
residual sedation. While nurse ratings of sleep variables (e.g.
onset latency, duration, continuity, etc.) are known to be
extremely unreliable in some patients (Kupfer et al. 1970; Weiss
et al. 1973), subjective evaluations of 'hangover effects' have
produced conflicting results. Pathy (1975), for example, compared
the hypnotic efficacy and residual effects of chlormethiazole
(base) 384mg, dichloralphenazone 1.3G, and placebo nightly for
seven night in 38 geriatric patients. Nurse ratings showed no
significant residual effects during either of the active
treatments. Middleton (1978), on the other hand, comparing
chlormethiazole (edisylate) 500mg with temazepam 10-20mg, reports
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both drugs, but particularly chlormethiazole, to be associated
with early morning drowsiness and increasing confusion over a
seven day period, in a group of 56 medical geriatric patients.
Again, these conclusions were based on nurse ratings. This
apparent unreliability in subjective methods of quantifying the
effects of the same hypnotic drug (in this case, chlormethiazole)
emphasizes the need for, and the value of, objective measures of
performance efficiency.
In a recently reported study, Murphy et al. (1982) combined
nurse ratings and objective performance measures in a repeated
dose study of nitrazepam and triazolam. In this trial, the
effects of five consecutive nightly doses of nitrazepam 2.5mg, and
triazolam 0.125mg were assessed in 16 geriatric inpatients. A
between groups design was used (n = 8/group), and subjects were
tested on four occasions: pre-drug (baseline); after one dose;
after five consecutive doses; and post drug. No placebo control
was included. Performance was assessed on a card sorting task
(similar to that described in Chapter 2). The authors concluded
that nitrazepam, but not triazolam, significantly impaired
processing time on the morning following the fifth dose. This
conclusion is supported only by paired comparisons, made within
each group, between pre-drug and fifth drug-dose test scores
(neither the test used, nor the statistic derived is reported).
It i£ evident from the data provided in this report, however,
that the mean baseline processing time for the triazolam group
(19.5sec) was almost twice that of the nitrazepam group (10.5sec).
The discrepancy between these scores considerably reduces the
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probability of baseline versus drug-score comparisons achieving
significance for the triazolam group. With regard to Philips'
(1977) observations (described below), the conclusions of Murphy
et al. (1982) would have been more appropriately supported by the
demonstration of a significant Group (nitrazepam/triazolam) by
Occasions (pre-drug/dose 1/dose 5) interaction following a
repeated measures analysis of variance.
Experimental Performance Studies
Few studies have attempted objectively to measure performance
in the non-hospitalized elderly, and few of these have compared
the post-drug performance of elderly and young subjects. Studies
which have reported objective performance measurement and age
group comparisons will be considered in some detail. In a single
dose study, Castleden et al. (1977) compared the performance of
healthy elderly (mean age = 74.7y) and young adult (mean age =
23.3y) subjects on a simple letter cancellation task following
nitrazepam lOmg and placebo. Elderly subjects made significantly
more errors on the test than did the young up to 36h after drug
administration. Motor performance, however, as judged by time-on-
task, and subjective ratings of alertness, as measured by 10cm
visual analogue scales, were reported to be similarly impaired in
both groups. The plasma elimination half-life of nitrazepam also
showed no significant difference between the groups (mean half-
lives: elderly group = 32.5h; young group = 32.Oh). These authors
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concluded, therefore, that their data indicate a pharmacodynamic
interaction between nitrazepam and the ageing brain.
A similar conclusion is reported by Swift et al. (1980). In
this study, the performance of nine healthy elderly (age range =
68-79y) and young adult (age range = 20-27y) subjects was
compared 0.5, 2, 4, and 11 hours after a single morning dose
of temazepam 20mg. Performance indices included critical flicker
fusion threshold (CFFT), choice reaction time (CRT), and postural
sway (as measured by Wright's ataxiameter). Relative to the
younger group, older subjects were reported to be significantly
more impaired on the sway test, CFFT, and CRT measures up to 6h,
llh, and 0.5h respectively following temazepam. In a similarly
designed study, and using the same objective measurements of
performance, Hockings et al. (1982) compared the effects of
dichloralphenazone 1.3G, and chlormethiazole 384mg (base) in
groups of 10 healthy elderly (mean age = 72.Oy), and 10 healthy
young (mean age = 23.Oy) subjects. Following chlormethiazole,
older subjects were reported to be relatively more impaired than
the young on tests of postural sway, CRT, and CFFT 2.Oh after
ingestion. Dichloralphenazone increased postural sway in the
elderly group 0.5h after ingestion, but had no other significant
effect on measured performance. Neither drug was associated with
residual effects after 4h. The authors concluded that
chlormethiazole 384mg shows an "accentuated, immediate response"
in the elderly relative to younger individuals.
In connection with Castleden et al.'s (1977), Swift et al.'s
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(1980), and Hockings et al.'s (1982) conclusions, it is relevant
to note actuarial considerations concerning group x treatment
interactions. Philips (1977) argues that where two experimental
groups (e.g. old/young) are subjected to two treatment conditions
(e.g. drug/placebo), the conclusion that a given treatment affects
one group relatively, and significantly, more than it does the
other demands the demonstration of a statistically significant F-
ratio for the treatment x group interaction. It is not an
adequate basis for concluding such an interaction if significant
differences from baseline are observed independently in one group,
but not in the other. Neither Castleden et al. (1977), nor Swift
et al. (1980) report significant drug x age interaction effects.
Indeed, in neither study are analysis of variance data reported at
all. In both cases, then, the conclusion of a drug x age
interaction is not adequately supported.
While subjective assessments of post-drug behavioural
efficiency may be unreliable, studies employing objective
performance measures, such as those just considered, have also
reported equivocal results. Briggs et al. (1980) examined the
effects of temazepam 20mg, chlormethiazole 384mg, and placebo in
10 old (mean age = 72.9y) and 10 young (mean age = 24.7y) healthy
female volunteers. Performance was assessed 4h and llh after a
single night-time dose of each treatment using subjective ratings,
a measure of postural sway (using an ataxiameter), and a letter
cancellation task (similar to that used by Castleden et al.
(1977], but timed over a two minute period). No significant
differences were found between the groups on subjective estimates
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of sedation, postural sway, or psychomotor performance (as
measured by the cancellation task). The authors concluded,
therefore, that neither drug causes "...detectable hangover
effects", a conclusion at odds with the findings of Swift et al.
(1980) for an identical drug regime (single dose temazepam 20mg),
and an identical measurement (postural sway).
Two possible factors, either alone, or in combination, may
have contributed to these conflicting results. The first of these
factors is specific to the design of Briggs et al.'s (1980)
study, and the second concerns subject-variables pertinent to the
testing of elderly individuals. First, for each treatment
condition in Briggs et al.'s study, measures of performance,
postural sway, and subjective state were obtained at 02.00, and
09.00 (i.e. 4h and llh) after administration. Thus, placebo
scores, against which both active drug treatments were compared,
may have confounded with the effects of disturbed sleep, and may
not have represented true baseline values. It is reasonable to
suggest that, if placebo scores were depressed as a result of
sleep disturbance, differences between drug and placebo conditions
might have been diminished.
The second factor concerns possible differences in the
characteristics of the elderly groups used by Briggs et al.
(1980) and by Swift et al. (1980). Hicks (1981) , reviewing the
pharmacokinetics of psychotropic drugs in the elderly comments
"...the ageing process varies from individual to individual, and
from one organ system to another within the same individual.
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Therefore, the concept of the 'geriatric' individual as a
homogeneous entity, demarcated by some age-related cutoff line, is
simplistic". Age alone, then, is not necessarily the only, or
even the best, predictor of increased sensitivity to hypnotics in
elderly individuals. Two further parameters which predict
sensitivity are implicated in the current literature, viz. sex,
and health status. Before considering these factors in detail, it
is relevant to note here that Briggs et al.'s subjects were all
female and "were apparently in good health", while Swift et al.
used a mixed group, the health status of which was not reported.
Individual Differences
Sex differences in hypnotic drug effects on performance in
the elderly have been reported by Salem et al. (1982). In this
study, single doses of nitrazepam lOmg, or temazepam 20mg were
administered, according to a crossover design, to 18 elderly
individuals (nine males and nine females) whose ages ranged from
62-72y. Performance, as measured by two flash fusion threshold,
simple reaction time, digital copying, a symbol digit modalities
test, and the Gibson spiral maze, was assessed at 1, 2, 3, 4, 7, 9
and llh after administration. The elimination half-lives of both
drugs were also assessed. The results showed that the detrimental
effects of nitrazepam (mean half-life: males = 43.2h; females =
32.9h) were greater in both magnitude and duration than those
associated with temazepam. Within the nitrazepam condition,
however, impairment on simple reaction time, digit copying, and
the Gibson spiral maze (time and errors) persisted longer in
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females, even though the estimated mean elimination half-life of
nitrazepam was over lOh longer in males. Only one test, symbol
digit modalities, showed a more persistent effect of nitrazepam in
males than in females. The authors concluded, therefore, that sex
differences in performance "cannot be explained by
pharmacokinetics". These apparent sex differences in drug
sensitivity may, however, simply reflect further, and, in terms of
drug effects, influential differences between older males and
females rather than sex per se (e.g. sex differences in physical
health status, body weight, or competitiveness, etc.).
Nevertheless, the sex of subjects remains a relevant
consideration.
The influence of health status on drug-performance
relationships in the elderly has not been specifically evaluated.
Several reports, however, have identified aspects of general
health status which appear to increase sensitivity to hypnotic
drugs. Evans and Jarvis (1972), for example, refer to the
" 'unmasking' of old cerebral damage" by repeated doses of
nitrazepam (in the case study described by these authors, the
'unmasked' symptoms included hemiparesis and disorientation, both
of which subsided on withdrawal of the drug). Similar
observations have emerged from controlled clinical trials.
Viukari et al. (1978) compared the effects of flurazepam 15mg,
nitrazepam 5mg, and fosazepam 60mg on the daytime performance of
17 psychogeriatric inpatients. A balanced crossover design was
used, and performance was measured on tests of memory, handgrip,
and tapping speed. None of the treatments significantly affected
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memory or handgrip strength in most patients, and only fosazepam
and nitrazepam significantly reduced tapping speed (these results
will be considered in greater detail later). However, two
patients "with evident cerebrovascular disease" were profoundly
affected by all three drugs, particularly on the memory tasks.
Specific examples of interactions between hypnotics and
physical health status are reported in the clinical literature.
The tendency for some hypnotics to exacerbate existing respiratory
diseases has been reported by Clark et al. (1971), who describe
three patients whose respiratory failure worsened following
nitrazepam 5mg (1 case) and lOmg (2 cases). In a controlled
double-blind trial Gaddie et al. (1972) report that nitrazepam
10mg reduced the ventilatory capacity of six patients with
obstructive chronic bronchitis; forced vital capacity, and forced
expiratory volume/second were significantly reduced 2h after drug
administration. This study also reported a tendency for arterial
oxygen tension to fall, and for hypercapnia to increase, after
nitrazepam. Impairment of effective cerebral oxygenation has far
reaching implications for the mental competence of elderly
individuals who, by virtue of ageing alone, appear to show
increased sensitivitiy to this particular drug (q.v. Castleden et
al. 1977).
[It is interesting to note that these studies showing the
interaction of hypnotic drugs with physical disease processes
admit the possibility that, in some elderly individuals, hypnotic
drugs may affect behavioural efficiency only indirectly. A
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further example concerns exercise. Early morning sedation, and
concomitant reductions in arousal, may tend to encourage periods
of decreased motor activity or, at worst, lethargy. It has been
demonstrated that physical fitness in the elderly, as measured by
activity levels (Spirduso, 1975; Spirduso and Clifford, 1978), or
by predicted V02 max (Tredway, 1978), correl ates positively and
significantly with the efficiency of psychomotor performance. An
hypnotic which affects activity level and, by inference, general
fitness, may also indirectly affect performance; see Spirduso
(1980) for review.]
Clearly, between-subject differences in older age groups can
contribute substantially to variable and heterogenous experimental
results. The need for replicable, clinically relevant
experimental data, therefore, requires that particular care is
taken in the selection of elderly experimental subjects. Few
studies employ objective selection criteria. Of the four
experimental studies involving non-hospitalized subjects so far
considered (Castleden et al. 1977; Briggs et al. 1980; Swift et
al. 1982; and Salem et al. 1982) none employed objective
assessments of cognitive status as selection criteria for
subjects.
Testing strategies for assessing drug effects in the elderly
From the clinical observations reported above, it is
plausible to suggest a spectrum of behavioural decrements in the
elderly arising from hypnotic drug use, and ranging in severity
from mild residual sedation (e.g. Greenblatt and Allen, 1978), to
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gross pseudo-dementia (e.g. Evans and Jarvis, 1972) . Existing
mental or physical impair ment appears to increase vulnerability.
This clinical profile suggests that the effects of hypnotic drugs
interact with existing age-dependent reductions in behavioural
efficiency and amplify the effects of abnormal - and possibly
normal - ageing processes. It should be remembered, however, that
much of this evidence is derived from hospitalized
populations, and, with particular regard to the more severe
behavioural deficits, does not necessarily generalize to healthy
elderly populations. [Differences in the rate of clearance and
the volume distribution of hypnotic drugs have been reported
between healthy, and non-healthy elderly individuals. While
Castleden et al. (1977) found no significant pharmacokinetic
differences between healthy elderly and young subjects following
nitrazepam lOmg, Iisalo et al. (1977), comparing sick elderly and
healthy young subjects, report significant differences in the mean
half-life (old = 40.4h; young = 28.9h) and the volume distribution
(old = 4.8 1/kg; young = 2.4 1/kg) of single-dose nitrazepam 5mg.]
Experimental studies which have reported post-drug performance
decrements in the elderly will now be considered in greater
detail, with the intention of identifying parameters of
performance likely to be influenced by hypnotics in this age
group.
Most of the experimental interest in post-hypnotic
performance in the elderly has been concerned only with the
presence or absence of decrements and, in the event, little
attention has focussed on the aspects of psychological functioning
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actually impaired. Such an approach is reflected in both the
detail, and the emphasis of reported results, which, in general,
emphasise characteristics of the drugs used, rather than those
of the performance measured. Consequently, although there are
comparatively few experimental studies concerning hypnotic drug
effects on performance in the elderly, the wide variety of test
procedures used makes direct comparisons between these studies
problematical. An indirect approach to comparing these studies is
shown in Table 5:1. A common feature of many of the tasks used is
that the dependent variable measured reflects the speed, or the
accuracy, of performance. Table 5:1 shows the residual effects of
a variety of hypnotic drugs on these parameters of performance in
the elderly. As several studies included testing sessions shortly
after the administration of drug (i.e. the assessment of acute
effects) "residual" effects are defined here as performance
decrements measured not less than six hours after drug
administration.
Speed appears to be the most consistently measured, and the
most consistently impaired, parameter of performance. Simple
tapping speed, as measured by the frequency of taps/min with the
palm of the preferred hand, was consistently impaired in
psychogeriatric patients following seven consecutive doses of
nitrazepam lOmg (Linnoila and Viukari, 1976) and 5mg (Viukari et
al, 1978), and fosazepam 60mg (Viukari et al. 1978). Thus, it
appears that, at least in mildly demented individuals, these drugs
can affect the efficient execution of repetitive motor
responses which are largely independent of information processing,
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Table 5:1 Residual effects of hypnotic drugs on the speed and
accuracy of performance in the elderly
Results
Study Test Drug speed accuracy
Linnoila & Viukari tapping N 10mg impaired -
(1976)p speed Th 25mg n.s. —
Castleden et al. letter N lOmg impaired impaired
(1977)h cancellation
Viukari et al. tapping N 5mg impaired -
(1978)p speed Fl 15mg n.s. -
Fo 60mg impaired —
Swift et al. choice re¬ T 20mg n.s. —
(1980)h action time
Briggs et al. letter Ch 384mg - n.s.
(1980)h cancellation T 20mg — n.s.
Salem et al. Gibson N lOmg:





simple re¬ N lOmg





Murphy et al. information Tr
(1982)g processing 0.125mg n.s. -
time N 2.5mg impaired —
Hockings et al. choice re¬ Dp 1.3G n.s. —
(1982)h action time Ch 384mg n.s. —
Cook et al.** letter T 20mg impaired n.s.
(1983)g cancellation N 5mg impaired n.s.
choice re¬ T 20mg impaired -
action time N 5mg impaired -
N (nitrazepam); Th (thioridazine); F1 (flurazepam); Dp (dichloral-
phenazone); Fo (fosazepam); T (temazepam); Ch (chlormethiazole);
Tr (triazolam).
g = geriatric patients; p = psychogeriatric patients;
h = healthy elderly subjects
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or decision making, skills. Speed of performance which is
dependent upon these skills (as in simple and choice reaction
time tasks) has also been shown to be impaired in healthy elderly
subjects, but not in young adult subjects, following single dose
temazepam 20mg (Salem et al. 1982). Impairment of simple reaction
time in healthy elderly subjects following nitrazepam lOmg is also
reported by Salem et al. (1982).
Where speed and accuracy of performance have been measured
from the same task, the results are less straightforward. In such
tasks (e.g. the Gibson spiral maze; Castleden et al.'s [1977]
letter cancellation test), efficient performance demands a "trade¬
off" between speed and accuracy, i.e. careful progress, though
resulting in lower error scores, increases the time taken to
complete the task, while faster performance increases the
likelihood of errors. Instructed to work as quickly, and as
accurately as possible, subjects select their own criterion of
optimal performance. Castleden et al. (1977) required subjects to
delete all the letter "e"s from a fixed-length page of prose. The
number of non-"e"s deleted represented the error score. Healthy
elderly subjects took significantly longer to complete the test,
and made significantly more errors, 12 and 36h after nitrazepam
lOmg, than they did 12 and 36h after placebo. Younger subjects,
however, although taking significantly longer to complete the test
after drug, did not make significantly more errors relative to
their own baseline performance (as already mentioned above, the
implicit assumption of a statistically significant drug-age
interaction is not explicitly reported in this paper). Under the
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drug condition, then, it would appear that younger subjects
maintained previous levels of accuracy by reducing speed, whereas
the older subjects failed to compensate for reduced accuracy
despite significantly slower performance. Castleden et al.
(1977) interpret these results as evidence for a central
interaction between nitrazepam and the ageing brain. Certain
aspects of this interpretation, however, may not be entirely
justified.
Castleden et al. (1977) base their conclusion of a central
interaction between nitrazepam and the ageing brain on the
assumption that motor performance and cognitive efficiency were
independently measured by the letter cancellation procedure.
This, in turn, comprises two further assumptions: 1) that the data
derived from the test reflect two discrete and independent
processes which; 2) vary independently accross age ranges. While
the first of these assumptions may be valid for younger age
groups, it is unlikely to be valid for the elderly. Evidence from
studies concerned with the speed of performance in the elderly
suggest that, in older subjects, unlike their younger
counterparts, central processing ability (or cognitive
efficiency) and motor speed are intimately linked, and cannot be
considered as independently varying. Birren (1965), reviewing
such studies, comments "Young people tend to add and write at
independent speeds whereas older people are jointly slow in both
tasks...the correlation between writing and addition speeds
indicates that one may not assume independence of output time
(writing) and association time (addition) in the ageing as in the
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young. These times grow interdependent with the age of the
subject". Contrary to Castleden et al.'s (1977) assumptions,
therefore, it would appear that speed of performance in the
elderly may vary as a function of either the "central" or the
"motor" effects of hypnotic drugs. Castlden et al.'s conclusion
also makes a further assumption: that the psychological processes
mediating performance on a given task are the same in the old and
the young, and that, between age groups, these processes are
equally robust. If, however, the elderly employ different, and
perhaps more vulnerable cognitive strategies than the young, then
these behavioural differences might also contribute to any
apparent differential sensitivity to drug effects. Some relevant
characteristics of performance in the elderly will briefly be
considered.
Reduced speed of responses characterizes performance in the
elderly. This reduction in speed is mediated by both physical and
psychological factors. Among the psychological changes which
contribute to slower performance in the elderly, Welford (1980)
emphasises the tendency for older subjects to monitor their own
responses in continuous performance tasks. Given a series of
signals and appropriate responses (e.g. letter "e"s and their
deletion) attention paid to the previous response will detract
from that required to recognize the next signal. Thus, both the
previous response and the subsequent signal compete for attention
in older subjects, increasing the time taken to complete the task
relative to younger individuals. This tendency for older adults
closely to monitor their own movements during a response, to the
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exclusion of immediate attention to new signals, has been reported
in several experiments (e.g. Rabbit and Rogers, 1965; Rabbit and
Birren, 1967). Speed of performance in the elderly, then, is
determined not only by reduced efficiency in effector organs, but
also by the cognitive strategy employed during a given task.
The efficient monitoring of performance also plays an
important role in the trade-off between speed and accuracy.
Achieving an optimal compromise between these two parameters
requires sensitivity to, and efficient use of continuous feedback
from test performance (Fitts and Posner, 1973). For example, a
percieved increase in errors will influence the degree of caution
exercised by the subject, resulting in a compensatory reduction of
speed. Thus, the the efficiency of the subject's judgement
during the task will greatly determine that individulal's
efficiency on the task. It is particularly interesting to note,
therefore, that Salem et al. (1982) report that, in their male
subjects, nitrazepam lOmg significantly impaired accuracy, but not
speed, on the Gibson spiral maze. This finding suggests the
possibility that, at least in some elderly individuals, the
efficient monitoring of performance, as suggested by the absence
of compensatory speed reductions, may be impaired by hypnotic
drugs. Both the recognition, and the appropriate use made of
feedback cues from performance involve many different processes,
including sensory perception, proprioception, and motivation.
Impairment of each, or all, of these processes by hypnotics may
result in poorly monitored, less accurate, performance which,
nevertheless, continues at the same, or similar, speed. This
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consideration is not without ecological validity. Such
impairment would have implications for the ability of the elderly
to recognize, and execute evasive action to avoid, the risk of
everyday accidents.
Methodological considerations relevant to the testing of elderly
subjects
Test Factors. While the Gibson spiral maze, as used by Salem
et al. (1982), and the letter cancellation task, as used by
Castleden et al. (1977), both yield measures of the speed and
accuracy of performance, they differ in at least one influential
characteristic, viz. the amount of irrelevant material presented
in each task. Relative to younger individuals, the elderly
demonstrate less ability to discriminate between relevant, and
irrelevant material - a further source of reduced speed of
response in this age group. Rabbit (1965), for example, required
elderly (65-74y) and young (17-24y) subjects to sort cards
according to certain criterion letters printed on each. The
addition of irrelevant letters to each card produced greater
slowing of performance in the elderly than in the young. Welford
(1977) suggests that, in the elderly, such irrelevant material
effectively weakens the "strength" of the target signal. Applied
to Castleden et al.'s (1977) letter cancellation task, non-"e"
characters in the prose would be irrelevant, detracting from, and
weakening the stimulus impact of target "e"s, thus providing a
further, and perhaps confounding, source of both slower, and less
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accurate performance relative to younger subjects. Indeed, under
these circumstances, it would be an appropriate further analysis
to examine the degree to which letters deleted in error
approximated the letter "e" (i.e. in terms of closed loops and
angles, open loops and angles etc.). In order, therefore, simply
to assess speed and accuracy of performance in the elderly, tests
which present unspecified amounts of irrelevant matter are
probably best avoided.
Design Factors. It has been noted (Rabbit, 1982) that
laboratory test performance in the elderly is frequently
suppressed by the anxiety and stress engendered by the testing
situation itself. As these anxieties diminish with repeated
exposure to the test situation, practice effects tend to be
greater among the elderly than among the young (Rabbit, 1980). It
also follows from this that the performance of younger subjects
will "plateau" earlier than that of older subjects. These
findings have two important implications for the design of
psychopharmacological experiments for older subjects. First,
relative to younger subjects, the elderly will require more
practice sessions to adapt to the testing procedures, and achieve
steady-state levels of performance. Second, if, relative to
younger subjects, performance in the elderly is suppressed by test-
associated anxiety, then performance in this group is likely to
be more profoundly affected by residual anxiolytic drug activity.
Unless older subjects are thoroughly adapted to the testing
procedures, such an anxiolytic effect could confound with any
detrimental residual effects. Indeed, it is possible that a drug
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with anxiolytic activity may produce an apparent facilitation of
performance in the elderly.
With regard to both these points, it is interesting to note
that none of the studies shown in Table 5:1 report any adaptation
or practice test sessions for young or old subjects. Murphy et
al. (1982), for example, report that data derived from the first
testing session were used as baseline measures.
Conclusions
Clinical and controlled observations, epidemiological
surveys, and experimental studies show that the elderly, relative
to younger age groups, are more likely to experience the untoward
behavioural consequences of hypnotic drug usage. Experimental
evaluations could provide a means for predicting the degree of
behavioral risk associated with different hypnotic drugs in
elderly patients. From the experimental studies examined, it is
apparent, however, that their exists no consensus as to: 1) which
aspects of performance should be measured for drug effects, or
2) which aspects of performance are most vulnerable to drug
effects in the elderly. Evidence that some drugs may affect both
speed and accuracy, or accuracy alone, provides a point of
departure for further, more detailed, analyses of hypnotic drug
effects on these parameters of performance in the elderly. The
design of, and the tasks selected for, such analyses should take
into consideration factors known to be relevant to the
psychological testing of elderly individuals. Finally, criteria
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used to select the experimental groups should ensure some degree
of homogeneity as regards both the mental, and physical health
status of elderly subjects, such that results may reasonably be
generalized to similarly defined populations.
The clinical relevance of behavioural side effects in the
elderly arising from the use of sedative-hypnotic drugs is, of
course, proportional to the actual extent to which these drugs are
prescribed for, and used by, elderly individuals. In the next two
chapters, the residual effects of hypnotics in the elderly are
considered in relation to the epidemiology of these drugs. It is
the intention of both chapters to place the results from
laboratory performance studies into the relevant context of the
prescribing and use of sedative-hypnotic drugs among the elderly.
** The study by Cook et al. (1983) shown in Table 5:1 will be
fully discussed in Chapter 8.
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Chapter 6
Review: Levels of hypnotic drug prescribing and usage among the
elderly
As the variety of drugs which modify behaviour has increased
over the past 20 years, so too has epidemiological interest in the
prescribing and use of these medications. Most of this attention
has focussed on psychotropic drugs as a single operationally
defined entity (variously including neuroleptics, tranquillizers,
hypnotics, stimulants, and anti-depressants). This literature
shows a consistent relationship between the use of psychotropic
drugs, when these drugs are considered collectively, and age.
Reports from the United Kingdom (e.g. Skegg et al. 1977), the
United States (e.g. Parry et al. 1973), Canada (e.g. Fejer and
Smart, 1973) and Sweden (e.g. Boethius and Westerholm, 1977)
concur in that the prevalence of psychotropic drug usage tends to
increase with age. Where surveys have examined the use of
individual drug groups, however, it is evident that hypnotics are
principally responsible for producing this particular age related
trend. More so than for any other psychotropic drug, the
prevalence of hypnotic drug usage has been shown consistently to
increase with advancing age (Parish, 1971; Mellinger et al. 1971;
Parry et al. 1973; Skegg et al. 1977; Murray et al. 1981).
In view of the higher incidence of adverse drug responses,
and the increasing likelihood of drug usage with advancing age,
the use of hypnotics among older age groups merits detailed
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assessment. In this chapter information concerning hypnotic drug
usage among the elderly is reviewed, and trends in usage are
analyzed. The present review has two further aims. First, to
assess the impact of relevant clinical reports and experimental
studies on the pattern and prevalence of sedative-hypnotic drug
usage among the elderly over the past 20 years. Secondly, to
evaluate the causal status of some of the demographic variables
associated with elderly hypnotic users.
Several drug-associated factors influence the probability of
adverse behavioural reactions occurring in older hypnotic users.
These include the pharmacological characteristics of the drug
(e.g. long half-life/short half-life), the pattern of usage
(intermittent/continuous; long term/short term), and the dosage
employed. A thorough appraisal of the degree to which elderly
individuals are exposed to the risks of hypnotic drug usage,
therefore, requires information on four specific aspects of
consumption: 1) the extent to which sedative-hypnotic drugs are
used by the elderly; 2) the duration, and the continuity of usage;
3) the drug used; and 4) the dosage used. This review considers
the epidemiological literature on hypnotic drug use among the
elderly in relation to these four aspects of drug consumption.
Methodological considerations
To minimize the problem of between-study comparisons arising from
differences in definitions, methodologies, and the demographic
characteristics of samples, the criteria employed to
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select studies have concentrated on prevalence rates of drug use.
For the studies which met these criteria, a further distinction
was made between surveys of institutionalized populations, and
surveys of community samples. This distinction broadly recognizes
the existence of differing clinical needs and environmental
pressures which possibly mediate hypnotic drug use within these
two elderly populations. The institutional settings included are:
hospitals (general, psychiatric, geriatric and psychogeriatric);
nursing homes (long or short stay); and residential homes for the
elderly.
It was also necessary to draw a distinction between studies
of prescribing, and studies of drug usage. Analyses of pre¬
scribing can utilize at least two sources of information,
physician's records of prescriptions issued, or pharmacist's
records of prescriptions dispensed. Both methods are likely to
overestimate, to an unknown extent, drugs actually used. As
Williams (1979) has pointed out, prescribed medicines are not
necessarily dispensed, and dispensed medicines are not necessarily
consumed. It is also the case, however, that studies of general
practice prescribing do not take into account the minority of
individuals who receive prescriptions from hospital outpatient
departments.
Questionnaire surveys, where individuals report taking, or
having taken, prescribed drugs may, on the other hand, under¬
estimate actual drug usage. Parry et al. (1970), comparing
interview and prescription data, report a tendency for some
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respondents falsely to report not taking drugs. Irrespective of
the merits or demerits of these two methodological approaches, the
posible influence of these error sources is recognized in this
review.
Method
Reports and surveys likely to include information on hypnotic
drug prescribing and/or usage were identified through social
science abstracting journals, Index Medicus, the Key Word in
Context Index of Sleep Research, and through cross references from
relevant articles. The present review includes prevalence rates
from those studies which met the following criteria: 1) the study
was published in an English language scientific or professional
journal, or appeared in an accessible government report, between
1960 and 1981. 2) An elderly population or sub-population was
implicitly (e.g. geriatric patients) or explicitly (e.g.
categories of 70y+, or 65-75y, etc.) defined. In this review,
"elderly" generally refers to those aged 65y and over; however,
studies in which the oldest age group defined was 60y+ were
considered acceptable. 3) Surveys of non-institutionalized
populations observed appropriate sampling procedures which reduced
the probability of over-including members of clinically defined
sub-groups with known sleep disturbances (e.g. those with sleep
associated respiratory impairment; the clinically depressed,
etc.). 4) If the study examined the prescribing and/or use of
more than one class of psychotropic drugs, data relating to
sedative-hypnotic substances were unambiguously specified.
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"Hypnotics", and "sedative-hypnotics" are defined here as drugs
with sedative properties, the administration of which is intended
to promote sleep. 5) The study provided either a prevalence rate,
or prevalence rates, of sedative-hypnotic drug usage among the
elderly, or presented numerical data from which such rates could
be calculated.
Studies which did not satisfy all of the above criteria, but
which did contain relevant information, are cited where
appropriate. All studies are evaluated with reference to the four
aspects of drug usage previously mentioned, viz. Prevalence of
drug usage: Both point- and period-prevalence are considered.
Duration and frequency of usage: Duration refers to the minimum
period that individuals within a particular sample have been
taking, or receiving prescriptions for, sedative-hypnotic drugs.
Frequency refers to the continuity of usage; in practice, where
studies have referred to the frequency of usage, the reference is
often descriptive rather than quantitative (e.g. "regularly",
"sometimes", etc.).
Drugs used: Drugs are considered in terms of pharmacological
categories (e.g. benzodiazepines; barbiturates, etc.), or specific
hypnotic preparations.
Dosage employed: Dose refers to the mg weight, and not to the
number of tablets or capsules, or to the volume of liquid
medicines consumed.
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Prevalence of Drug Usage
Studies which yielded prevalence rates of hypnotic drug
prescribing and/or usage among the non-institutionalized and the
institutionalized elderly are shown in Tables 6:1 and 6:2
respectively. Collectively, the 18 prevalence rates show wide
inter-study variations, ranging from 5.9% (Wilks, 1975) to 54.0%
(Mulligan and O'Grady, 1971) . While these studies represent a
variety of methodologies and designs, it would be over simplistic
to conclude that the observed inter-study variations arose
primarily from procedural differences. Studies which have
employed standardized research methodologies have shown similarly
wide variations in hypnotic drug prescribing and usage between
countries (Baiter et al. 1974), within a country (Parry et al.
1973), and between medical practices (Parish, 1971) and hospital
units (Winstead et al. 1976) within cities. Thus, when
methodologies are controlled, variations in prevalence continue to
emerge, probably as a characteristic of the drug-use phenomenon
itself, and not as a characteristic of the way that phenomenon is
quantified.
Individual differences in prescribing behaviour may also
contribute to inter-study variations in reported prevalence.
Wilks (1975), for example, reports a one-year prevalence rate for
the patients of a single practitioner, viz. 5.9%. The one-year
prevalence rate for the age group 60y+ reported by Skegg et al.
(1977), 21.6%, represents the combined prescribing of 19
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Studiesreportingprevalenceat sofhypno cdrup escrihing/usa emong theinstitutionalizedelderly Study
Mulliganand0'Gr dy(1971) Ingmanetal(1975) Christopheretal(1978)
Typeof institution psychogeriatric units extendednursing carefacility generala d psychiatric hospitalunits
Ageof population 65y+
SaltzmanandV nderKolk(1980)ge eralhospit60y+
SizeofPrevalencer tes(%) populationmalefe let t l 189--Sh.O 131-22.9 873-51.8 195-22.6
-informationnotrep rted
practitioners in five group practices. Both studies were
conducted in England, and both used prescription records as a
primary source of information. These differences also serve to
illustrate a further and, in terms of reported prevalence,
influential feature of some prescribing surveys. Many surveys of
general practice prescribing are conducted by physicians who
analyze their own prescribing behaviour. Williams (1979) has
suggested that practitioners interested in such research are
possibly atypically low prescribers. In this respect, it is
relevant to note that, of the three studies reporting the lowest
prevalence rates shown in Table 6:1, two of these (Wilks, 1975;
and Law and Chambers, 1976) were conducted by general
practitioners within their own practices.
Differences in the characteristics of survey samples present
a further source of inter-study variability in reported prevalence
rates. Two characteristics in particular appear to exert a
systematic influence on the total levels of hypnotic drug usage
shown in Tables 6:1 and 6:2, namely, the age structure, and the
institutionalized/non-institutionalized status of samples. These
two factors will be considered in turn.
Many of the studies included in this review report data only
for open-ended age categories (e.g. 60y+, 65y+, etc.). Those
studies which provided a more detailed analysis of their elderly
samples, however, show a continuing age related increase in
hypnotic drug usage, from 65y+ to 75y+ (McGhie and Russell, 1962) ,
from 60-69y, through 70-79y, to 80-89y (Stevenson and Gaskill,
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1971), from 60-69y to 70y+ (Karacan et al. 1976), and from 60-74y
to 75y+ (Skegg et al. 1977). It can be seen from Table 6:1 that
most of the total prevalence rates are derived from samples having
four minimum age levels viz, 60y, 65y, 70y, and 75y. The
average total prevalence reported for each of these four minimum
age levels is shown in Table 6:3. This rather simplistic analysis
does indicate that rates of hypnotic prescribing and/or usage tend
to increase with the minimum age of the elderly sample studied.
This influence of sample age structure on reported levels of drug
prescribing/usage is also relevant when comparing the US and UK
studies shown in Table 6:1. Although sedative-hypnotic drug usage
appears (from Table 6:1) to be lower in the United States, three
out of the four US total prevalence rates are for the age group
60y+ (i.e. Manheimer et al. 1968; Mellinger et al. 1971; Parry et
al. 1973) and probably underestimate usage in older age groups.
This conclusion is supported by the study of Karacan et al. (1976)
which reports a considerably higher prevalence rate for American
adults aged 70y+.
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Table 6:3. Total prevalence rates from Table 6:1
averaged according to the minimum age of the sample
minimum age average prevalence





Comparing the prevalence rates reported for institutionalized
populations and community samples, it is clear that the higher
levels of sedative-hypnotic drug usage are found among elderly
hospital patients. The evidence also suggests that levels of
usage are highest in those hospital units which specialize in the
care of the elderly, i.e. geriatric and psychogeriatric units.
Mulligan and O'Grady (1971) report a prevalence rate of 54% for
psychogeriatric patients, and Christopher et al. (1978) found that
patients in geriatric units were more likely to receive sedative-
hypnotic drugs than were elderly medical, surgical, psychiatric,
or mentally subnormal patients. Salzman and Van der Kolk (1980),
on the other hand, report relatively lower levels of usage for
elderly general hospital patients (22.6%), a rate similar to that
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reported by Ingman et al. (1975) for nursing home residents, and
by Bruce (1982) for a small residential home. Thus, it appears
that high levels of physical dependency in the elderly are
associated with high levels of hypnotic drug usage.
Temporal trends. Methodological differences which obstruct
direct inter-study comparisons also prevent detailed conclusions
being drawn regarding temporal trends in usage. One conclusion
that is possible, however, is that in the 20 years covered by
Tables 6:1 and 6:2, the elderly have remained a popular target
group for sedative-hypnotic substances. Considering only the
community-based samples in Table 6:1, it can be seen that, more
often than not, the rate of hypnotic drug usage among the elderly
is reported to approach, or to exceed 10%. Viewed as estimates
(in many cases, very crude estimates) of usage in the general
population, these rates must be interpreted against the background
of change in both the size, and the structure, of the elderly
population over the past 20 years. The absolute number of
individuals aged 65y+ rose by 8.1 million between 1960-1979 in the
United States, and by 1.7 million between 1962-1977 in the United
Kingdom (United Nations, 1964; 1980). Similar percentage
estimates of hypnotic drug usage reported periodically between
these dates therefore, represent in absolute terms, increasing
number of elderly individuals. Thus, assuming a conservative
prevalence estimate of 10%, the number of elderly individuals
consuming hypnotic drugs in the United Kingdom has risen from 0.6
million in 1962, to 0.8 million in 1977. The proportion of
elderly individuals aged 80y+ has also increased during the period
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covered by this review. The very elderly, i.e. those 80y and
over, constitute approximately 20.7% of the elderly population in
the United States, and 17.2% in the United Kingdom (1979 and 1977
census data respectively). Given, then, that in some studies the
prevalence of hypnotic drug usage reported continues to increase
until well after the 65th year of age, then these rates, too, are
progressively representing an ever increasing number of very
elderly individuals.
The pattern of usage also shows some consistency over time.
McGhie and Russell (1962), Dunnell and Cartwright (1972), and
Murray et al. (1981) all report that levels of hypnotic drug usage
increased progressively with age from early adulthood onward.
Whatever clinical or psycho-social circumstances mediate the use
of sedative-hypnotic drugs across all age groups, the bias towards
the elderly arising from these circumstances has remained largely
unchanged for almost 20 years.
Sex-differences in usage. The most consistently reported
demographic feature of the surveys shown in Table 6:1 is the
presence of sex diferences in usage. Irrespective of when or
where the study was conducted, whether prescribing or usage was
analysed, or how hypnotic drugs were defined, the use of sleeping
drugs is generally reported to be higher among elderly females
than among elderly males. [The clinical importance of this
finding is emphasized by the data of Salem et al. (1982) which
suggests that elderly females may be more profoundly affected by
some hypnotics; see previous chapter]. Only two exceptions to
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this trend are shown in Table 6:1, Wilks (1975), and Williamson
and Chopin (1980). The study by Wilks (1975) is clearly
uncharacteristic in other respects, for example, the single-
practitioner methodology, and the extremely low total prevalence
reported. It is not unreasonable to conclude, therefore, that the
higher usage of hypnotics found among male patients in this study
reflects, to some extent, the atypical prescribing practices of a
single practitioner. The results of Williamson and Chopin (1980)
are derived from prescription analyses of patients consecutively
admitted to 49 geriatric centres in England and Wales. The
slightly higher usage of hypnotics by males found by these
researchers will be discussed later in this review.
Sex differences in the use of prescription sedative-hypnotic
drugs are less clearly defined among the young than they are among
the middle-aged or elderly. Manheimer et al. (1968), Mellinger et
al. (1971), Karacan et al. (1976), and Murray et al. (1981) all
report very similar levels of usage for males and females in the
age group <30y. Usage is generally shown to increase with age for
both sexes, but in most analyses of age-stratified samples, this
increase has been shown to be more profound for females (McGhie
and Russel, 1962; Manheimer et al. 1968; Melinger et al. 1971;
Parry et al. 1973; Murray et al. 1981). McGhie and Russell
(1962), for example, comment that "... the habit of taking a
hypnotic increases for both sexes with advancing years, but that
both the incidence and its acceleration with age are more
pronounced in the case of women." Similarly, Murray et al. (1981)
observed that "The proportion of drug consumers taking an hypnotic
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increased with age (particularly for women)Clearly, then, both
sex and age combine to influence the usage of hypnotic drugs in
later life. In order, therefore, adequately to account for sex
differences in usage among older adults, the interacting factor of
age must be taken into consideration.
It is interesting to note that these consistently reported
sex-differences in the use of sleeping drugs do not appear to be
mediated by similarly consistent differences in the objectively
measured (electroencephphalographic) sleep patterns of elderly
males and females. While Williams et al. (1974) report superior
sleep efficiency in elderly females relative to elderly males, the
studies of Kahn and Fisher (1969) and Kahn et al. (1970) suggest
that elderly males sleep better than elderly females. In a more
recent study, Hayashi and Endo (1982) found no significant
differences between the electroencephalographically recorded
sleep of five males (mean age = 79y) and ten females (mean age =
83.5y) on measures of total sleep time, total sleep stages 1 and 2
(drowsiness and light sleep), total sleep stages 3 and 4, or total
rapid eye movement (REM) sleep.
Few of the studies shown in Table 6:1 attempted to account
for sex differences in drug usage, and, of those that did, none
addressed the interacting influences of ageing and sex on sedative-
hypnotic drug consumption. Furthermore, attempts to account for
gender differences in usage tended to encompass, not only all age
groups, but also all psychotropic drugs. Such broadly based
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explanations do not differentiate the clinical and therepeutic
needs which mediate the use of hypnotics from those which mediate
the use of other psychotropics, and therefore can only partially
explain the age/sex pattern so characteristic of hypnotic drug
usage. Parry et al. (1973), for example, list sociological,
psychological, and physiological factors which might lead to
higher rates of prescription psychotropic drug usage among adult
females. Also, both Mellinger et al. (1971) and Parry et al.
(1973) suggest that males are more likely to use "alternative
coping drugs" like alcohol and marihuana. With particular regard
to older women, the possible influence of menopause and
bereavement on tranquillizer, sedative, and hypnotic usage was
further recognized by Parry et al. (1973). In the absence of data
collected specifically to test these hypotheses, whether, and to
what extent these factors influence the pattern of hypnotic drug
usage among the elderly, remains a matter for speculation. From
the available literature it is, nevertheless, possible to identify
demographic variables which might plausibly contribute to higher
levels of hypnotic drug consumption among older females.
Associations between bereavement and hypnotic drug usage are
noted in several studies. Manheimer et al. (1968), not dis¬
tinguishing between the sexes, report that the highest level of
sedative-hypnotic drug use was among widows/widowers. More
specifically, Stevenson and Gaskell (1971) report that 37% of
their female hypnotic users were widowed, compared with only 8% of
males in the same survey. In an earlier study of 97 users of
repeat prescriptions for hypnotic drugs, Johnson and Clift (1968)
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found that the proportion of widows (35%) , but not widowers, was
significantly higher than that found in the general population.
These associations between the use of sleeping tablets and
bereavement may be interpreted at two different levels. Parry et
al. (1973), for example, emphasize the immediate emotional stress
of bereavement, and suggest that the prescribing of sedatives and
hypnotics for women during mourning is "commonplace". This
suggestion is consistent with the sociological model of pre¬
scribing presented by Cooperstock (1971) which argues that
(predominantly male) prescribers expect female patients to be more
emotionally reactive, and more in need of psychotropic drugs. Not
all elderly widows, however, are in mourning, and those that are
probably represent only a minority of bereaved women. Among those
women who have been widowed for seme years, it is likely that
marital status, as a predictor variable, has been confounded with
other age-dependent variables, particularly health status.
Statistically, women tend to live longer than men, and are
therefore more exposed to the debilitating consequences of
advanced age. Thus, it is possible that increasing age among
females is associated, not only with an increased probability of
widowhood, but also with reduced physical health status relative
to males.
The relationship between physical health status and hypnotic
drug usage in the elderly has not been thoroughly investigated.
Both Cooperstock (1971) and Murray et al.(1981) suggest that sex
differences in psychotropic drug usage as a whole are independent
of health status. Using global self-assessments of health, and
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the General Health Questionnaire, Murray et al. (1981)
demonstrated that, when age and health status are controlled, sex
differences in consumption persist. However, such analyses do
not consider the use of hypnotic drugs alone, nor the more
frequent use of hypnotics in the treatment of physical, as opposed
to psychiatric, illnesses. Stevenson and Gaskell (1971) , for
example, report that almost 40% of their adult patients receiving
repeat prescriptions for hypnotic drugs commenced taking these
drugs for essentially somatic disorders. The divergent patterns
of sedative-hypnotic drug usage between ageing males and ageing
females are also ignored when psychotropic drugs are grouped as a
single therapeutic entity. Indeed, as the data of Murray et al.
(1981) show, when psychotropic drugs are considered collectively,
the effects of ageing are the same for both sexes, which is
certainly not the case when hypnotics are considered alone.
Consequently, the findings of this, and other similar analyses, do
not rule out the possibility that seme of the variance in hypnotic
drug usage between ageing males and ageing females may be
accounted for in terms of further sex differencesin physical
health status.
That a relationship does, in fact, exist between physical
health and sleeping drug usage is strongly inferred by demographic
data collected by the American Cancer Society in 1959-60, and by
subsequent six-year follow-up interviews. This extensive survey
of over 800,000 individuals showed that mortality among
respondents who reported using sleeping tablets "often" was twice
that of age matched controls who reported no sleeping tablet use
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(Kripke et al. 1979). This is not to suggest that sleeping
tablets are causally implicated in the higher mortality rates, but
rather that the need for drug-induced sleep, and the associated
higher mortality risk, have a common cause, possibly lower
physical health status.
The hypothesis that health status differences between ageing
males and females may influence the observed sex difference
in hypnotic drug usage within this age group necessarily
predicts that, when health status variables are controlled in the
analysis of an elderly population, sex differences in hypnotic
drug use will, at least, be attenuated. If we can assume that
physical health status is much less variable among elderly
hospital admissions than itis among the elderly at large in the
community, then the study of Williamson and Chopin (1981)
provides hypnotic drug-use data for an aged population in which
the severity of physical illness has, to some extent, been
controlled. These authors analyzed the prescription medications
of 1998 consecutive admissions to geriatric units and, as can be
seen from Table 6:1, the proportions of males and females
receiving sedative-hypnotic drugs is almost identical. Also, as
would be expected if physical health status is related to hypnotic
drug usage, the total prevalence rate is relatively high when
compared with other United Kingdom surveys. It is also
interesting to note that, of the 1321 females, and 677 males
included in this survey, proportionately more females were aged
over 75y.
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On the same grounds, a similar 'ironing out' of sex
differences might be predicted for residential institutions.
Unfortunately, the only relevant study shown in Table 6:2 (Ingman
et al. 1975), does not provide separate drug-use information for
both sexes.
Finally, the possibility that males employ substitutes for
prescription hypnotic drugs does find some support in the current
drug use literature. Both Mellinger et al. (1971), and Parry et
al. (1973) report that, when non-prescription drugs (particularly
the so called "over-the-counter hypnotics") are taken into
consideration, sex differences in total drug usage are
diminished. The data of Mellinger (1971) indicates that males and
females over 60y are equally likely to report the use of non¬
prescription "psychotherapeutic" compounds. A study of insomniacs
in Los Angeles conducted by Guilleminault et al. (1977) directly
linked the use of alcohol among males with hypnotic drug
substitution. These researchers found that significantly more
males made frequent use of alcohol as a remedy for poor sleep.
However, age related trends in this practice were not
investigated.
Sex differences in the pattern of hypnotic drug usage among
the elderly are also evident from the studies reviewed here.
These differences are more relevantly discussed in the next
section.
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Duration and Frequency of Usage
Information on the duration and/or frequency of sedative-
hypnotic drug usage among the elderly was provided in only a
minority of the studies shown in Tables 6:1 and 6:2. All the
surveys of institutionalized populations yielded point-prevalence
data, as did the study by Williamson and Chopin (1980). These
surveys report only the prevalence of drug usage at a particular
point in time, without reference to antecedent patterns of usage.
Of the community based surveys, those of Dunnell and Cartwright
(1972) and Murray et al. (1981) provide two week prevalence rates,
and that of Skegg et al. (1977) provides a one year prevalence
rate. These period prevalence studies report the proportion of
individuals taking, or receiving prescriptions for, hypnotic drugs
at any time within the period specified. None of these studies
distinguished between regular or irregular, frequent or infrequent
usage.
In the remaining studies, the research methodology allowed
for a minumum duration and/or frequency of usage to be assessed.
This was done either directly, by including more than one response
category relating to the use of hypnotic drugs in a survey
questionnaire (e.g. used sometimes, often, always, etc.), or
indirectly, where the use of repeat prescriptions implied regular
consumption. Table 6:4 shows the total prevalence rates reported
in relation to the duration and frequency of usage derived from
these studies. Excluded from this table are the studies of
Melinger et al. (1971) and Parry et al. (1973). While both of
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TABLE6:4
Studiesreportingfrequ ncyand/ordurationofhypn ti drugprescribing/usa eamongthelderly prevalencerat s(%)
McGhieandRussell(1962) Manheimeretl(1968) Stevensona dG skell(1971) Gruer(1975) Wilks(1975) LawndCh lmers(1976) Karacanetl(1976) Gerrardtal(1978)
used 'regularly' 25.0(M) 45.0(F) 11.2 14.6 19.0 5.9 8.6 8.2(M) 4.9(F) 15.0(M) 31.0(F)
used 'occasionally' 4.1(M) 17.1(F) 3.0(M) 9.0(F)
minimumduration ofusage 1year 3.5%>1year 2.3%<1year
-informationnotrep rted
these studies provided information on duration and frequency of
psychotropic drug use, in neither case did these data relate
specifically to hypnotics and the elderly.
As can be seen from Table 6:4, many of the total prevalence
rates already discussed are rates of frequent usage. Two
exceptions to this, Karacan et al. (1976) and Gerrard et al.
(1978) , show differing trends in usage. In an urban county of
Florida, USA, Karacan et al. (1976) found that hypnotic drug use
among elderly females was more likely to be reported as
occasional, whereas among elderly males it was more likely to be
reported as "often or all the time". On the other hand, Gerrard
et al. (1978) found less occasional usage among their elderly
sample in London, with both males and females more likely to
report taking hypnotics "every night". While this discrepancy
between the two surveys might be attributable to the respondent's
interpretation of different questions, it is also possible that
these results indicate a real difference in the pattern of usage
between the two communities. In this respect it is relevant to
note that the surveys of Melinger et al. (1971), and Parry et al.
(1973), both of which were conducted in the United States, show
that, among psychotropic drug users, males are more likely to
report regular use, over long periods of time, than are females.
Only two studies provided numerical information on durations
of hypnotic drug usage. Stevenson and Gaskell (1971), using
clinical records, found that among their sample of hypnotic drug
users the minimum duration of usage was one year. It is also
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interesting to note that, in follow-up interviews, these authors
further observed that "Elderly patients, in particular,
were....more likely to underestimate the length of time they had
been taking hypnotics". This comment emphasizes the need for
caution in interpreting questionnaire data on certain aspects of
drug use among the elderly. Wilks (1975) examined the duration of
hypnotic drug usage in some detail, and reports that of ten
patients who had received hypnotics for more than one year, nine
were aged over 65y, and five of these were aged over 80y.
Further evidence that the elderly are likely to continue taking
sedative-hypnotic drugs for long periods of time (i.e. more than
one year) is provided by the longitudinal studies of Boethius and
Westerholm (1976; 1977). These authors analyzed the prescription
records of 2,566 individuals in a single county of Sweden.
Substantial proportions of elderly outpatients who, in 1970, were
categorized as regular, intermediate, or occasional users of
"hypnotics, sedatives, and/or tranquillizers" continued to
purchase these drugs up to five years later.
Drugs and Dosages Used
Several of the studies shown in Tables 6:1 and 6:2 provide
information on specific drugs, or drug groups, used as hypnotics
by adults of all ages. Only a few surveys report these data for
elderly samples, and few of these report any dosage information.
During the period covered by this review (1962-1981) the
prescribing of barbiturate psychotropic drugs declined in
popularity, and non-barbiturate preparations, particularly
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benzodiazepines, showed a reciprocal increase in usage. This
historical trend, well documented by Parish (1971) and Howie
(1975) in the United Kingdom, and by Cooper (1977) in the United
States, is clearly reflected in the hypnotic drug-use data
considered in this section. In the studies conducted by Manheimer
et al. (1968), Mellinger et al. (1971), and Parry et al. (1973),
the questionnaire definitions of hypnotics are exemplified mainly
by barbiturate drugs, the principal exception in all three cases
being glutethimide. Stevenson and Gaskell (1971) report that
almost 80% of their hypnotic prescriptions (for all age groups)
were for barbiturate drugs, particularly amylobarbitone. Wilks
(1975), on the other hand, reports the use of barbiturates in only
41% of hypnotic users, the remaining 59% receiving nitrazepam or
methaqualone (as Mandrax). The increasing use of nitrazepam in
Europe is also illustrated by the data of Boethius and Westerholm
(1976). This single drug was found to represent 28% of
sedative-hypnotic purchases in 1970, and 55% in 1975.
As regards the elderly, most of the detailed analyses of
drugs prescribed are provided by the surveys of institutional¬
ized populations. Of 102 psychogeriatric patients receiving
hypnotics, Mulligan and O'Grady (1971) found that 70% received
methaqualone (as Mandrax), 17% dichloralphenazone, 7%
chlormethiazole, and 7% nitrazepam or barbiturates. No dosages
are reported. Several years later, a very different pattern of
drug use among elderly hospital inpatients was reported by
Christopher et al. (1978). These researchers note that, of 452
elderly patients prescribed hypnotic drugs, 62% of prescriptions
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were for chloral derivatives, 21% were for nitrazepam, and 17%
were for other non-barbiturate hypnotics. Contrasting these two
hospital surveys, both nitrazepam and chloral derivatives (e.g.
dichloralphenazone) appear to have increased in popularity as
hypnotics for the elderly. For nitrazepam, this increase in
popularity seems to be general to all age groups (at least in
Europe). Compare, for example, the results of the general
practice survey conducted by Stevenson and Gaskell (1971), in
which only 3.8% of patients were found to receive nitrazepam, with
that of Skegg et al. (1977) which reports that nitrazepam was one
of the most commonly prescribed of all drugs. In contrast, the
use of chloral derivatives among elderly hospital patients may
reflect the preferential use of these drugs in this age group.
Support for this possibility is provided in a survey of
medications received by nursing home residents in the US, and
reported by Ray et al. (1980). These researchers comment on the
extensive use of chloral/benzodiazepine combinations as hypnotics
among nursing home residents in Tennessee, USA.
General practice analyses of hypnotic drug prescribing among
patients of all ages tend to show a consistent low-level of
prescriptions for chloral derivatives. Stevenson and Gaskell
(1971), and Wilks (1975) report that Trichloryl and/or
chloral represented 2.6% and 3.4% respectively of total
hypnotic prescribing. Similarly, of the 1,145 hypnotic
prescriptions analyzed by Parish (1971), 4% were for chloral
derivatives. If these low levels of prescribing are due to
selective use among the elderly, then higher rates of usage,
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possibly approximating those of the hospital surveys, would be
expected if the elderly were considered alone. The conclusion
that dichloralphenazone is used preferentially among the elderly
is certainly consistent with the drugs reputation as a "...safe
and satisfactory hypnotic of first choice" for the elderly patient
(Evans and Jarvis, 1972). It is cautionary to note, however, that
long-term chloral hydrate use has been associated with confusion
and hallucinations in dependent geriatric patients (Kramer, 1967).
The increasing use of benzodiazepine sedative-hypnotic drugs
among the elderly is also shown in the more recent North American
surveys. An extensive report on the risks and benefits of sedative-
hypnotic drugs compiled by the National Institute on Drug Abuse,
and edited by Cooper (1977), shows that the hypnotic most
extensively prescribed by general practitioners in the United
States is flurazepam. The preferential use of this benzodiazepine
among the institutionalized elderly in the United States is
clearly shown in two further studies. Saltzman and Van der Kolk's
(1980) survey of 192 general medical inpatients over the age of
60y shows that, of the 44 patients prescribed hypnotics, 39
received flurazepam, 3 chloral hydrate, and 2 received
barbiturates. Marttila et al. (1977) , in a study of 750 elderly
patients in intermediate care facilities, report that 26% of these
patients regularly received flurazepam.
Despite the overall paucity of information concerning
hypnotic drug dosages typically prescribed for elderly patients,
two of the more recent hospital surveys report dosage
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distributions for nitrazepam and flurazepam respectively.
Christopher et al. (1978) found that, among the 96 patients
prescribed nitrazepam, 54 were prescribed 5mg, and 42 lOmg. Of
the 39 patients receiving flurazepam in Saltzman and Van der
Kolk's (1980) survey, 15 received a 15mg dose, and 24 a 30mg dose.
Conclusions. Since the early study by McGhie and Russell (1962)
the overall pattern of sedative-hypnotic drug use shows several
consistent features. Prescription hypnotic drug usage continues
to show an age-related increase; in the community this increase
continues to be greater for females than for males. Also, for the
elderly, institutional care appears to be consistently associated
with a higher probability of receiving hypnotic drugs. Clearly,
then, prescribing hypnotics has become firmly established as the
intervention of choice in response to sleep complaints in the
elderly.
While the epidemiological pattern of usage shows
remarkably consistent features over time, the pattern of drugs
actually prescribed has shown considerable changes. Among the
adult general population, prescriptions for barbiturate hypnotics
declined with increasing awareness of their toxicity and abuse
potential, and the concomitant introduction of non-barbiturate
sedative-hypnotic products. This transition is clearly reflected
in the data relating specifically to the elderly. For very
similar reasons, the rapid increase in the popularity of
methaqualone (as Mandrax) was followed by an equally rapid
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decline, a trend similarly reflected in the data derived
exclusively from elderly populations. On the one hand, these
trends suggest that hypnotic prescribing habits can change fairly
uniformly as new information becomes available, and as viable
alternative products are developed. On the other hand, it is not
apparent that drugs of choice for the treatment of sleep
disorders differ greatly between the old and the younger, despite
the differential sensitivity to these drugs reported for different
age groups.
From the more recent surveys, the extensive use of
benzodiazepine hypnotics, particularly nitrazepam and flurazepam,
also appears to be common to all age groups. Thus, with the
exception of chloral derivatives for elderly inpatients, the
information reviewed here provides no basis for concluding that
the advanced age of the patient significantly influences the
choice of hypnotic drug prescribed. Furthermore, from the scant
data available, it is also impossible to conclude that caution in
the prescribing of hypnotic drugs for the elderly is generally
exercised at the level of dosage. While over half the nitrazepam
users in Christopher et al.'s (1978) survey received a "low" (5mg)
dose, 44% were prescribed lOmg. As Christopher et al. (1978)
point out "While a dose of up to lOmg (of nitrazepam) is common
for younger patients the official data sheet recommends up to 5mg
per day for elderly patients." Saltzman and Van der Kolk (1980)
show that well over one half of their small sample of flurazepam
users received a 30mg dose. At this dosage flurazepam has been
consistently associated with excessive CNS depression in elderly
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patients (Greenblatt, Allen and Shader, 1977).
Currently available benzodiazepine sedative-hypnotic
preparations differ widely in their duration of action, i.e. their
elimination half-lives. Both nitrazepam and flurazepam are long
acting, with reported half-lives within the range 21-28 hours
(Breimer et al. 1977) and 47-100 hours (Kaplan et al. 1973)
respectively. A problem associated with such long acting
compounds is accumulation, either of the drug itself or of its
active metabolites, with repeated use. The behavioural
consequences of accumulation have been demonstrated by Oswald et
al. (1979) for flurazepam. Over a 16 day period of nightly
flurazepam (30mg) consumption, middle-aged volunteers became
progessively more impaired on a variety of performance tasks.
Where long half-life hypnotics are concerned, then, the frequency
and duration of usage are of particular importance. Table 6:4,
however, shows that the protracted use of sleeping tablets among
the elderly is certainly not uncommon, supporting the suggestion
that "...despite good intentions to the contrary, hypnotics are
often prescribed for years rather than for short courses of
treatment" (British Medical Journal, 1980).
From the more recent surveys, there is no evidence that
short-life hypnotics are used either preferentially, or
extensively, among the elderly.
Studies of hypnotic and psychotropic drug use are conducted
for a variety of reasons, each study employing a design and
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methodology suited to its particular objectives. These
differences in approach produce differences in the detail and
emphasis of reported data. Consequently, in this review it has
been necessary to infer trends from information which is
fragmented, and often lacking in detail. If we assume that the
more recent surveys are representative of current hypnotic
prescribing practices, then there is little to indicate a
systematic attempt on the part of the prescribers to mitigate
adverse behavioural reactions in elderly users. It should be
remembered, however, that much of the information concerning
specific drugs and dosages is derived from hospital-based surveys,
and may, therefore, not be representative of the bulk of
prescriptions which emanate frcm general practice. Caution is
also necessary in evaluating the demographic data reviewed here.
Frcm the studies which report some hypnotic user characteristics,
relationships are inferred between sex, marital and health status,
and the use of hypnotic drugs. Again, in the absence of data
which specifically elucidate these relationships, the role of
these factors in determining hypnotic drug usage among the elderly
remains obscure.
The assessment of behavioural risk within an elderly hypnotic drug-
using population requires detailed information, not only on the
specific drug types used, but also on the age structure of that
population, the health status of drug users, the specific drug
dosages employed, and the frequency and duration of usage. These,
however, are among the most frequently emitted items of data in
surveys of psychotropic or hypnotic drug usage. The present
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review, therefore, emphasizes both the need for, and
the information required of, clinically and psychologically
relevant studies of hypnotic drug usage among the elderly.
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Chapter 7
TWo surveys of hypnotic drug usage, and factors influencing
hypnotic drug usage in the elderly.
Introduction
From the current epidemiological literature it is evident
that the use of prescription medications increases with the age of
the patient (e.g. Knox, 1980). Adverse reactions arising from
multiple prescribing for older patients have also recently been
emphasized (Petersen and Thomas, 1975; Caird, 1977; Moir et al.
1979; Petersen et al. (1979); Knox, 1980; Williamson and Chopin,
1980; Raffoul et al. 1981; Bliss, 1981). Several surveys have
further shown that hypnotics in particular are among the most
frequently prescribed drugs for this age group (Christopher et al.
1978; Williamson and Chopin, 1980) . The evidence reviewed in
Chapter 5 indicates that, to an unknown extent, some elderly
individuals are at risk from the use of some hypnotic drugs;
certain characteristics of both drug and recipient may interact to
increase the likelihood of adverse behavioural reactions
occurring. Surveys of hypnotic drug usage, therefore, provide a
means for estimating the degree of risk within an elderly drug-
using population. Appropriately designed surveys of hypnotic drug
use among the elderly can also serve to focus experimental
attention on the most widely used drugs and dosages.
Frcm the previous chapter, however, it is also clear that
most surveys of sedative-hypnotic drug use among the elderly (or
surveys which have included such information) place little
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emphasis on the actual drugs, or the dosages, typically prescribed
or used. As also pointed out, seme hypnotics (e.g. long-acting
cumulative compounds) are more likely to be associated with
behavioural deficits in the elderly, and that the severity of such
effects appear to be dose dependent. Thus, prevalence rates of
hypnotic drug usage per se do not accurately predict the degree
of risk within elderly populations, and, as a consequence, their
value as feedback is diminished. In the present chapter, two
surveys of hypnotic drug use among the elderly are described and
evaluated. These studies were designed and conducted in order to
provide the type of information which, as shown in Chapter 6, is
most frequently emitted frcm the epidemiological literature.
In addition to prevalence rates, therefore, the present surveys
aimed to provide: i) details of drugs and dosages prescribed for,
and used by, the elderly; ii) demographic characteristics of
elderly hypnotic drug users; iii) details of any additional
centrally acting medication prescribed for hypnotic users; and iv)
seme indication of the typical duration and frequency of hypnotic
drug usage among the elderly. It was a specific intention of
these surveys to identify, for subsequent experimental
evaluations (Chapters 8 and 9), the most widely used hypnotic
products in this elderly population. In both the design of the
present surveys, and the selection of the survey population,
three methodological issues were recognized and taken into
consideration.
1) Defining Hypnotic Drugs
Hypnotic drugs form a semantic, rather than a pharmacological,
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category of therapeutics. Drugs used as hypnotics may include
drugs which are not marketed exclusively (and, therefore, are not
readily identified) as hypnotics. Oswald (1980), for example,
points out that "drugs which are sold for the treatment of anxiety
are drugs which can be used as hypnotics". Certain neuroleptic
and antidepressant drugs, while used to treat a primary
psychiatric condition, may also be selected to exploit their
sedative-hypnotic properties (British Medical Journal, 1980). It
is also clear from some of the surveys reviewed in Chapter 6 (e.g.
Ray et al. 1980) that phenothiazine tranquillizers are not
infrequently used as the sedative-hypnotic of choice for some
institutionalized elderly individuals. To minimize possible
ambiguities in the present surveys, hypnotic drugs were
operationally defined.
2) Prescribing and Usage
As fully described in the previous chapter, surveys of drug
prescribing may overestimate the prevalence of actual drug usage.
For this reason, the surveys reported here aimed to provide
information only on drugs actually consumed.
3) The Survey Popoulation
Much of the detailed information relating to hypnotic drug usage
among the elderly is derived from hospital-based surveys, while
the majority of prescriptions emanate from general practice (see
Chapter 6). Knox (1980) commenting on drug use surveys among the
elderly observes that "There appears to be undue readiness to
extrapolate results from hospital-based studies (relating to
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highly selected populations) and to apply these to the community
in general". Care was taken in the present studies to select an
elderly population in which primary health care was provided by
general practice physicians. The pattern of drug usage reported
here, therefore, particularly as regards the drugs used, can
reasonably be assumed to reflect the prescribing trends of general
practitioners.
Methods
Survey Population. The surveys included all local authority
homes for the elderly in Lothian Region, Scotland. This
accommodation is defined in, and provided under, Part 4 of the
National Assistance Act (Scotland) 1948. Within the terms of
this act, accommodation is provided for those who, for reasons of
"age or infirmity", are considered to be at risk in the community.
[Detailed analyses of the health status, age structure, and sex
distribution of this population are described below]. At the time
of both studies, Lothian Regional Council provided 1160
residential places for the elderly in 24 different homes. Homes
varied in size from 15 to over 300 beds. While larger homes
contained both male and female residents, several of the smaller
homes (i.e. <30 beds) admitted only males, or only females. All
residents were under the care of their own general practitioner.
Study Design. The survey questionnaire was designed in
collaboration with Lothian Regional Social Work Department, and
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piloted in selected homes before the main surveys. The proforma
eventually used is reproduced in Appendix 4:1. A glossary of
drugs showing product and non-proprietary drug names likely to be
used as hypnotics was attached to each proforma. This glossary is
reproduced in Appendix 4:2. The surveys employed a point-
prevalence design, the data for each being collected on a single
specified night.
Prior to the first survey, the purpose of the study, and the
nature of the information required, was explained to the Head of
each home. Survey proformas were issued approximately 1 week
before the surveys, and completed on the same nights throughout
the region. For each resident receiving a hypnotic on those
nights (15 October 1980; and 31 March 1981) data were collected on
the age and sex of the recipient, the drug and dose received,
whether that drug was given on the previous night, and on
concomitantly prescribed centrally acting medication. For the
purposes of these studies hypnotics were defined as drugs with
sedative properties the administration of which was intended to
promote sleep.
Additional Information. Details of the number, age, and sex
of residents not receiving hypnotics, and consequently not
included on the survey returns, was provided by Lothian Regional
Social Work Department.
Analysis of Data. Survey data and additional information
were combined, and frequency distributions for the variables of
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interest were derived. Chi-square analyses of association were
performed where appropriate.
The results from Survey 1 and Survey 2 will be presented in
turn. The combined results from both surveys will then be
discussed in detail.
Results (Survey 1)
The total study population comprized 1154 residents (373
males and 781 females). 387 residents (33.5%) received hypnotics
on the night of the survey, and on the preceding night. The age
distribution of hypnotic users and non-users is shown in Table
7:1. A significantly greater proportion of those aged 80y+
received hypnotic drugs (chi-square = 13.9, df = 3, p<0.01). The
proportions of male and female hypnotic users are shown in Table
7:2. No significant association was found between hypnotic drug
usage/non-usage, and sex (chi-square = 2.52, df = 1, NS).
Each hypnotic was grouped into one of ten categories. Eight
of these categories were of single drugs (e.g. nitrazepam), the
remaining two categories contained compounds having
pharmacological and/or therapeutic similarities, viz.
antidepressants, and major and minor tranquillizers. The
phenothiazines promazine, chlorpromazine, and thioridazine, and
the benzodiazepines diazepam and chlordiazepoxide accounted for
most of the drugs in this latter category. The frequency with
which each category of drug was used is shown in Figure 7:1. Of
- 161 -
Table 7:1. Age distributions of hypnotic users and non-users:
(Survey 1)
Age (years)
0-69 70-79 80-89 90+ Totals
No. (%) 37 ( 9.5) 111 (28.7) 199 (51.4) 40 (10.4) 387 (100.0)
users
No. (%) 88 (11.5) 273 (35.6) 306 (39.9) 100 (13.0) 767 (100.0)
non-users
Chi-square = 13.9, df = 3, p<0.01
Table 7:2. Hypnotic usage by sex: (Survey 1)
Males Females Totals
Users: No. (%) 137 (35.4) 387 (64.6) 387 (100.0)
Nonusers: No. (%) 236 (30.8) 531 (69.2) 767 (100.0)
Chi-square = 2.52, df = 1, NS
Table 7:3. Dosage distributions for the four most frequently
used single drugs: (Survey 1)
No. receiving No. receiving
higher dose lower dose
nitrazepam (lOmg) 87 (ClOmg) 40
chlormethiazole* (>0.5G) 43 (0.5G) 21
triazolam (0.125mg) 13 (<0.125mg) 22
temazepam (20mg) 16 (<20mg) 15
* edisylate or equivalent
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PERCENTAGE DISTRIBUTION OF HYPNOTICS BY DRUG/DRUG GROUP (N = 387)





























Figure 7;1 Distribution of hypnotic users by drug
(Survey 1)
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HYPNOTIC USAGE WITHIN 24 LOCAL AUTHORITY HOMES
FOR THE ELDERLY






























Figure 7:2 Distribution of hypnotic usage by home
(Survey 1)
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the four most frequently used single-drug hypnotics, nitrazepam
was used by 127 individuals, chlormethiazole by 64, triazolam by
35, and temazepam by 31. Dosages for these four drugs, divided
into "higher" and "lower" dose categories, are shown in Table 7:3.
For nitrazepam, chlormethiazole, and triazolam, these dosages
were also analyzed in relation to the age of the recipient. No
significant relationship was found between age and the dosage of
nitrazepam (chi-square 2.05, df = 1, NS), chlormethiazole (chi-
square = 4.06, df = 1, NS), or triazolam (chi-square [Yates*
correction] = 3.44, df = 1, NS).
Of the 387 residents receiving hypnotics at the time of the
survey, 163 (42.1%) were concomitantly receiving at least one
centrally acting medication. These included major tranquillizers
(62 cases), minor tranquillizers (20 cases), antidepressants (31
cases), and analgesics (31 cases). The remaining 19 cases
comprized anticonvulsants, and antiparkinsonian treatment regimes.
The percentage of residents receiving hypnotics within each
of the 24 establishments is shown in Figure 7:2. The prevalence
of hypnotic drug use between homes showed wide variations, ranging
from 16.6% to 54.5% (see Figure 7:2).
Comment
The prevalence of hypnotic usage found in this study, while
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less than that reported for geriatric inpatients (Christopher et
al. 1978), was greater than that reported for elderly individuals
living in the community (Gerrard et al. 1978). In general, no
preference was shown for the prescribing of short half-life
hypnotics. It is likely, however, that in this age group,
caution in the prescribing of hypnotic drugs is exercised at the
level of dosage. Thus, Table 7:3 shows that, for the two most
used single-drug hypnotics (nitrazepam and chlormethiazole), lower
dosages were preferred.
It is interesting to note that, as predicted in Chapter 6,
gender differences in usage are not prominent in this population.
Table 7:2 shows no significant association between usage and sex.
It is also relevant to note that the age diffences in usage shown
in Table 7:1 accord with the earlier observation (Chapter 6; Table
6:3) that the use of hypnotic drugs continues to increase into the
seventh or eighth decade of life.
Survey 2: Introduction
The second survey, conducted 24 weeks after the first, aimed
to assess the consistency of the pattern and prevalence of drug
usage reported above. A further interest of this second study,
however, was the wide between-home variations in drug usage shown
in Figure 7:2. In addition to age, sex, and drug-use information,
this second survey included the simultaneous collection of data
relating both to the social environment within each home, and to
the general health status of individual residents. By examining
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these data for factors associated with between-home variations in
hypnotic drug consumption, it was hoped to identify possible
determinants of drug usage at the level of the home, and at
the level of the individual.
Methods
The survey was arranged to coincide with the 1981 Social
Work Services Group (SWSG) census of residential accommodation.
This national census requires each home to provide details of sex,
date of birth, date of admission, and health status for each
resident. For each individual resident, health status is also
assessed using six dichotomous ratings (i.e. present/absent) of
handicap and infirmity, viz. physical handicap; mental handicap;
mental illness; chairbound or bedfast; regular incontinence; and
mental confusion. The disabilities, or the degrees of disability,
which merited a positive rating on each of these six indices of
health status are shown in Table 7:4. These criteria for rating
disability are derived from Social Work Services Group
guidelines. A survey proforma, identical to that used in survey
1, was attached to, and completed with each SWSG census return.
Additional Information. Lothian Regional Social Work
Department provided further data on: 1) the number of staff
employed in each home; and 2) the number of General Practitioners
attending each home.
Analysis of data. Drug survey, and SWSG census data were
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Table 7:4. Scope of dichotomous handicap/infirmity ratings:
summary of guidelines provided by the Social Work
Services Group for the completion of SWSG census
forms: (Survey 2)
Rating Disability or Degrees of Disability
Physical Handicap Blindness, Deafness, Severe Epilepsy,
Limb Loss, Severe Arthritis, Cardio¬
vascular Disease, CNS diseases
(stroke, multiple sclerosis, cerebral
palsy).
Mental Handicap Developmental delay such that the in¬
dividual's mental performance is
noticeably and consistently below that
expected for any given chronological age.
Mental Illness Diagnosed conditions under current
treatment.
Mental Confusion Residents whose confusion arises from
brain pathology and is of a permanent
irreversible nature.
Regular Incontinence Daily incontinence of urine and/or faeces.
Chairbound/Bedfast All immobile residents
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combined, and frequency distributions of the variables of interest
were derived. Chi-square analyses of association were computed
where appropriate. Five measures relevant to the social
environment within each home were also computed, viz. the
percentage of male residents; the percentage of female residents;
staff/resident ratio; general practitioner/resident ratio; and the
total number of residents per home. Pearson product-moment
correlation coefficients between each of these measures, and the
level of hypnotic usage within each home were then computed.
Results
Analysis of Hypnotic Usage
All but one of the homes (rank 6, Figure 7:3) completed the
survey proforma. The total survey population comprized 1122
residents. Of these, 382 residents (34.0%) received hypnotics
both on the night of the survey, and on the previous night. The
population parameters of the present (1981) and previous (1980)
surveys are compared in Table 7:5. Figure 7:3 shows the
distribution of hypnotic usage across homes. A Spearman rank
order correlation was computed between these levels of usage, and
those from the 1980 survey; a significant correlation obtained
(rho = 0.67, p<0.01).
The age and sex distributions of hypnotic users and non-
users are shown in Tables 7:6 and 7:7 respectively. No
significant relationship was found between hypnotic usage/non-
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Table 7;5. Comparison of populations from Survey 1 (1980) and
Survey 2 (1981)
Survey n Females Males % Receiving n of
Hypnotics Homes
(1) 1980 1154 781 373 33.5 24
(2) 1981 1122 763 359 34.0 23
Table 7:6. Age distributions of hypnotic users and non-users:
(Survey 2)
Age (years)





31 ( 8.1) 117 (30.6)
81 (10.9) 250 (33.8)
185 (48.4) 49 (12.8) 382 (100.0)
311 (42.0) 98 (13.2) 740 (100.0)
Chi-square = 5.1, df = 3, NS










Chi-square = 0.6, df = 1, NS
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Hypnotic usage within 23 local authority homes for the elderly





































Correlation with 1980 survey: p = 0.67, p < 0.01
data not collected
DISTRIBUTION OF 382 HYPNOTIC USERS BY DRUG/DRUG GROUP









































Table 7:8. Dosage distributions for the four most frequently-





nitrazepam (lOmg) 35 (<10mg) 92
chlormethiazole* (1.0G) 16 (<1.0G) 37
triazolam (0.125mg+) 22 (<0.125mg) 20
thioridazine (50mg+) 12 (<50mg) 24
*edisylate or equivalent
Table 7:9. Age distributions of hypnotic users receiving, and not
receiving, other psychotropic drugs: (Survey 2)
Age (years)
No. (%) hypnotic users
not receiving other 15( 5.3) 76(27.0) 147(52.1) 44(15.6) 282
psychotropic drugs
No. (%) hypnotic users
receiving at least one 16(16.0) 41(41.0) 38(38.0) 5( 5.0) 100
other psychotropic
drug
0-69 70-79 80-89 90+ Totals
Chi-square = 24.6, df = 3, p<0.001
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usage and age (chi-square = 5.1, df = 3, NS) or sex (chi-square =
0.6, df = 1, NS). Hypnotics were grouped into 14 categories.
Eleven of these categories were of single drugs, and the remaining
three contained compounds having pharmacological or therapeutic
similarities. The frequency with which each category of drug was
used is shown in Figure 7:4. The four most frequently used single
drugs were further divided into "higher" and "lower" dose
categories. For each of these drugs, the number of residents
receiving "higher" and "lower" doses is shown in Table 7:8.
Of the 382 residents receiving hypnotics on the night of the
survey, 100 (26.2%) were concomitantly receiving centrally acting
medications (Table 7:9). These included phenothiazine major
tranquillizers (40 cases), analgesics (18 cases), antidepressants
(17 cases), benzodiazepine minor tranquillizers (12 cases), anti¬
convulsants (12 cases), and in one case, an antihistamine based
expectorant. The use of these medications was significantly
associated with the age of the recipients, hypnotic users who did
not receive concomitant psychoactive medications tended to be
older than those who did (chi-square = 24.6, df = 3, p<0.G01).
Analysis of Factors Influencing Hypnotic Usage
The six indices of resident health status, and the five
indices relating to home environment were categorized as "Resident
Variables" and "Home Variables" respectively. Correlation
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coefficients computed between prevalence rates and Resident
Variables are shown in Table 7:11. No significant correlations
were found between hypnotic usage and any of the five Home
Variables. Of the six Resident Variables, hypnotic usage
correlated significantly and negatively with the levels of mental
illness, chairboundness, and incontinence within each home.
Subsequent analyses considered the survey population as a
whole. From the total survey population, 431 individuals were
negatively rated on all six indices of health status. This group,
defined as non-Impaired, was used as a control against which to
compare those rated positively on selected Resident Variables.
These groups (the non-Impaired, and the Impaired) were considered
in relation to hypnotic usage in 2 x 2 contingency tables (Table
7:12). Significant associations were present between hypnotic
usage/non-usage and incontinence (chi-square = 11.02, df = 1,
p<0.01), mental confusion (chi-square = 4.45, df = 1, p<0.05), and
mental handicap (chi-square = 6.91, df = 1, p<0.01).
The most frequently rated impairment was that of physical
handicap (441 individuals). Hypnotic usage within this group
did not differ significantly from that within the non-Impaired
group (Table 7:12). In a final analysis, those rated as
physically handicapped were further sub-divided into those rated
as physically handicapped and confused, and those rated as
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Table 7:10. Correlation coefficients between Home Variables and
levels of hypnotic usage within each home: (Survey 2)
Home Correlation n of
Variable Coefficient Homes
percent
male -0.03 23 p<0.44
percent
female 0.03 23 p<0.44
staff/resi¬
dent ratio 0.09 23 p<0.33
GP/resi-
dent ratio 0.03 23 p<0.43
residents
per home -0.09 23 p<0.33
Table 7:11. Correlation coefficients between Resident Variables
and levels of hypnotic usage within each home: (Survey 2)
Resident Correlation n of
Variable Coefficient Homes
physical
handicap -0.33 23 p<0.06
mental
handicap -0.05 23 p<0.40
mental
illness -0.48 23 p<0.01 **
chairbound/
bedfast -0.39 23 p<0.03 *
incontinent -0.47 23 p<0.01 **
mentally
confused -0.30 23 p<0.09
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Table 7:13. Levels of hypnotic usage within physically handicapped









No. (%) No. (%)
physically
handicapped




confused 228 (63.7) 130 (36.3) 358 1.84 NS
* - p<0.05 ** = p<0.01 NS = not significant
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physically handicapped and not confused. Hypnotic usage within
these two groups did not differ significantly (Table 7:13). The
relevance of this latter analysis is explained in the discussion.
Discussion
Hypnotic Usage
The overall level of, and between home differences in,
hypnotic usage show little variation over the 24 week inter-study
period. In combination, these data suggest that many of the
individual hypnotic users identified in Survey 1 are also
represented in Survey 2, indicating long term prescribing
strategies in the treatment of sleep disorders in the elderly.
The absence of a significant gender difference in hypnotic drug
usage shown in Survey 1, is again shown in Survey 2. This finding
reinforces the conclusion that the greater usage of hypnotics
among elderly females in the community may be predicted from
factors other than sex per se.
While the age distribution of hypnotic users is similar for
both surveys, a significant relationship between age and usage
did not emerge in the second study. The age related use of
concomitantly prescribed centrally acting medications, however,
indicates the existence of differing clinical needs, predictable
from further age parameters, within this elderly population. It
is a matter of some concern, however, that the very elderly
(i.e. those 80-89y), irrespective of sex, were the group most
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likely to receive more than one psychotropic drug. Williamson and
Chopin (1980), for example, have recently confirmed the
intuitively plausible prediction that the occurrence of adverse
drug reactions in the elderly is directly related to the number of
drugs prescribed.
The pattern of hypnotic drug usage is also similar for both
studies, with nitrazepam being most frequently used. In the
second survey, the category "Major/Minor Tranquillizers" was
analyzed in more detail, viz. as chlormethiazole, diazepam,
chlordiazepoxide, and other phenothiazines. It can be seen from
Figure 7:4 that phenothiazines and nitrazepam represented almost
half of the total hypnotic usage. The widespread use of
phenothiazine major tranquillizers in single night-time doses may,
in part, reflect an attempt to exploit the sleep inducing
properties of drugs prescribed for a primary psychiatric
condition. However, the low level of mental illness reported for
hypnotic users (only 28 individuals, see Table 7:12) suggests
that, in many cases, phenothiazines are employed as the night
sedation of choice for this age group, irrespective of psychiatric
status. The widespread use of thioridazine in particular, clearly
shown in Survey 2 (Table 7:8), serves to emphasize this point.
In both surveys, a substantial minority of the individuals
prescribed nitrazepam received a (10mg) dose contraindicated in
this age group (Data Sheet Compendium, 1980-81). It is
interesting to note also that nitrazepam was the most consistently
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prescribed hypnotic; in Survey 2, variations in total hypnotic
usage across homes (Figure 7:3) correlated significantly with
across-homes variations in nitrazepam usage (r = 0.4, n = 23,
p<0.05). Neither survey shows an overall preference for
prescribing short half-life hypnotics. Nevertheless, three of the
drugs shown in Figure 7:3 (representing 34.1% of total hypnotic
usage) have been experimentally evaluated in, and recommended as
suitable for, the elderly, viz. triazolam (Reeves, 1977),
chlormethiazole, and temazepam (Briggs et al. 1980). As shown in
Table 6:4, hypnotics are frequently prescribed for years rather
than weeks or months. Under these circumstances, patients may
develop a preference for a particular hypnotic drug, and resist
its being substituted or withdrawn. Thus, it is possible that the
trends in hypnotic usage shown in these surveys are not
representative of the drug regimes which may be commenced at the
present time. With regard to the drugs currently used, the
concomitant use of centrally acting medications, and, in some
cases (e .^. nitrazepam) the choice of dose, the overall pattern of
hypnotic usage shows no consistent approach to the problem of
minimizing adverse behavioural reactions to hypnotic drugs in the
elderly.
Factors influencing Hypnotic Usage
The analyses presented in Table 7:10 tested the possibility
that between-homes variations in levels of hypnotic drug usage
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may be related to specific characteristics of the home
environment. The absence of a significant relationship between
Home Variables and hypnotic usage (Table 7:10) does not
necessarily imply, however, that environmental factors do not
influence hypnotic drug prescribing. The five factors analyzed
possibly represent only single components in a complex chain of
influences, many aspects of which were not recognized in the
current analyses. Indices of resident health status, on the other
hand, showed two levels of association with hypnotic drug usage.
First, at the level of the home, variations in hypnotic usage were
inversely related to the prevalence of mental illness,
incontinence, and bedfast/chairboundness (Table 7:11). Second, at
the level of the individual, ratings of incontinence, confusion,
and mental handicap were all associated with a reduced
probability of receiving hypnotic drugs relative to the unimpaired
group (Table 7:12).
The negative correlations between hypnotic usage and reduced
health status suggest the existence of a positive relationship
between superior health status (low dependency) and hypnotic drug
use. Similarly, when compared with the confused, the mentally
handicapped, and the incontinent (Table 7:12) non-Impaired
individuals show a significantly higher probability of receiving
hypnotics. Accepting that positive or negative ratings on these
dichotomous variables reflect differing degrees of general
physical dependency, these findings are consistent with a
conclusion that, in institutional settings, the less dependent
residents tend to be more likely to receive hypnotic drugs.
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Prevalence rates reported for hypnotic drug prescribing
among the elderly in the United Kingdom (and reviewed in Chapter
6) vary frcm approximately 10% (Murray et al. 1981) to 27% (Skegg
et al. 1978). In relation to these levels, the present data may
be interpreted as showing a relative increase in hypnotic usage
among the non-Impaired elderly in residential care, rather than a
relative decrease in usage among the more dependent, less healthy,
residents.
This relationship between dependency and hypnotic drug usage
was considered in the final analysis (Table 7:13). The most
frequently rated impairment, physical handicap, showed no
association with hypnotic usage (see Table 7:12). This broadly-
defined health status category included deafness, arthritis,
cardiovascular disease, and limb-loss. Such a grouping would
include individuals of widely differing degrees of dependency.
If, then, hypnotic drug usage in the present study was related to
dependency, this group should demonstrate similarly wide
variations in hypnotic usage if appropriately sub-divided. To
test this possibility, the physically handicapped group was
further sub-categorized as described above, and as shown in Table
7:13. Those rated as physically handicapped and confused, and
those rated as physically handicapped and not confused were
considered as high dependency, and lower dependency groups
respectively. In the event, hypnotic usage within these two sub¬
groups did not differ significantly. However, it can be seen from
Table 7:13 that hypnotic usage within the physically handicapped
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confused and non-confused cells is almost identical with that of
the confused and non-Impaired groups respectively shown in Table
7:12. Thus, while Table 7:13 does not significantly confirm the
conclusion that lower degrees of dependency are associated with a
higher probability of receiving hypnotics, the trend shown _is in
the predicted direction.
These analyses indicate that, within residential homes for
the elderly, there exist low dependency groups having a high
probability of being prescribed, and of receiving, hypnotic drugs.
It is interesting to note that a similar observation has been
reported by Ingman et al. (1975) for "intermediate care
facilities" for the elderly in the USA. Various factors, acting
singly or in combination, might account for this relationship.
Disturbed sleep in a residential home can arise frcm several
causes (for example, unfamiliar surroundings, sharing a room,
departures from established daily routines, etc.). If such
problems are, as has been suggested by Herford (1982) ,
selectively referred by the staff to the general practitioner,
then it is possible that the prescribing of hypnotic drugs is, to
some extent, mediated by the staff's perception of need. It is
plausible that the needs of the least dependent, perhaps more
demonstrative, residents are better communicated to the staff
than are the needs of more dependent individuals. As Clarke et
al. (1982) have pointed out, care staff draw the attention of
general practitioners to the needs of the resident as a relative
might if they were at home.
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Conclusions
The design of the present study ensured that the information
collected was of drugs actually administered. The levels of
hypnotic drug usage shown in both surveys emphasize the value of,
and the need for, relevant psychopharmacological assessments of
sedative-hypnotic products likely to be prescribed for elderly
individuals. However, it is also apparent that such information,
where available, has, at the present time, less of an impact on
prescribing trends than is desirable. Several published studies
(reviewed in Chapter 5), for example, indicate that the elderly
are particularly sensitive to the cumulative, residual effects of
nitrazepam, especially in lOmg doses. The above surveys, however,
show nitrazepam to be the most consistently and the most
popularly used hypnotic drug.
As regards the design of further experimental studies, two
specific points, emerge from these surveys. First, considering
all drugs, the data suggest long term, repetitive use of sedative-
hypnotic products by the elderly. Simulating this pattern of
usage under controlled conditions demands a multiple-dose, and
not a single-dose, design. Second, the dosage distributions for
nitrazepam (shown in Tables 7:3 and 7:8) reflect the assumption,
reported by Castleden et al. (1977), that the adverse behavioural
effects arising from the use of this drug in lOmg doses by the
elderly may be modified by employing a lower (5mg) dose. As a
consequence of the information provided in the above surveys, this




Experiment 2: An evaluation of the effects of single and repeated
low doses of nitrazepan on performance in the elderly.
In Chapter 5 it was noted that nitrazepam, in night time doses of
lOmg, has been reported to impair the daytime performance of both
healthy (Castleden et al. 1977) and hospitalized (Linnoila and
Viukari, 1976) elderly individuals. The survey data presented in
the previous chapter showed that, although nitrazepam is still
widely prescribed for the elderly, a dose of 5mg was recorded for
the majority of recipients. This finding is consistent with the
recommendations of Castleden et al. (1977) that "the dose of
nitrazepam should be decreased in elderly patients". However, the
assumption that adverse behavioural reactions to this drug in
healthy elderly individuals can be significantly offset by
employing a lower dose is not empirically supported.
The clinical literature contains few studies concerned with
the effects of low dose nitrazepam on performance in the elderly.
Nayal et al. (1978) compared the effects on psychomotor
performance of single dose nitrazepam 5mg and chlormethiazole
(base) 384mg in 18 rehabilitating medical geriatric inpatients.
While performance, as measured by a letter cancellation task, did
not differ significantly between the two drug conditions, it is
relevant to note that this study did not include a placebo control
and does not, therefore, represent a definitive evaluation of low
dose nitrazepam in the elderly. Furthermore, the effects of drug
accumulation, inherent in long half-life hypnotics like
nitrazepam, are not evaluated in single dose studies. Witts et
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al. (1979), for example, report computer predictions of
nitrazepam plasma concentrations in the elderly which suggest
that peak concentrations may more than double between the first
and seventh repeated doses of this drug (i.e. from approximately
100 ng/ml after dose 1, to over 250 ng/ml after dose 7).
Extrapolating from these data, it is reasonable to assume that
residual concentrations will similarly increase with repeated
doses. Two studies have reported the effects of repeated low
doses of nitrazepam in elderly hospital patients. Viukari et
al.'s (1978) comparison of the effects of repeated dose flurazepam
15mg, fosazepam 60mg, and nitrazepam 5mg (discussed in Chapter 5)
in psychogeriatric inpatients does report a significant slowing of
tapping speed during the nitrazepam condition. Results frcm this
severely impaired patient group, however, which included
individuals with diagnoses of senile dementia, cerebral
arteriosclerosis, Korsakov's psychosis, and schizo-affective
psychosis, do not readily generalize to those elderly persons who
receive primary medical care from general practitioners. Murphy
et al.'s (1982) data, which suggest impaired performance on a card-
sorting task in medical geriatric inpatients following five
repeated doses of nitrazepam 2.5mg, present similar problems of
generality. Furthermore, the design of this latter study
(critically reviewed in Chapter 5), which compared the effects of
nitrazepam and triazolam 0.125mg, did not include a placebo
control. The decrements reported, therefore, are relative only to
the effects of repeated dose triazolam.
In healthy young adults, nitrazepam 5mg has been associated
with few residual effects on performance. Malpas et al. (1970)
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compared performance on the Crossman card-sorting task in 12 male
subjects (aged 18-24y) 13h after the ingestion of single dose
nitrazepam 5mg or lOmg, and placebo. No significant effect was
reported following nitrazepam 5mg on measures of movement or
choice reaction times, while a significant slowing of movement
time was reported for the larger, lOmg dose. Bond and Lader
(1972) compared the residual effects of single dose nitrazepam 5mg
and lOmg in 10 healthy subjects (aged 21-34y). Tests included
choice reaction time, simple reaction time, tapping speed, letter
cancellation, digit symbol substitution, and the Gibson spiral
maze. While nitrazepam lOmg significantly impaired performance on
the simple reaction time, tapping speed, and digit symbol
substitution tests, only digit symbol substitution showed
impairment following the 5mg dose. In young adults, then,
nitrazepam in single 5irg doses is clearly associated with a
reduced probability of residual sequelae. In the present study,
the effects of single and repeated low doses of nitrazepam on the
performance of healthy elderly people are evaluated and compared.
A further purpose of the present study was to pilot an
experimental methodology for assessing the residual effects of
hypnotic drugs in the elderly. Methodological considerations
relevant to the design of, and selection of tests for
psychopharmacological performance studies involving elderly
subjects have been discussed in Chapter 5. These considerations,
which have been recognized in the design of the present




All subjects were resident within local authority homes for
the elderly in the Edinburgh area. Ttoo men (aged 77 and 79y) and
ten women (aged 76, 77, 80, 84, 85, 86, 88, 89, 91, and 96y)
participated on a voluntary basis. The group mean age was 84.Oy.
None was receiving psychoactive medication, and each abstained
from alcohol for the duration of the study. All subjects were in
good general physical health, and each participated with the
consent of their own general practitioner, and with the consent
and cooperation of Lothian Regional Social Work Department.
Prior to their inclusion in the study the mental and physical
competence of each subject was assessed using the Survey Version
of the Clifton Assessment Procedures for the Elderly (Pattie and
Gilleard, 1979). These procedures include the assessment of
physical disability (PD) which is expressed as a ED score, and
general mental competence, which is expressed as an
information/orientation (I/O) score. In both cases, high scores
indicate low dependency, and vice versa. The PD score is then
deducted from the I/O score, and the resultant value is converted
into an overall grading, which can range from Grade A ("No
impairment") to Grade E ("Severe impairment - maximum
dependency"). Grades A or B were achieved by all participating
subjects. These selection procedures ware employed for two
reasons. First, to exclude individuals with significant mental
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or physical impairment, and second, to reduce variability in the
group as regards mental and physical abilities.
Experiment Design
The design of the experiment is shown in Diagram 8:1. A
double-blind, group controlled design was used to reduce the
duration of the experiment, and thus reduce the risk of subject
drop-outs. [It was felt that an alternative within-subjects
design, which included practice, baseline, and washout periods,
and which would have taken proportionately longer to administer,
would have increased the probability of drop-outs in this high-
risk elderly group]. Subjects were blind to the experimental
conditions throughout the study; the experimenter was blind to
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Diagram 8:1 Experiment design and testing schedule
Subjects were randomly assigned to the control or drug
groups (n = 6/group) with the single constraint that each group
should contain one male. Both groups received identical capsules
on 22 consecutive nights. For the drug group, capsules contained
placebo on nights 1-14, and nitrazepam 5mg on nights 15-22. The
control group received placebo throughout. Testing sessions
commenced on the morning following the first administration of
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capsules, and then at regular weekly intervals for the succeeding
three weeks. Thus, the drug group was tested twice under placebo
conditions, the morning after the first, and the morning after the
eighth consecutive dose of nitrazepam. Each subject was tested 12-
14h after receiving a capsule. Test sessions were conducted in a
performance laboratory at the Royal Edinburgh Hospital. Subjects
attended the laboratory in groups of six, and were individually
tested in turn. The same order of testing was maintained
throughout the experiment.
Before commencing the experiment proper, each subject
received two informal practice sessions on the test apparatus
described below. These practice periods, conducted within the
residential homes, allowed the subjects to gain familiarity with
the requirements of the task.
Testing Procedure
The main criteria for the selection of an appropriate
performance task were as follows:
1) the task should measure both the speed, and the accuracy
of performance;
2) the amount of potentially irrelevant stimuli generated
by the task should be minimal;
3) the demands of the task (i.e. the degree of task
complexity) should be variable;
4) efficient performance on the task should not require a
level of manual dexterity outwith the physical competence of very
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elderly individuals. (This latter criterion effectively precluded
many tests which load heavily on writing skills).
A task which met all these criteria was a modification of the
reciprocal tapping task described by Fitts (1954), and
subsequently employed in aged populations by Welford et al.
(1969). In the present experiment the apparatus consisted of a
metal board (20.5cm x 45.5cm) into which could be fitted identical
pairs of metal disks (targets), which were placed 25cm apart
(centre to centre). These targets were symmetrically placed in
the mid-line of the board. A diagram of this apparatus is shown
in Appendix 5:1. The subject was provided with a pen-like
contact stylus and required to tap each target alternately as
quickly, and as accurately as possible over a 30s period.
Contacts with either of the two targets (hits) or with the
surrounding fascia (errors) completed an electric circuit and
registered on an appropriate digital counter. Three different
target sizes were used: 6cm; 4cm; and 1.5cm diameters. These
three pairs of targets were presented first in descending order,
and then in ascending order of size. Scores were averaged over
ascending and descending presentations. A constant time interval
of 1 minute was observed between each 30s trial. The subject used
the preferred hand.
Two measures were recorded from this task:
1) mean total contacts (hits + errors) for each target size;
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2) mean total errors for each target size.
Subjective Ratings
Throughout the study Home staff completed, according to
their own observations and judgement, daily ratings of the
subject's general behaviour. The 10cm visual analogue scales used
for this purpose are reproduced in Appendix 5:2. Five subjective
variables were rated: Sleep Quality, "better than usual" to "worse
than usual"; Morning Alertness, "very alert" to "very drowsy";
Daytime Alertness, "extremely bright and alert" to "generally
lethargic and drowsy"; Steadiness of Gait, "more steady than
usual" to "less steady than usual"; and Mental Competence,
"extremely lucid and clear" to "generally confused".
Analysis of Data
The first test session (TO, Diagram 8:1) was for adaptation
and practice only. Data from the remaining three sessions were
analyzed by repeated measures analysis of variance with one
grouping factor (drug/placebo) and two trial factors (test
sessions 1, 2, and 3; target sizes 6cm, 4cm, and 1.5cm). As test
session 1 was a placebo condition for both groups, drug effects,
if present, were expected to emerge as interactions between
session and group, rather than as main effects of group alone.
Where appropriate, paired comparisons were subsequently undertaken
using t-tests for independent samples. Two tailed tests of
significance were used throughout.
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Further analyses were then undertaken to evaluate the
sensitivity of the task at all three levels of task complexity.
Unweighted deviation scores for each target condition (6cm, 4cm,
and 1.5cm) were calculated by deducting a given subject's scores
for test sessions 2 and 3 from that subject's appropriate scores
for test session 1. Deviation scores for each of the three target
sizes were then individually analyzed by repeated measures
analysis of variance with one grouping factor (drug/placebo) and
one trial factor (test session 2 and 3).
Subjective Ratings
Daily ratings collected during a seven day period following
the eighth night of capsule ingestion (see Diagram 1) were
considered as baseline data. For each of the five subjective
variables, each subject's mean baseline score for this period was
calculated. Unweighted deviation scores were then calculated for
each rating collected during the seven day period following the
15th night of capsule ingestion. This latter period corresponds
to the first seven days of nitrazepam ingestion by the drug
group. For each individual day within this period, and for each
subjective variable, deviation scores (calculated as the mean
baseline score minus the subsequent raw score) from the drug and
placebo groups were compared using the Mann-Whitney U test.
Results
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One female subject (age = 86y) in the placebo group
withdrew from the experiment in the second week owing to a chest
infection. The mean age of the remaining 11 subjects was 83.8y.
(drug group, n = 6; mean age = 83.5y; control group, n = 5, mean
age = 84.2y)
Analysis of mean total contacts for all three target
conditions (Table 8:1) showed no significant main or interaction
effects which distinguished performance in the drug group from
that in the placebo group. Analysis of mean errors, however,
(Table 8:2) showed a significant group by session interaction
(F = 6.92; df = 2,18; p<0.01). This interaction is illustrated in
Figure 8:1. From this figure it can be seen that mean errors
increased under the nitrazepam condition. Results frcm paired
comparisons between the groups for each of the three test sessions
are presented in Table 8:3. These results show that differences
between the groups reached significance in session 3 (t = 2.38;
p<0.05). (Havlicek and Peterson (1974) have demonstrated that the
t value remains an effective and robust index of differences
between means where group sizes differ only slightly, and where n
= 5 in one of the groups].
Analyses of the deviation scores for each individual target
size are presented in Tables 8:4 (6cm targets), 8:5 (4cm
targets), and 8:6 (1.5cm targets). For the target sizes 6cm and
4cm, error deviation scores showed no significant main or
interaction effects which distinguished performance in the drug
group fran that in the placebo group. Analysis of error deviation
- 194 -
Table 8;1 Analysis of variance of mean total contacts
(reciprocal tapping task)
Source Sum of df Mean F
Squares Square
Mean 91488.975 1 91488.975 298.74
Group (G) 56.324 1 56.324 0.18
Error 2756.265 9 306.252
Session (S) 204.927 2 102.464 8.17
S x G 55.624 2 27.812 2.22
Error 225.738 18 12.541
Target (T) 164.586 2 82.293 4.18
T x G 14.200 2 7.100 0.36
Error 354.087 18 19.671
S x T 61.607 4 15.402 1.75
S x T x G 11.038 4 2.760 0.31









Table 8:2 Analysis of variance of mean total errors
(reciprocal tapping task)
Source Sum of df Mean F
Squares Square
Mean 798.000 1 798.000 34.24
Group (G) 27.445 1 27.445 1.18
Error 209.768 9 23.308
Session (S) 26.416 2 13.208 3.64
S x G 50.214 2 25.107 6.92
Error 65.346 18 3.630
Target (T) 269.648 2 134.824 11.73
T x G 20.658 2 10.329 0.90
Error 206.857 18 11.492
S x T 89.249 4 22.312 4.91
S x T x G 35.996 4 8.999 1.98









Group = drug group/placebo group
Session = test session 1, 2, and 3
Target = 6cm, 4cm, and 1.5cm diameters
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Session x Drug: F = 6.92; df = 2, 18; p < 0.01
Effects of single, and eight repeated doses
of nitrazepam 5mg on perfromance in the
elderly
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Effects of single, and eight repeated doses





8:3 Paired comparisons between drug and placebo groups:
reciprocal tapping (mean total errors)
Test Mean Errors (SD) t-value
Session drug group placebo group
1 1.78 (1.33) 2.60 (1.21) 1.08
2 3.58 (2.73) 2.23 (1.21) 1.09
3 4.78 (2.36) 2.13 (1.24) 2.38*
* = p<0.05
Table 8:4 Analysis of variance of mean error deviation scores:
reciprocal tapping task (6cm Targets)
Source Sum of df Mean F
Squares Square
Mean 4.097 1 4.097 0.43
Group (G) 22.552 1 22.552 2.36
Error 86.017 9 9.557
Session (S) 2.933 1 2.933 1.11
G x S 1.024 1 1.024 0.39





Table 8:5 Analysis of variance of mean error deviation scores:
reciprocal tapping task (4cm Targets)
0.608
0.200
Source Sum of df Mean F
Squares Square
Mean 0.947 1 0.947 0.28
Group (G) 6.402 1 6.402 1.91
Error 30.167 9 3.352
Session (S) 5.638 1 5.638 1.75
S x G 0.547 1 0.547 0.17
Error 29.067 9 3.230
Group = drug group/placebo group




Table 8:6 Analysis of variance of mean error deviation scores:
reciprocal tapping task (1.5cm Targets)
Source Sum of df Mean F P
Squares Square
Mean 286.046 1 286.046 16.30 0.003
Group (G) 155.637 1 155.637 8.87 0.015
Error 157.954 9 17.550
Session (S) 10.064 1 10.064 1.07 0.328
S x G 23.109 1 23.109 2.54 0.152
Table 8:7 Analysis of variance of mean total contacts as devi¬
ation scores: reciprocal tapping task (1.5cm Targets)
Source Sum of df Mean F P
Squares Square
Mean 530.558 1 530.558 12.50 0.006
Group (G) 77.217 1 77.217 1.82 0.210
Error 381.897 9 42.433
Session (S) 25.508 1 25.508 4.39 0.066
G x S 1.167 1 1.167 0.20 0.665
Error 52.322 9 5.814
Session = test session 1, 2, or 3
Group = drug group/placebo group
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TOTAL RECIPROCAL TAPPING FREQUENCY







control group (n = 5)
Test Session
Figure 8:3 Effects of single, and eight repeated
doses of nitrazepam 5mg on frequency
of tapping in the elderly











Figure 8;4 Effects of nitrazepam 5mg on daily
ratings of morning alertness
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scores for the 1.5cm target condition, however, showed a
significant main effect of group (F = 8.87; df = 1,9; p<0.05).
Figure 8:2 shows that, for the 1.5cm. targets, the placebo
condition was associated with superior performance. The analysis
of total contacts (as deviation scores) for the 1.5cm target
condition is shown in Table 8:7, and illustrated in Figure 8:3.
Analysis of variance of these scores showed no significant main or
interaction effects which distinguished performance in the drug
group from that in the control group.
Subjective Eatings
For ratings of Sleep Quality, Daytime Alertness, Steadiness
of Gait, and Mental Competence, scores varied little from day to
day. None of these variables showed systematic differences
between the drug and placebo groups. However, for ratings of
Morning Alertness, differences between the groups did show a trend
towards significance in the latter part of the week. The mean
daily scores for morning alertness are shown in Figure 8:4. On
this variable, scores differed significantly on the mornings
following the 5th (U = 4.5, p = 0.05) and the 7th (U = 3.0, p =
0.03) dose of nitrazepam in the drug group
Discussion
On the reciprocal tapping task, the overall frequency of
tapping, as measured by total contacts, reflects the speed of the
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subject's performance, while the error score indicates the degree
of accuracy. Increased accuracy on this task may be achieved at.
the cost of speed, and vice versa. In the present experiment,
repeated low doses of nitrazepam 5mg impaired psychomotor
accuracy, but did not significantly affect the speed of motor
responses in this elderly group. The significant increase in
errors shown by the drug group between test sessions 2 and 3
(Figure 8:1), is consistent with drug accumulation during this
period. Table 8:2 shows no interaction between Target and Group
(F = 0.90; df = 2, 18; p = 0.425), suggesting that impairment was
independent of the differing demands of the task. However, such
an interaction may have been attenuated by the inclusion of test
session 1 (placebo for both groups) in the analysis. Results from
the analysis of deviation scores (Tables 8:4, 8:5, and 8:6)
suggest, rather, that the smallest target size (1.5cm) was most
sensitive to the drug effects shown here. That repeated doses of
nitrazepam 5mg selectively affected accuracy on this task is
again emphasized in Figures 8:2 and 8:3. While both groups showed
similar levels of psychomotor speed on, and similar levels of
improvement between, test sessions 2 and 3 (Figure 8:3), the drug
group showed a marked and significant decrease in accuracy over
the same period (Figure 8:2).
As noted in Chapter 5, elderly individuals are adept at
improving their accuracy on sensory-motor tasks by making
compensatory reductions in their speed of performance. Kay
(1955), for example, reports that on relatively simple tasks, the
elderly tend to be slower, but more accurate than younger
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subjects. It is reasonable to assume, then, that reductions in
tapping efficiency (i.e. an increase in errors), if perceived by
the subject, would result in a compensatory slowing of
performance. Thus, subjects in the drug group could have
maintained error scores at about pre-drug levels had they reduced
their frequency of tapping. Clearly, however, this did not
occur. Following both the first, and the seventh repeated doses
of nitrazepam, subjects in the drug group maintained a frequency
of tapping incompatible with efficient performance (as defined by
their own baseline values). Such a result may relevantly be
considered in terms of impaired judgement of accuracy.
The reciprocal tapping task provides the subject with no
augmented feedback. Thus, in order to monitor the efficiency of
their own progress, subjects must rely on visual, and
proprioceptive cues. This process corresponds to the subjects
"judgement of accuracy", and can be assumed to mediate the
selection of tapping frequency (Welford, 1980). Should this
judgement be impaired, then it is possible that subjects will be
less aware of their own errors and, as a consequence, fail to
compensate for them. In this respect it is particularly relevant
to note that performance in the control group (Figure 8:1)
deviated little between sessions 1 and 3, suggesting that, after
practice on this task, these elderly subjects selected, and
maintained their optimal "trade-off" between speed and accuracy
throughout the study. Support for this conclusion is provided by
the data of Salem et al. (1981) who report that the time taken to
complete the Gibson spiral maze was increased in elderly females
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llh after a single dose of nitrazepam lOmg, while accuracy was
unimpaired at this time. Unlike the reciprocal tapping task used
in the present experiment, errors on the Gibson spiral maze are
clearly and permanently visible to the subject, and probably allow
more efficient monitoring of performance and compensatory
reductions in speed. [The Gibson spiral maze, fully described in
the next chapter, requires the subject to track through a printed
maze with a pencil. Contact between pencil and the "walls" of the
maze constitute errors].
Ratings of early morning alertness also show a pattern of
results which, in part, are consistent with cumulative drug
effects over the seven day period. This result, however, must be
interpreted with seme caution. It can be seen from Figure 8:4
that deviation scores for the control group suggest an increase
in alertness between the first and seventh days of recording.
Nevertheless, mean scores in the drug group remain below baseline
levels throughout this period. If the placebo scores reflect a
response bias in the raters, such a bias may have been "corrected"
by an overt drug-induced reduction in morning alertness in the
nitrazepam group.
The absence of any significant effects on staff ratings of
sleep quality does not challenge the known hypnotic efficacy of
nitrazepam in middle-aged (Adam et al. 1976) and elderly (e.g.
Haider, 1967, 1968; Linnoila and Viukari, 1976) individuals.
These particular ratings were scored by the night staff on the
basis either of personal judgement, or by replies elicited frcm
the subjects. In general, these visual analogue scales showed a
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marked tendency for staff to favour a "no change" score throughout
the experiment, suggesting an absence even of normal variations in
sleep quality. While the ratings used in the present study were a
departure from the, apparently more sensitive, instruments used in
Experiment 1 (and described in Chapter 4), they nevertheless
served the important function of focussing the attention of the
staff on to this high-risk elderly group during the course of the
experiment.
Conclusions
The results from the present study challenge the assumption
that adverse behavioural reactions to nitrazepam in the healthy
elderly can be effectively offset by employing a 5mg dose. While
impaired performance was not apparent after a single 5mg dose,
repeated doses clearly disrupted the efficiency of performance in
this elderly group. This effect was consistent with drug
accumulation over the seven day experimental period, and might
plausibly be attributed to the subject's impaired judgement of
error.
Support for this conclusion is provided by the recently
published study of Cook (1983) , in which single and repeated doses
of temazepam 20mg, and nitrazepam 5mg, were evaluated and compared
in 58 rehabilitating hospital inpatients. Both nitrazepam and
temazepam were associated with worsening performance on a choice
reaction time task between the first and seventh nights of drug
consumption (see Table 5:1). Pharmacokinetic data from this study
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show that the mean residual concentrations of both drugs
increased over the seven day drug taking period: from 126 ng/ml to
190 ng/ml for temazepam; and from 23 ng/ml to 49 ng/ml for
nitrazepam. A particularly interesting finding of Cook's (1983)
study concerns performance on a letter cancellation task similar
to that used by Castleden et al. (1977), and described in Chapter
5. Following both drug treatments, and relative to placebo
scores, speed on this task was reported to be slower, while
accuracy was reported to increase. Thus, under the drug
conditions, subjects apparently improved their accuracy on the
cancellation task by reducing speed. In the event, overall
efficiency (as measured by time x errors) following both drug
conditions did not differ significantly from placebo. These data
reinforce the suggestion that drug impaired accuracy, if apparent
to the subject, may be compensated for by a suitable reduction in
speed.
At a methodological level, the present study has demonstrated
the effectiveness of the reciprocal tapping task in assessing
residual drug effects in the elderly. Both this task, and aspects
of the present study design, are further developed in Experiment
3. Two specific points will be noted here. First, from the
analyses of raw and deviation scores, it is apparent that both
were sensitive measures of drug effects. Second, it is also
apparent that the informal practice sessions conducted prior to
the experiment proper, facilitated relatively steady levels of
performance on the reciprocal tapping task. Together, these
findings suggest that, in a conventional crossover design
- 205 -
experiment, the study duration can be reduced without loss of
sensitivity by omitting practice or baseline sessions. These
considerations are implemented in the design of the next
exper iment.
Footnote
It should be noted that the studies of Murphy et al. (1982)




Experiment 3: A comparison of the effects of repeated dose
nitrazepam 5.0mg, lormetazepam l.Omg and placebo on daytime
performance in the elderly.
Introduction
The results from the previous experiment (Chapter 8) indicate
that impairment of performance efficiency in the elderly may
accompany the repeated use of long-acting hypnotics, even when low
doses are specifically employed. The impairment shown was
consistent with drug accumulation over the eight nights of
consumption. Given this characteristic of the residual effect, it
remains probable that (as argued in Chapter 2) repeated doses of
short acting compounds, being less likely to accumulate, will also
be less likely to impair daytime efficiency. This conclusion is
supported by the results presented in Chapter 3; the effects on
performance of repeated doses of triazolam (mean elimination half-
life = 2-4h) and loprazolam (mean elimination half life = 15h)
showed no evidence of drug accumulation over the 16 consecutive
nights of consumption in middle-aged subjects. Nevertheless,
repeated 0.5mg doses of the very short acting triazolam were
associated with a relative increase in subjectively rated anxiety,
a finding consistent with daytime withdrawal effects. So far as
untoward behavioural reactions are concerned, then, it is
reasonable to suggest that the optimal elimination half-life for
an hypnotic drug lies within the range >4h to 15h. Within this
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range repeated doses would be less likely to produce either
cumulative effects, or possible daytime withdrawal effects, on
performance. In the present experiment, this hypothesis is
tested in elderly subject-volunteers; the effects on performance
in the elderly of the short-acting hypnotic lormetazepam are
evaluated, and compared with those of low-dose nitrazepam and
placebo.
Lormetazepam [7-chloro-5-(2-chlorophenyl)-3-hydroxy-l-methyl-
1, 3-dihydro-2H-l, 4-benzodiazepine-2-one] is a recently
introduced benzodiazepine derivative. In healthy young adults
(mean age = 24.2y) the mean plasma half-life is reported to be
approximately lOh, while in healthy elderly individuals (mean age
65.8y) the mean plasma half-life is increased to approximately 15h
(Humpel et al. 1982). Oswald et al. (1979) compared the hypnotic
and residual effects of repeated dose lormetazepam and flurazepam
in two groups of volunteers. During a three week period of drug
consumption, EEG sleep recordings showed lormetazepam (2.5mg and
l.Omg) and flurazepam (30mg) to be effective hypnotics in nine
middle-aged subjects (mean age = 61y). In a further 12 subjects
(mean age = 53y) neither dose of i-drmgr^zerim was associated with
significantly impaired performance on tests of auditory vigilance,
manual dexterity, digit-symbol substitution, or card sorting
following 16 consecutive doses. Flurazepam 30mg, over the same
period, showed a pattern of worsening performance between the
third and sixteenth doses consistent with drug accumulation. In a
single dose study, however, Nicholson and Stone (1982) report
that, while lormetazepam 0.5mg, l.Omg and 2.0mg were all effective
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hypnotics, the 2.0mg dose was associated with impaired performance
on a visuo-motor coordination task (Borland and Nicholson, 1974)
and on the digit-symbol substitution test in six healthy male
subjects (mean age = 22y). The reasons for these discrepant
results concerning higher doses of lormetazepam are obscure,
though the possibility exists that Oswald et al.'s older subjects,
who were all self-reported poor sleepers, actually derived some
daytime behavioural advantage frcm the use of lormetazepam 2.5mg.
The impact of lormetazepam on the daytime performance of
healthy aged subjects has not been investigated. In the present
study, the effects of repeated dose lormetazepam l.Omg, nitrazepam
5mg, and placebo are evaluated and compared. The study had three
specific objectives.
First, to test the hypothesis that repeated doses of short-
acting hypnotics, whose elimination half-life in the elderly falls
within the range >4-15h, are less likely to be associated with
impaired daytime performance in this age group.
Second, to replicate the results of Experiment 2 (Chapter 8)
concerning the impact of low-dose nitrazepam on performance in the
elderly.
And third, to further investigate the effects of repeated
doses of hypnotic drugs on speed and accuracy in the elderly by
extending the use of the reciprocal tapping task (Chapter 8) , and
by including other tasks which measure these aspects of
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performance. Thus, in addition to the reciprocal tapping task
the present test procedures included the Gibson spiral maze
(Gibson, 1978) , and a letter cancellation task (as described by
Briggs et al. (1980). Both tests have previously been used in
studies concerned with the residual effects of hypnotic drugs in
the elderly (Salem et al. 1982, and Briggs et al. 1980
respectively; see Table 5:1).
Subjects
All subjects were resident within Local Authority Homes for
the Elderly in the Edinburgh area. Three men (aged 80, 75 and
78), and nine women (aged 83, 96, 82, 79, 90, 78, 78, 81 and 77)
participated. The group mean age was 81.4y. Each subject was
paid on completion of the study. None was receiving psychoactive
medication, and each abstained from alcohol for the duration of
the study. All subjects were in good general physical health, and
each participated with the consent of their own general
practitioner, and with the consent and cooperation of Lothian
Regional Social Work Department. Prior to their inclusion in the
study the mental and physical competence of each subject was
assessed on the Survey Version of the Clifton Assessment
Procedures for the Elderly (Pattie and Gilleard, 1979). Grades of
A or B were achieved by all participating subjects (see Chapter
8) . These procedures were employed to exclude individuals with
significant mental or physical impairment, and to reduce
variability in the group as regards mental and physical abilities.
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Design
The present study includes many of the design features
employed in Experiment 2 (Chapter 8), particularly pre-
experimental practice sessions, and experimental performance
testing after single and multiple doses of drug. Unlike the
previous experiment, however, baseline weeks were emitted frcm,
and a within-subjects design was used in the present study.
Identical matching capsules of lormetazepam l.Omg, nitrazepam
5.0mg, and placebo were administered in a within-subjects design
experiment (Diagram 9:1). Subjects received each of these
treatments for a period of seven nights, in a balanced double-
blind sequence (see Diagram 9:1).
Each of the seven treatment nights was preceded by two nights
of placebo. Thus, subjects received the capsules continuously for
27 nights. The sequence of performance testing is also shown in
Diagram 1. A practice session followed the second placebo capsule
prior to each treatment week. Each subjects was then tested on
the morning following the first, and the morning following the
seventh capsule within each drug week. Subjects ware blind to the
experimental conditions throughout the experiment; the
experimenter was blind to the experimental conditions only during
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T = Day of Testing Session
D = Drug (lormetazepam l.Omg or nitrazepam 5mg)
P = Placebo
Diagram 9:1 Study design and testing schedule
Before commencing the experiment proper, each subject
received two informal practice sessions on the tests described
below. These practice sessions were conducted in the residential
homes, in rooms subsequently used for experimental testing.
Method
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Drugs were administered by senior care staff within each Home
at the subject's normal bedtime. Each subject was tested 12-14h
after receiving a capsule. A quiet rocm in which testing could be
completed without interruption was allocated by the staff, and
used on each testing occasion. The performance tests, which took
approximately 25 minutes to complete, were as follows:
1. The reciprocal tapping task. (The apparatus for this task
is described in Chapter 8, and Appendix 5:1). The subject was
required to tap two identical circular targets placed 10 inches
apart (centre to centre) alternately with a contact stylus as
quickly and as accurately as possible over a 30-second period.
Contacts with either target (hits) or with the surrounding fascia
(errors) completed an electric circuit and registered on digital
counters. Four different target sizes were used (2cm, 3cm, 4cm
and 6cm diameters). Targets were presented first in descending
order and then in ascending order of size. A constant time
interval of one minute was observed between each trial. Scores
for each target size were averaged over ascending and descending
presentations. The subject used the preferred hand. Two measures
were analyzed from this task.
i. Mean total contacts (hits + errors) for each target size;
ii. The mean percentage errors for each target size (i.e. [the
mean total errors/mean total contacts] x 100)
2. The Gibson spiral maze (Gibson, 1978). This paper and pencil
- 213 -
test requires the subject to track through a simple spiral
maze as quickly, and as accurately, as possible. The test was
scored according to the manual (Gibson, 1978). The 15sec time
stresses (i.e. verbal requests, made every 15sec, for the subject
to proceed faster) have been found to be unsuitable in older
populations (see Gilleard, 1982), and were therefore omitted.
Three measures were recorded and subsequently analyzed.
i. The time taken to complete the maze,
ii. The error score (errors are scored when the "walls"
of the maze are touched, or penetrated by the pencil).
and iii. The total efficiency score, calculated as time x
(log (error + 1)) .
3. A large print letter cancellation task (after Briggs et
al. 1978). The subject was presented with a single page of large
print prose (5.0nm characters) and asked to delete as many letter
"e"s as possible over a two minute period. A different page was
used on each testing occasion. A representative page is
reproduced in Appendix 6:£. Three measures were analyzed from
this task.
i. The total number of "e"s deleted (i.e. the number of hits).
ii. The total number of "e"s missed (i.e. the number of "e"s
not deleted between the first and the last "e" successfully
deleted).




Throughout the study Home staff completed, according to their
own observations and judgement, daily ratings of the subject's
level of morning alertness. Each morning throughout the study,
subjects completed ratings of sleep quality. The 10cm visual
analogue scales used for both ratings are reproduced in Appendix
6:1. Sleep quality was rated on a scale from "better than usual"
to "worse than usual"; the scale for ratings of morning alertness
varied from "very alert" to "very drowsy".
Analysis of data. Results from the performance tasks were
analyzed using repeated measures analysis of variance. Where
appropriate, paired comparisons were subsequently undertaken using
correlated t-tests. For the large print letter cancellation task,
and for the Gibson spiral maze, the analyses of variance were run
with two trial factors: treatment (lormetazepam; nitrazepam; and
placebo); and test session (session 1 after the first dose and
session 2 after the seventh dose). For the reciprocal tapping
task data the analyses of variance contained a further trial
factor: target size (6cm; 4cm; 3cm and 2cm). For both subjective
variables, the average weekly rating for each Drug/Placebo week
(Diagram 9:1) was calculated for each subject. The mean weekly
ratings for each of three drug conditions were then compared using
Friedman's non-parametric analysis of variance.
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Results
Throughout this and the following section, the four target
sizes on the reciprocal tapping task will be considered as four
"target conditions".
None of the test measurements from the Gibson spiral maze
(Tables 9:1, 9:2 and 9:3) or frcm the large print letter
cancellation task (Tables 9:4, 9:5 and 9:6) showed significant
main effects of, or significant interaction effects with, drug
treatment. For the reciprocal tapping task, total contacts showed
no significant main effect of, and no significant interaction
effect with drug treatment (Table 9:7). Analysis of percent
errors, however, while showing no significant main effect of drug,
did show two significant interaction effects.
1. Drug treatment x session (F = 8.26; df = 2, 22; p<0.005); and
2. Drug treatment x target x session (F = 2.85; df = 6, 66;
p<0.05); see Table 9:8.
The two-way interaction (drug treatment x session) is shown in
Figure 9:1. T-tests calculated between the treatment means
following a single dose showed that while neither lormetazepam nor
nitrazepam error scores differed significantly frcm placebo,
performance associated with nitrazepam was significantly superior
to that associated with lormetazepam (t = 2.90, df = 11, p<0.05;
Table 9:13). After seven consecutive doses, however, performance
following nitrazepam was significantly impaired relative to both
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lormetazepam (t = 2.54; df = 11; p<0.05), and placebo (t = 3.CO;
df = 11, p<0.01).
The significant three-way interaction (drug treatment x
target x session) was further analyzed by repeating the analyses
of variance for each target size independently (i.e. one ANOVA for
the 2cm target condition, one for the 3cm target condition,
etc.). The results from these four analyses of variance are shown
in Tables 9:9, 9:10, 9:11 and 9:12. The 6cm and 4cm targets
showed no significant main effect of, and no significant
interaction effects with the drug factor. Both the 3cm and the
2cm target conditions, however, showad significant interactions
between drug and test session (F = 12.43; df = 2, 22; p<0.001, for
the 3cm targets; and F = 3.76; df = 2, 22; p<0.05, for the 2cm
targets). These interactions are shown in Figures 9:2 and 9:3
respectively.
For the 3cm target condition, paired comparisons between the
treatments showed that, after single doses, error scores
associated with the two active drugs did not differ significantly
frcm placebo values. At this time of testing significant
differences were present betwaen the drug conditions,
performance under the nitrazepam condition being significantly
superior to that under lormetazepam (t = 4.03, df = 11, p<0.01).
After seven consecutive doses, however, performance under
nitrazepam was significantly worse than that associated with both
placebo (t = 3.46; df = 11, p<0.01) , and lormetazepam (t = 3.32;
df = 11; p<0.01). For the 2cm targets, there ware no significant
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TABLE 9:1. Analysis of variance of Gibson spiral maze: (Time)
Sum of Mean
Squares df Square F P
Mean 534129.981 1 534129.981 129.67 0.0000
Error 45310.527 11 4119.138
Drug 809.249 2 404.624 2.28 0.125
Error 3904.362 22 177.471
Session 709.388 1 709.388 3.28 0.097
Error 2377.341 11 216.121
D x S 551.442 2 275.721 1.13 0.342
Error 5385.117 22 244.778
Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
TABLE 9:2. Analysis of variance of Gibson spiral maze: (Error)
Sum of Mean
Squares df Square F P
Mean 59627.555 1 59627.555 35.40 0.001
Error 18527.111 11 1684.282
Drug 62.861 2 31.430 0.21 0.808
Error 3219.472 22 146.339
Session 227.555 1 227.555 5.34 0.041
Error 468.444 11 42.585
D x S 200.861 2 100.430 1.72 0.201
Error 1282.138 22 58.279
Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
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TABLE 9:3. Analysis of variance of Gibson spiral maze: (Log Error)
Sum of Mean
Squares df Square F P
Mean 981638.571 1 981638.571 203.41 0.000
Error 53085.325 11 4825.938
Drug 1250.093 2 625.046 0.83 0.447
Error 16503.782 22 750.172
Session 839.953 1 839.953 1.67 0.223
Error 5545.177 11 504.107
D x S 434.730 2 217.365 0.25 0.783
Error 19381.740 22 880.988
Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
TABLE 9:4. Analysis of variance of letter cancellation task:
("e"s Hit)
Sum of Mean
Squares df Square F P
Mean 71820.500 1 71820.500 79.91 0.0000
Error 10271.833 11 933.80
Drug 55.083 2 27.541 1.15 0.3348
Error 526.583 22 23.935
Session 60.500 1 60.500 1.32 0.274
Error 503.823 11 45.803
D x S 2.583 2 1.291 0.09 0.911
Error 305.083 22 13.867
Drug = lormetazepam 3. mg ; nitrazepam 5 mg; placebo
Session =: test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
- 219 -
TABIE 9:5. Analysis of variance of letter cancellation:
("e"s missed)
Sum of Mean
Squares df Square F P
Mean 21562.722 1 21562.722 41.15 0.0000
Error 5764.277 11 524.025
Drug 134.694 2 67.347 0.47 0.633
Error 3180.305 22 144.559
Session 12.500 1 12.500 0.18 0.675
Error 745.166 11 67.742
D x S 166.583 2 83.291 1.17 0.329
Error 1567.750 22 71.261
Drug lormetazepam 1. mg ; nitrazepam 5 mg; placebo
Session =: test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
TABLE 9:6. Analysis of variance of letter cancellation task:
(percent "e"s hit)
Sum of Mean
Squares df Square F P
Mean 309645.090 1 309645.090 180.74 0.000
Error 18845.361 11 1713.214
Drug 110.357 2 55.178 0.41 0.66
Error 2942.758 22 133.761
Session 36.551 1 36.551 0.32 0.584
Error 1265.520 11 115.047
D x S 193.676 2 96.838 1.23 0.312
Error 1734.181 22 78.826
Drug = lormetazepam 1 mg ; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
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TABLE 9:7. Analysis of variance of reciprocal tapping task:
(total contacts)
Sum of Mean
Squares df Square F P
Mean 1004003.542 1 1004003.542 374.84 0.0000
Error 29463.572 11 2678.506
Drug 437.137 2 218.568 1.29 0.295
Error 3732.529 22 169.660
Session 4.882 1 4.882 0.06 0.80
Error 836.440 11 76.040
D x S 295.192 2 147.596 1.20 0.320
Error 2707.640 22 123.074
Target 4397.002 3 1465.667 37.07 0.0000
Error 1304.674 33 39.535
D x T 70.411 6 11.735 0.80 0.571
Error 964.255 66 14.609
S x T 70.134 3 23.378 1.01 0.399
Error 761.334 33 23.070
D x S x T 101.383 6 16.897 0.93 0.477
Error 66
Drug : lormetazepam 1 mgi; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
Target = 2cm; 3cm; 4cm and 6cm target sizes
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TABLE 9:8. Analysis of variance of reciprocal tapping task:
(percent errors)
Sum of Mean
Squares df Square F
Mean 28384.299 1 28384.299 72.09
Error 4331.329 11 393.757
Drug 148.536 2 74.268 1.14
Error 1436.901 22
Session 162.119 1 162.119 4.17
Error 427.245 11 38.840
D x S 556.164 2 278.082 8.26
Error 740.798 22 33.672
Target 601.604 3 4200.534 73.88
Error 1876.371 33 56.859
D x T 234.453 6 39.075 1.29
Error 1997.412 66 30.263
S x T 20.430 3 6.81 0.41
Error 552.935 33 16.755
D x S x T 288.703 6 48.117 2.85
Error 1114.297 66 16.883
Drug : lormetazepam 1 mg ; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and










Target = 2cm; 3cm; 4cm and 6cm target sizes
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TABLE 9:9. Analysis of variance of reciprocal tapping task:
(2cm Target Errors)
Sum of Mean
Squares df Square F P
Mean 30696.209 1 30696.209 127.10 0.0000
Error 2656.601 11 241.509
Drug 367.112 2 183.556 1.66 0.213
Error 2435.210 22 110.691
Session 76.322 1 76.322 1.50 0.246
Error 560.168 11 50.924
D x S 404.613 2 202.306 4.89 0.0175
Error
Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session =: test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
TABLE 9:10. Analysis of variance of reciprocal tapping task:
(3cm Target Errors)
Sum of Mean
Squares df Square F P
Mean 6837.869 1 6837.869 57.97 0.0000
Error 1297.612 11 117.964
Drug 2.096 2 1.048 0.05 0.948
Error 433.773 22 19.716
Session 66.393 1 66.393 3.29 0.097
Error 222.150 11 20.195
D x S 346.673 2 173.336 12.43 0.0002
Error 306.902 22 13.950
Drug lormetazepam 1 mg ; nitrazepam 5 mg; placebo
Session == test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
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TAB IE 9:11. Analysis of variance of reciprocal tapping task:
(4cm Target Errors)
San of Mean
Squares df Square F
Mean 2736.396 1 2736.396 19.66
Error 1530.878 11 139.170
Drug 6.115 2 3.057 0.23
Error 296.326 22 13.469
Session 30.458 1 30.458 2.79
Error 119.932 11 10.903
D x S 63.768 2 31.884 2.17






Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
TABLE 9: 12. Analysis of variance of reciprocal tapping task:
(6am Target Errors)
Sun of Mean
Squares df Square F P
Mean 715.428 1 715.428 10.89 0.007
Error 722.609 11 65.691
Drug 7.665 2 3.832 0.31 0.734
Error 269.003 22 12.227
Session 9.374 1 9.374 1.32 0.274
Error 77.929 11 7.084
D x S 29.812 2 14.906 1.04 0.370
Error 314.830 22 14.310
Drug = lormetazepam 1 mg; nitrazepam 5 mg; placebo
Session = test session 1 (after a single dose) and
test session 2 (after seven consecutive doses)
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EFFECTS OF NITRAZEPAM, LORMETAZEPAM, AND PLACEBO ON THE ACCURACY OF
RECIPROCAL TAPPING IN 12 ELDERLY SUBJECTS (MEAN AGE = 81.4fEARS)



















DIFFERS FROM PLACEBO: P = 0.012
** differs significantly from
lormetazepam p = 0.014
EFFECTS OF NITRAZEPAM, LORMETAZEPAM, AND PLACEBO ON THE ACCURACY OF



















DIFFERS SIGNIFICANTLY FROM PLACEBO: P = 0.005
DIFFERS SIGNIFICANTLY FROM LORMETAZEPAM: P = 0.002
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EFFECTS OF NITRAZEPAM, LORMETAZEPAM, AND PLACEBO ON THE ACCURACY OF
RECIPROCAL TAPPING: 2 CM TARGETS
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DIFFERS SIGNIFICANTLY FROM PLACEBO! P 0.05
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TABIE 9:13. Reciprocal tapping task (mean percent errors):
Values of t (correlated) for paired comparisons































TABLE 9; 14. Reciprocal tapping task (percent errors: 3cm target):
Values of t (correlated) for paired comparisons
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TABLE 9:15. Reciprocal tapping task (percent errors: 2cm targets)
Values of t (correlated) for paired comparisons























nitrazepam 5 mg 1.38 0.195
Two-tailed significance values throughout
- 228 -
differences between either of the drug treatments and placebo
after a single dose, but significantly more errors were made
following seven consecutive doses of both nitrazepam (t = 2.32; df
= 11, p<0.05) and lormetazepam (t = 2.50; df = 11; p<0.05). The
results of paired comparisons (t-values) for the treatment means
illustrated in Figures 9:1, 9:2 and 9:3, are shown in Tables
9:13, 9:14 and 9:15 respectively.
For both subjective variables, Friedman's analysis of
variance showed no effect of drug condition on either sleep
quality (chi-square = 0.292; df = 2; p = 0.864) or morning
alertness (chi-square = 3.167; df = 2; p = 0.205) .
Discussion
The results from each test will be discussed in turn.
Conclusions are presented at the end of this section.
Reciprocal Tapping Task.
Neither drug significantly affected speed of performance (as
measured by mean total contacts) on the reciprocal tapping task.
Nitrazepam 5.0mg, however, was associated with an overall
impairment of accuracy consistent with drug accumulation, with
mean errors increasing significantly between the first and seventh
consecutive doses (Figure 9:1). This decrement was not
independent of the differing demands of task. Figures 9:2 and 9:3
- 229 -
show similar patterns of nitrazepam-associated impairment for the
3cm and 2cm target conditions respectively; again, errors
increased significantly between the first and seventh consecutive
doses. Thus, as the target sizes decreased, task complexity
increased, and errors became more probable following seven
consecutive doses of nitrazepam 5.0mg. These results accord with
the data presented in the previous chapter.
A very different pattern of effects is shown for lormetazepam
l.Omg. For this shorter acting drug, mean errors tended to
decrease between the first and seventh doses. At low (6cm and
4cm targets) and intermediate (3cm targets) levels of task
complexity, performance following lormetazepam did not differ
significantly from placebo. At the highest level of task
complexity (2cm targets), errors did increase following seven
consecutive doses (Figure 9:3). [From Figure 9:3 it can be seen
that while the mean error score following single dose lormetazepam
was greater than that following seven consecutive doses, only the
latter values differed significantly from placebo. From the
standard deviations shown in Table 9:15, however, it is evident
that the scatter of data was greater following the single dose.]
In young adult (Nicholson and Stone, 1982) and middle-aged (Oswald
et al. (1979) subjects lormetazepam in l.Omg doses has been
reported to be devoid of measurable residual effects on
daytime performance. The presence of impaired tapping accuracy in
the present study, therefore, emphasizes the increased
vulnerability of elderly individuals to the detrimental residual
effects of hypnotic drugs.
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The performance decrements on this task associated with
repeated doses of nitrazepam 0.5mg are both consistent, and
profound. In terms of overall accuracy (Figure 9:1), performance
following seven repeated doses of nitrazepam was significantly
inferior to that following both placebo and lormetazepam.
An interesting feature of these data is the apparent
facilitation of accuracy following single dose nitrazepam 5.0mg,
which achieved significance relative to lormetazepam in mean total
errors (Figure 9:1) and in the the 3cm target condition (Figure
9:2). This finding is consonant with the suggestion made in
Chapter 5 that, as test performance efficiency in the elderly
appears to be particularly vulnerable to stress factors engendered
by the testing process (Rabbit, 1982), residual anxiolytic
activity may enhance performance. Should this have been the case,
it is clear that any such advantage is rapidly negated by drug
accumulation.
Gibson Spiral Maze
None of the measurorients derived from the Gibson spiral maze
showed significant differences between drug and placebo
conditions (Tables 9:1, 9:2, and 9:3). Salem et al. (1982) report
significant slowing on this task in elderly females llh after
single dose nitrazepam lOmg; in the same experiment, no effect was
reported for elderly males. Given that the present subjects were
predominantly female, these results suggest a dose-dependent
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relationship between nitrazepam and the occurrence of residual
effects in the elderly. Such a relationship has already been
noted in healthy young adult subjects (e.g. Maipas et al. 1970;
Bond and Lader, 1972).
Letter Cancellation
None of the measurements derived from the letter cancellation
task distinguished between drug and placebo conditions (Tables
9:4, 9:5, and 9:6). Nayal et al. (1978) used a version of this
task in which elderly subjects were required to delete all the
letter "e"s from a complete page of prose as quickly as possible.
Measuring both the speed (in seconds) and the number of "e"s
deleted, these researchers found the test to be similarly
insensitive in distinguishing between the residual effects of
single dose nitrazepam 5mg and chlormethiazole 384mg (base), but
suggested that the sensitivity of the task might be improved if
the procedure was paced (i.e. conducted over a fixed period of
time). Just such a modification to the cancellation task was
employed by Briggs et al. (1980) in their comparison of the
residual effects of chlormethiazole 384mg (base) and temazepam
20mg in young and elderly subjects. In this case, performance
timed over two minutes on the task did not distinguish between
the drug and placebo conditions. More recently, Cook et al.
(1983), using an un-paced version of the same task, found a
significant slowing of performance following single dose temazepam
20mg, and multiple dose nitrazepam 5mg. However, these authors
also report slowing of performance following repeated doses of
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placebo treatments, and comment that, on the cancellation task,
some subjects "tended to lose interest with repeated testing".
Consequently, Cook et al. (1983) suggest that the test would yield
more consistent results if administered over a two minute period.
Combining these previous findings from, and equivocal comments
regarding this test with the results from the present study, it
cannot be concluded that the letter cancellation task is a
particularly reliable, stable or sensitive measure of residual
effects in the elderly following low-dose, or short-acting
hypnotic drugs.
Subjective Ratings
Neither of the subjective ratings proved to be sensitive in
distinguishing between drug and placebo conditions. As regards
the subject's own ratings of sleep quality, these showed extreme
daily variations which were more suggestive of dichotomous (i.e.
either satisfaction or disatisfaction with) rather than
analogue judgements of the previous night's sleep. Cn the other
hand, staff ratings of alertness were conservative throughout,
reflecting the tendency, already seen in the previous experiment,
for staff to favour the "no change" position on the scale. The
efficiency of the subjective rating as a research tool is entirely
dependent on the comprehension and motivation of those completing
the scales. In the present circumstances, then, it must be
concluded that these negative results, particularly as regards
sleep quality, do not challenge previously reported findings.
Oswald et al (1979) , for example, report that middle aged subjects
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consistently reported their sleep as improved following
lormetazepam lmg and 2.5mg, a finding in agreement with EEG
recordings frcm the same study.
Conclusions
The present study provides clear evidence that, relative to
the longer acting nitrazepam, repeated doses of lormetazepam l.Omg
are less likely to be associated with profound performance
decrements in the elderly. Repeated doses of nitrazepam produced
a generalized and significant reduction of efficiency on the
reciprocal tapping task relative to both placebo and lormetazepam
l.Omg (Figure 9:1). Gonversely, the detrimental effects of
lormetazepam were seen only at the highest level of task
complexity (Figure 9:3). The overall pattern of performance
following single and repeated doses of nitrazepam was consistent
with drug accumulation, a finding in agreement with the results of
Experiment 2 and with the recently reported results of Cook et al.
(1983). In general, such was not the case following
lormetazepam. That neither drug significantly affected the speed
of performance on the reciprocal tapping task again suggests that
such decrements in efficiency are related to impaired judgement of
accuracy as described in Chapter 8. Both drugs, in the doses used
in the present study, have been shown to be effective hypnotics in
older subjects in sleep laboratory investigations (Adam et al.
1976 for nitrazepam 5.0mg; Oswald et al. 1979 for lormetazepam
l.Omg). It is therefore reasonable to conclude that, for the
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short-term treatment of disturbed sleep in the elderly, a shorter
acting hypnotic drug is clinically and psychologically
preferable. Caution is, nevertheless, appropriate here. Qi the
reciprocal tapping task detrimental residual activity was
apparent following the seventh consecutive dose of lormetazepam at
the highest level of task complexity (2cm targets) .
The pattern of performance decrements shown for nitrazepam
5.0mg in the previous chapter is adequately replicated in the
present study. The testing procedure used in these studies,
therefore, offers a robust means for evaluating the residual
effects of further hypnotics in this age group. As regards the
testing procedures and the experimental methodology, one further
point deserves to be emphasized. While the previous experiment
(Chapter 8) was conducted in a purpose-built performance
laboratory, the present study was conducted in the homes of the
participating subjects. Nicholson and Stone (1982) have recently
criticised multiple dose experimental evaluations of hypnotic
drugs, suggesting that such studies: 1) do not guarantee
compliance in the taking of experimental drugs; 2) cannot provide
adequate supervision over the "circumstances and behaviour of
subjects" in the period immediately preceding performance testing,
and therefore 3) are more likely to produce variable and
unreliable data. Nicholson and Stone (1982) contrast these points
with the experimental control possible in single-dose studies
where subjects are constantly supervised by the experimenter in
the laboratory.
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None of these criticisms, however, gains support from the
present study. Compliance, for example, was guaranteed by the
standardized drug administration procedures of the residential
homes. While control over the "circumstances and behaviour of
subjects" was, indeed, not possible between testing sessions, it
can be seen from the results presented here that the data are far
from variable. Table 9:13 for example shows that, under placebo
conditions, mean total errors on the reciprocal tapping task
differed by less than one percentage point between the first and
second testing sessions (a period of one week) . As regards
variability, the standard deviations of these mean values differ
by less than 0.2 of a percentage point (Table 9:13). Thus, the
present study offers, not only a reliable test procedure for
evaluating residual drug effects in the elderly, but also offers a
reliable alternative to costly and, in this age group,
inconvenient attendances at performance laboratories. Through
the use of efficient subject selection procedures (e.g. the
Clifton Assessment Procedures for the Elderly), appropriately
selected and validated tests (e.g. the reciprocal tapping task) ,
and strictly standardized performance testing procedures, it is
clear that an effective degree of experimental control can be
maintained outside the laboratory.
The demerits of the present study should not, however, be
overlooked. The apparent insensitivity of the subjective ratings
requires particular attention. In single dose laboratory studies
with elderly subjects, visual analogue scales have proved
sensitive in distinguishing nitrazepam lOmg (Castleden et al.
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1977), chlormethiazole 384mg, and temazepam 20mg (Briggs et al.
1980) from placebo. The sensitivity of these instruments in
multiple dose evaluations in the elderly has not been
established. While nurse ratings have been favoured in multiple-
dose hospital studies of hypnotics in the elderly (e.g. Linnoila
and Viukari, 1976; Viukari et al. 1978), sleep questionnaires
have been used in community samples. Reeves (1977) , for example,
in a 28 day study of the hypnotic efficacy of triazolam 0.25mg in
geriatric outpatients (mean age = 68.6y) successfully used a
forced-choice questionnaire to assess sleep quality, morning
alertness, and side-effects. Relative to the scales used in the
present study, one possible advantage of Reeves' (1977) procedures
is that forced choice responses are cued (e.g. "did you sleep:
very well?; well?; poorly?; very poorly?"). In very elderly
subjects, many of whom have low expectations of sleep
satisfaction, such cues may in turn prompt a more thoughtful
response. Certainly, the need exists here for future research and
development. It is relevant to point out, nevertheless, that
even in younger, motivated and experienced subjects (such as the
participants in Experiment 1) visual analogue ratings are not
flawless, and may reflect demand characteristics and response
bias. The daily ratings of sleep quality shown for Experiment 1
(Chapter 4) show a clear tendency for subjects to rate their sleep
as improved under placebo conditions (Figure 4:1).
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Chapter 10
A synopsis of the studies presented in this thesis, and a summary
of conclusions.
Before discussing the implications of the studies reported
here, it would be useful to reiterate the overall aims of this
thesis and present, in brief, the rationale and a summary of
findings for each study. This chapter will also allow an
opportunity to present relevant research findings which have been
reported since the work here was undertaken.
The overall aim of the thesis, as described in chapter 1, was
to identify, and respond to areas of the drug-performance
literature where clinically relevant information concerning the
influence of ageing was particularly lacking. Chapters 1 and 2
showed that, while age has long been regarded as a relevant
subject variable in the assessment of the residual effects of
hypnotic drugs, it has nevertheless received little experimental
attention. Chapter 2 further showed that the consensus of opinion
among researchers suggested that residual effects on behaviour are
less likely to accompany the use of short half-life hypnotic
drugs. These two factors were brought together in Experiment 1
which examined the effects of repeated doses of two relatively
short-acting hypnotics, triazolam and loprazolam, both within a
group, and between sub-groups of middle aged individuals. The
results provided no evidence of cumulative residual activity of
either drug within the group, and no clear systematic differences
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in overt performance between the early and late middle-aged sub¬
groups. Nevertheless, subjective ratings made by each subject
throughout the study showed a significant increase in feelings of
daytime anxiety following repeated doses of triazolam 0.5mg
relative to the longer acting loprazolam. This latter finding has
since been confirmed by Kales et al. (1973). These researchers
compared self-reports of daytime anxiety following repeated doses
of two short-acting (triazolam 0.5mg and midazolam 20mg) with
those following repeated doses of two long acting hypnotics
(flurazepam 30mg and quazepam 30mg), and report a relative, though
significant increase in anxiety after 2 weeks administration of
triazolam, and after 1 week of midazolam. In agreement with the
conclusions presented in Chapter 4, Kales et al. (1983) attribute
these findings to daytime withdrawal phenomena.
Certain characteristics of the data from Experiment 1
indicated that, in general, these middle-aged subjects may have
efficiently compensated for residual drug effects.
Epidemiological, clinical, and experimental evidence reviewed in
Chapter 5, however, suggested that the behavioural integrity of
elderly individuals (defined as the age group 65y+) is relatively
more vulnerable to the residual effects of hypnotic drugs. It
was also noted that experimental interest in this age group was
particularly lacking. Furthermore, in several of the studies
reporting the presence or absence of residual drug effects in the
elderly, it was clear that theoretical issues highly relevant to
the testing of elderly individuals had been ignored. While
Chapter 5 emphasized the increased risk of untoward behavioural
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reactions to hypnotics in the elderly, Chapter 6 analyzed and
emphasized the greater probability of hypnotic drugs being
prescribed for and used by this age group. The temporal trends
observed in this review showed that sleeping drug use, and the
consequent risk of behavioural impairment, has not decreased in
relative or absolute terms over the past 20y. The drug-use
literature was not sufficiently specific to allow for the
identification, for subsequent experimental analyses, of typical
drugs and typical dosages in current use among the elderly.
The two surveys of hypnotic drug usage in residential homes
for the elderly were conducted both for their intrinsic clinical
value as feedback for practitioners, and to guide clinically
relevant experimental research. Both surveys showed that
extensive use was not being made of short-acting hypnotic drugs,
despite the theoretical advantages associated with these products.
On the contrary, the long-acting hypnotic nitrazepam was most
used. A similar finding in the United States has since been
reported by Stewart et al. (1982). This study examined the
prescription hypnotics of 210 elderly individuals in a retirement
community in Florida, and found that almost 75% of all
prescriptions were for the long-acting drug flurazepam. From
evidence reviewed in Chapter 5 it was concluded that reduced
mental and physical health status in the elderly was associated
with an increased susceptibiltiy to the adverse behavioural
effects of hypnotic drugs. The survey data were therefore
examined for evidence of discrimination in the prescribing of
drugs for impaired and non-impaired groups of residents. From
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these analyses it was apparent that, while reduced health status
was associated with a reduced probability of receiving hypnotic
drugs within the homes, usage in the impaired groups was equal to,
or greater than that found in many community surveys. These data,
therefore, indicated a relative increase in usage in the non-
impaired group rather than a relative decrease in usage among
the impaired. Again, it should be noted that examining the
characteristics of prescribing practices within institutional
settings is not without broad clinical relevance. Recent
estimates suggest that, at any one time, almost half a million
elderly individuals in the UK are in some form of institutional
care, which includes 131,000 in local authority homes (Department
of Health and Social Security, 1980), 70,000 in private and
voluntary homes (DHSS, 1980), and 31,000 in voluntary hospitals
and private nursing homes (DHSS, 1980). A further 220,000 elderly
individuals are estimated to occupy National Health Servive beds
(DHSS, 1980; Chaplin, 1981). Insofar as they affect the
prescribing of hypnotic drugs, it would not be unreasonable to
assume that the relationships which exist between carers, the
elderly, and the prescribing physicians, share some common
features within these different institutions.
Assumptions concerning the safety of low dose nitrazepam in
the elderly, apparent from the survey data presented in Chapter 7,
were tested in Experiment 2 (Chapter 8). The results from this
study conformed with the predictions made in Chapter 2 regarding
long acting hypnotics. The performance deficit seen in the
elderly subjects was consistent with drug accumulation over the
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eight days of continuous usage. To further assess the prediction
that, in elderly individuals in particular, significant residual
effects are less likely to accompany the use of short-acting
hypnotics, Experiment 3 (Chapter 9) compared the effects of
multiple dose nitrazepam 5mg with those of the shorter acting
lormetazepam lmg. While nitrazepam 5mg again produced a
generalized and significant reduction in performance efficiency,
impairement associated with lormetazepam lmg was specific to high
levels of task complexity. Comparisons of the behavioural effects
of long and shorter acting hypnotics in hospitalized elderly
groups have subsequently shown similar relative differences
(Murphy et al. 1982; Cook et al. 1983). It was also proposed in
Chapter 5 that, on the basis of previous experimental results,
interactions between the speed and accuracy of performance may be
sensitive and reliable indicants of residual drug effects in the
elderly. The results obtained in Experiments 2 and 3 supported
this proposal.
This thesis has presented two distinct experimental
approaches to the evaluation of the behavioural consequences of
hypnotic drug use in older age groups. Experiment 1 characterizes
the first approach in which relatively new hypnotic products are
intensively investigated using subjects of an age representative
of the drug's target population. Such an approach not only
produces information of immediate clinical relevance, but also
generates a substantial data-base that can be exploited in
subsequent research. Experiments 2 and 3, on the other hand,
address specific issues which emanate from the currently available
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experimental and drug-use literature. Common to all three
experiments, however, is the assumption that drug effects on
psychological tasks provide a relevant and meaningful index of a
drug's influence on "in vivo" behaviour. This premise will
briefly be considered before the conclusions from this thesis are
presented.
It is recognized here that the use of psychological testing
procedures is not the only means by which the behavioural effects
of hypnotic drugs may be evaluated. In recent years, a growing
interest has developed in the assessment of drug effects on quite
specific skills, particularly motor car driving. Evaluations of
both simulated (e.g. Linnoila et al. 1974) and actual (e.g. Betts
et al. 1972) car driving ability indicate that measurable
impairment of this integrated skill may follow the use of various
sedative and hypnotic drugs. When contrasted with the somewhat
more esoteric data derived from laboratory performance tasks, the
results from such studies certainly appear to be more immediately
applicable to "real life" situations. It is realistic to
enquire, therefore, with what degree of certainty can results be
extrapolated from psychological test procedures?
This question can be approached from several different
directions. In the case of car driving, for example, correlations
may be sought between performance on psychological tasks and
actual driving abilty. Such an approach is not without its
methodological problems. Clayton (1976), for example, observes
little relationship between a given individual's efficiency on
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laboratory performance tasks, and that individual's traffic
accident and violation rate, but points out that the lack of such
a relationship "is unsurprising if accidents are regarded, not as
a homogeneous body of events, but rather a collection of events
with widely different causative processes whose sole common
characteristic is the resultant collision". More recently,
however, Hindmarch (1979) has reported data from a study in which
subjects were tested on laboratory measures of critical flicker
fusion threshold and choice reaction time and actual car driving
ability following single doses of the benzodiazepine lorazepam.
Hindmarch (1979) concludes that "The impairment of performance
shown in the laboratory tests following the administration of a
1,4 derivative, lorazepam, has been mirrored in the reduced
performance on actual car driving tests of brake reaction,
steering, width estimation, parking, and garaging". Such data are
in accord with the findings of Skegg et al. (1979) who report an
association between serious road traffic accidents in five
patients, and the use in each case of benzodiazepine minor
tranquillizers.
Concern for and comparisons with undoubtedly useful
laboratory-simulated or actual "real life" skills tends, however,
to detract from the merits of psychological assessment in general.
Fundamental to the notion of assessment, whether of perceptual-
motor or cognitive skills, is the concept of pervasive
psychological characteristics which mediate efficient
performance. If laboratory studies reveal impairment on tests of
say vigilance, then it is reasonable to extrapolate these findings
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to "real" tasks which require, for their efficient execution, high
levels of sustained attention. Such extrapolations are reasonable,
however, only if the characteristics of performance measured
possess an acceptable degree of construct validity, i.e. the
degree to which the dependent variable (for example, auditory
vigilance performance) is really measuring that with which we are
concerned (the ability to sustain attention). In the experiments
reported here, considerable emphasis has been placed on the
constructs of vigilance (the auditory vigilance task), and
information processing ability (the Crossman card-sorting task,
the reciprocal tapping task). The validity of these constructs is
both established (e.g. Mackworth, 1970; Welford, 1980) and widely
recognized. Thus, as regards car driving efficiency, Clayton
(1976) concludes that "drugs which have the potential for
affecting attention or the speed of performance may be of
particular danger in actual driving", and "if the tasks are
measuring a reduced rate of information processing as a result of
drug ingestion, then a translation of the effect to the driving
situation may be expected". With particular reference to the
elderly, a large proportion of whom do not drive, extrapolations
to the driving situation are, at present, of limited relevance.
Hypnotic drugs associated with daytime performance decrements in
this age group do, nevertheless, represent a real threat to their
quality of life.
Conclusions
Cn the basis of the evidence reviewed, it was suggested in
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Chapter 5 that the residual effects of hypnotic drugs may amplify
normal or abnormal ageing processes. An extreme example of this
would be the hypnotic drug induced "pseudodementias" described by
Evans and Jarvis (1972) and by Rudd (1972). In Experiments 2 and
3, the performance decrements following nitrazepam 5mg and, to a
lesser extent, lormetazepam lmg were characterized by a reduction
in accuracy, but not speed. These results suggested a specific
impairment of the processes mediating judgement, rather than a non¬
specific consequence of general sedation. Indirect support for
this conclusion is provided by data reported by Kendrick and Moyes
(1979) concerning the influence of anxiolytic and antidepressant
drugs on sub-test performance in a diagnostic battery (the Revised
Kendrick Battery). It was found that continued drug therapy with
barbiturate hypnotics or tricyclic antidepressants was, in a
significant number of patients, associated with a test profile in
depressed groups similar to that in demented groups, a profile
described by these authors as a reversible "drug-induced
'pseudodementia'". While the specific concern of the experiments
reported here has been the integrity of performance following
hypnotic drugs, these characteristics of the performance deficits
observed, and their relationship to the ageing process, provide a
basis for collateral and relevant future research.
The evidence reviewed in Chapter 5 further suggested that
elderly individuals with existing cognitive impairments due to,
say, dementia (Linnoila and Viukari. 1976; Viukari et al. 1978)
may be more susceptible to the adverse behavioural effects of
hypnotic drugs. It is, therefore, relevant to note a recently
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published article which comes to exactly the opposite conclusions,
that is, that the demented elderly are less sensitive to the
residual effects of hypnotic drugs. Mead and Castleden (1982)
report a balanced, within-subjects comparison of the effects of
single- dose chlormethiazole 384mg, temazepam 20mg, and placebo in
11 elderly demented hospital inpatients. Eleven hours after each
treatment subjects were tested on: 1) standardized questions to
assess mental status; a two-minute letter "e" cancellation task;
and a "sway" test using an ataxiameter. No difference was found
between drug and placebo values for each test, and Mead and
Castleden (1982) conclude "The lack of impaired psychomotor
performance lends no support to the contention that confused
patients are more sensitive to sedative drugs". The validity of
this conclusion demands scrutiny. Of the two tests measuring
psychomotor efficiency (sway and letter cancellation) the authors
report that "The (sway) test was abandoned because of inability of
most of the patients to cooperate". For the remaining letter
cancellation task, data were collected from only 7 patients, of
the remaining 4 "One was unrousable the next morning, one had lost
her glasses and two could not see the print" (op. cit.). It can
be assumed from these latter comments that no pre-experiment
practice sessions were conducted. Even for the 7 patients who
did complete the cancellation task, the authors remark that
"poor vision hampered attainment". Given these circumstances,
then, the available test results from this study hardly represent
sensitive indicants of psychomotor ability. Other features of
this study deserve attention. The dose of chlormethiazole is
described as "(edisylate) 384mg". If this was the case, then a
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dose of untypically low potency was used. More likely, however,
the authors used (base) 384mg (equivalent to edisylate 500mg).
[Indeed, a preparation of chlormethiazole (edisylate) 384mg is not
manufactured]. As mean plasma concentrations for both drugs were
considerably higher than those reported in a previous experiment
(Briggs et al. 1980), the authors concluded that the data reflect
a relative decrease in sensitivity to hypnotics in the demented
elderly. Considered in relation to the literature and the issues
discussed in Chapter 5, this study does not represent a
sufficiently rigorous test of the hypothesis that existing
cognitive impairment exacerbates the detrimental effects of
hypnotic drugs on performance in the elderly.
As pointed out in Chapter 6, four factors contribute to the
probability of adverse behavioural reactions accompanying hypnotic
drug use: 1) the pharmacological characteristics of the drug; 2)
the dose of drug used; 3) the duration of usage; and 4) the age
(and health status) of the recipient. The results from the
present studies will be considered in relation to each of this
factors, and also in relation to the broader issue of an hypnotic
drug prescribing policy in older patients.
The present studies demonstrate that elimination half-life is
a reliable predictor of daytime residual effects. However, some
of the results clearly indicate that residual effects, i.e.
those effects associated with persistent pharmacological
activity, are not the only potential source of behavioural
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disruption from hypnotic drugs. Problems of increased anxiety
associated with repeated doses of the very short acting triazolam
were identified in Experiment 1. It is also relevant to note
that, in the elderly, the elimination half-life of the drug may
not be the only pharmacokinetic feature predictive of behavioral
side effects. The data of Witts (1979) show that, while seven
repeated doses of chlormethiazole in elderly patients did not
affect the elimination half-life of the drug, peak plasma
concentrations increased considerably between the first and
seventh consecutive doses. The authors concluded that multiple
dosing results in increased bioavailabilty of chlormethiazole in
elderly patients. The acute pharmacological response to a non-
cumulative drug may, therefore, increase with repeated doses in
elderly patients.
From the results presented in Experiments 2 and 3 it is clear
that untoward behavioural effects are probably best avoided at the
level of drug, rather than at the level of dose. The cumulative
properties of nitrazepam were evident in both experiments, even
though the dose used was low and, for this age group, recommended.
Dose factors are, nevertheless, of importance even in non-
cumulative compounds. It is possible that the relative increase
in anxiety following triazolam usage in Experiment 1 was dose-
dependent, and that such effects may be avoided by using lower
dosages. Thus, these results indicate that the effects of
hypnotics on daytime performance can be significantly controlled
through the use of shorter acting drugs in the lowest dose
compatible with hypnotic efficacy. Oswald (1983), has recently
- 249 -
suggested that an elimination half-life of lOh is probably optimal
for hypnotic drugs. It should be remembered, however, that mean
elimination half-lives estimated in younger age groups are not
necessarily applicable to the elderly.
Clinical concern for the increasing use of prescription
medicines with age, and the consequent risks of iatrogenic
disorders, were noted in Chapter 7. The use of sedative-hypnotic
drugs among the elderly has attracted, not only clinical, but also
sociological and political concern (Dement, Miles et al. 1982;
Green, 1982). It is appropriate, therefore, that the results
reported here should finally be considered in the wider context of
drug prescribing policies. In combination, the interrelated
factors of age and the duration of hypnotic drug usage represent
a particularly important issue in drug prescribing for the older
patient.
The results from the experiments reported here clearly show
that, in older subjects, prolonged hypnotic drug usage increases
the probability of daytime behavioural disruptions. The relative
increase in anxiety reported for triazolam 0.5mg in Experiment 1
reached significance only in the second and third weeks of
administration. The reductions in overall efficiency reported
for nitrazepam 5mg were significant only after eight (Experiment
2) and seven (Experiment 3) consecutive doses. Significant
impairment associated with lormetazepam l.Omg on the reciprocal
tapping task (Experiment 3) was apparent only after seven
consecutive doses. Thus, these experimental findings strongly
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support the conclusions of the Conmittee on Safety of Medicines
(1980), which recommended that the use of benzodiazepine therapy
for insomnia in the elderly "be undertaken for short periods of
time, and only after careful consideration". The results from
Surveys 1 and 2, however, indicate that the long-term prescribing
and use of hypnotic drugs among the elderly is not untypical, a
finding reflected in several of the studies reviewed in Chapter 6.
Clearly, then, there exists at present a discrepancy between
policy and practice.
Dement et al. (1982) have recently pointed out that hypnotic
drugs are of optimal value in the symptomatic relief of "transient
situational insomnia". Such a diagnostic category, however, far
from characterizes the sleep disturbances reported for ageing
populations. Chapter 6 shows that dissatisfaction with sleep
increases predictably with age. Dement, Miles et al. (1982), for
example, comment that disturbed sleep "appears to be ubiquitous
among the elderly". Thus, in a significant number of elderly
individuals, dissatisfaction with sleep is neither transient nor
situational but appears, rather, to be permanent and
constitutional. Consequently, and despite recommendations to the
contrary, the prolonged use of hypnotic drugs remains more likely
among elderly individuals. A further question that needs to be
addressed, therefore, is whether or not the prescribing of
hypnotic drugs is, in general, an appropriate clinical response to
complaints of sleep dissatisfaction in the elderly. Dement, Miles
et al. (1982), for example, refer to the prescribing of hypnotics
for the institutionalized healthy elderly as "an abomination".
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It is apparent from the information considered in Chapter 6,
however, that the processes mediating the prescribing of hypnotics
in older patients are multi-factorial, a feature which pre-empts
any attempt to produce a simplistic solution. Equally complex,
however, are the effects of regularly taken psychotropic drugs on
the ecology of human behaviour. While experimental research of
the type reported here aims to assist in the decision to prescribe
one drug or another, further research and action is needed to
assist in a more fundamental clinical decision - that between
prescribing something, and prescribing nothing.
Summary of Conclusions
1) Unlike longer acting compounds, hypnotic drugs in which
the elimination half-life does not exceed 15h are not associated
with progressive impairments of performance with repeated doses
in early and late middle-aged subjects.
2) Hypnotic drugs in which the the elimination half-life is
less than 4h can, with repeated doses, produce subjective feelings
of increased anxiety in early and late middle-aged subjects, such
reactions being attributable to daytime drug withdrawal.
3) Intensive experimental evaluations of residual effects on
performance, using subjects of an age group representative of the
drugs target population, should precede the introduction of any
new hypnotic compound. Such evaluations should simulate the
clinical use of hypnotic drugs.
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4) Quantifying residual drug effects in the elderly presents
special methodological problems which do not apply in younger age
groups. Attention to such factors as the assessment of cognitive
status of subjects, the inclusion of practice sessions, and the
appropriateness of tests can result in both reliable, and
sensitive measures of a drugs pharmacological effect in this age
group.
5) In elderly subjects, repeated low-doses of cumulative
hypnotic drugs can impair performance. Such impairment is not
seen after single dos^
6) In elderly subjects, drugs in which the elimination half-
life is less than 15h are less likely to impair performance than
are long acting cumulative drugs, even when the latter are
administered in low doses.
7) Hypnotic drug-induced performance decrements in the
elderly appear to be characterized by reductions in the efficiency
of behaviour in the absence of significant compensatory
reductions in speed. Such decrements suggest that the subject
may, therefore, be unaware of the deficit. This feature of the
performance deficit has broad implications for the safety of
indepedent elderly individuals.
8) The ability to compensate for the residual effects of
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hypnotics may differentiate between middle-aged and elderly
individuals. Performance curves suggestive of compensation were
present in the data from middle-aged subjects.
9) Clinical and experimental evidence concerning the
behavioural disadvantages of long acting, cumulative hypnotic
drugs is not, at this time, reflected in the prevalence with which
these drugs are prescribed and used. The prescribing patterns
observed in an elderly population continue to show the widespread
use of drugs and dosages contra-indicated for use in this age
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This is a task of coding symbols into their corresponding numbers.
You are to code as many symbols as accurately as you can.
The symbols and their coding appear at the top of the first page and
obviously, if you can remember them you will get more completed in the
time allowed. It is not expected that you will get all the coding
completed but remember to work steadily and accurately.
THE TIME FOR THIS TASK IS:
If you' have any questions, ASK NOW.
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Appendix 1:1
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Appendix 2 Analysis of Variance Tables for the data summarized
in Table 3:1.
For each table, the factors (source) are as follows:
Age (A) = older sub-group; younger sub-group.
Drug (D) = loprazolam l.Omg; loprazolam 0.5mg; triazolam 0.5mg;
placebo.
Week (W) = week 1 testing session; week 2 testing session;
week 3 testing session.
Time (T) = 08.30 time of testing; 12.30 time of testing;
16.30 time of testing.
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Appendix 2:1 Analysis of variance of Auditory Vigilance
task data: percent correct detections over lh
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Appendix 2:2 Analysis of variance of
Auditory Vigilance Task data: percent
correct detections for final 40min
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Appendix 2:3 Analysis of variance of
Auditory Vigilance Task data: false
positive responses over lh
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Appendix 2:4 Analysis of variance of
Digit Symbol Substitution test data:
items correctly coded
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time into four categories




CJ — cj nr. -o f a CO C-J -c r -^ -c UO OJ CO C J
f— CP G o G O rS> Ga C5 o Ca nu G G G Ga nrCD
CP
C-
r ~ *f o- a— c"< r-x ro c: ro CO C- O- Cx -co- CJ co ro co *f- -o *T" M? ro uj r cj lo cjU- ■ • • • ■ • a a a a a a
«r-> nr. nsa Ga G"' Cn G C5 r-
IO <1 LO UJ O- CJ cr- a- -O a— CO r-a -o C-J C j Ca r- c j a— ca G-; OJ O-uj co in r- - o- rx c- r- CO «a Co -o ro C-J ro <r G ro C-J C J UJ -O b" r^ in32.' CP cr< *-■>. co ea uj co <s3 o t53 ^ o w 1— uj a~ co co Ga LJ o ro L~" Is- CO<c <r co to ro -o o- ro -c o- <r -o <r uj co O- C-J a— C ro r~ ro cc <*- ro rjUJ ID -o -o Ga -0 a— ro T O- a— CO CJ O- T CO Ca r-., c- -.q T ■»-- «Pf- —fx *tr~ •*—x: cd a a a a a a a a a a a a a a a a a a a a a a a a






uj uj a— a— Ga ro ro o C-J C-J G -C **0 Ga c-J C J Ga -O <1 ns> <r Ga Ci CJ 65CP uj a— ro CJ -O CJ -o arf- a— v— C-JCD cp
uj u_
cp
ca uj ea ■cr* «r x0 <r co ro uj O- <f <3- ro a— cj ro o rx uo rx CO a-- G3CO CO uj -o OD CJ UJ c-J.r-a a— a— <1 uj uj r. «r a— CC- D- CO G a— o- uj CJu- uj cct r- r-x cj r- o- tsa ro tsa Cr- O- C-J CJ Ga CO co o- uj G C J «r uj CO a—o cp CO CO CO co co -o n cn o CO Cx Ga O Cr- CJ G: -C' «— Ga CJ -r «u- ro<x -o -o ro O- UJ a— O- O- CO a— <r UJ ro r-. <n- ro u". CO r. r- ro r > C-J -ox: ZD a a a a a a a a a a a a a a a a a a a ■ a a a a
ID C5 O- co en r j -o ea «T a— C-J a— rx r . -o ro e> CJ c- r- ■rf a— o- r-x rxCO CO c j •»— in uj ro co C-J -*3" a— rx a G? c-J c-J o- UJ a— ro
c-j ro
uj
cd cp cp cp cp cc CP CP CPCP SP CD CD CD uc o CD uj o CD CD <r cdID <r uj cp ZD CP uj cp <E CP x: CP <r CP cp t— J— CPcd uj cd cp cp <r cp uj <c dc 3 3 Cri 1—! <E CP »— »— CP r— r cp 13 13 CPCO s: <r uj i—! cd uj d d uj p p uj r— h- uj CP CP uj D D U cp cp uj
cj ro <r UJ -a r-. CO
280 -
Appendix 2:7 Analysis of variance of Card
Sorting data: movement time into eight categories
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Appendix 2:8 Analysis ef variance of Card
Sorting data: two category sorting times
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Appendix 2:9 Analysis of variance of Card
Sorting data: four category sorting times
i—» CO c-«* r»-. <r -O CO CJ r- -o -o c fO r- CO r s
—J r- ■*■0 CJ t*U 03 e* r-i CO •O CO r? •-O -r~~ CJ ir.< tS:
1 ro CO p-» bO <i" O -•0 1:0 ro <r C-J oo T~ C3 '—
»—! LO ro T— b? o- -i— -o a- bO CO ro CO r • <r ■>— o
4-r <r > • * ■ ■ ■ » • • • ■ ■ • • "
"


















ro uo cj o- -o CO r - co a— «tr -.0 MO «r - -o L'O C J uo «r Cv
ro te= uo tea o- Cr- ro uo uo -o C-J C-? uo <S3 to *— uo CO ro C3
C-J -o tCi ro CJ r-~ -c ,— MD tea T' *— O eu -o b- r. r-. CJ C-. CO 03
CO uo -a- o- tSi O o- uo tO «T «r<- -o -0 r-v U'. ro c- r. <r CJ CJ
uo -a ,— !*0 c- ,— tS5 CO CJ CJ O- CJ o C> -o uo Cw. •uD CO «£:■ tSi CJ t■■*
• a • ■ ■ ■ a a m ■ a • a a ■ ■ ■
" ■ ■ ■ "
ro eea tea -O -r— mo CJ ro tea «r o CJ ■^o -a* UO C J C:' r j C-J r? <3*
















C J CJ C:
t— f— C-J
, ro <3" -o «-o ro r- r- CO CO c- C-J CO c- CO uo uo tsa CO a— r*o «r r.
to r'3 ts* L'O tsa C- N ro r . uo o- -o uo CO tea a— a—- T <r tea o- tea tea a—
U_ UJ C-J -o UO Cr- CO CO C-J C-J T~ CJ C- CJ Cla 1— a— -o «r uo -C- tea ro t£i -o «?"
co DC CO uo esa CJ r--. ro Cr- CO ro CO r - CJ CJ C-J a— *T -o r- o- a*~ ft ro C-J
<E uo -o — tS3 ro CJ i— r- i— ro -o •— c- uo «"J" r- CJ uo CJ o-- C- r- o-
x~ a . a a a a a a a a a a a a • » •
* ■ • ■ " • ■
ro cr. ro te~ o- UO ro tea o- UO o uo <C Ca uo ro r- uo CO ro CO a— CO «r













to cn Cr: cn Cr: Cr: D: en en
en CD to CO CD CO UJ o CO CD <n o
7"! <r UJ cn a: UJ cn <Z a: 23 Ct <r Cr: <r en ►— r- Cr:
o UJ to Zcl ct: <c a: UJ •<r a~ en »—! c Cr: f— r— en Y— h— en
*
ZD —a- en




Analysis ef variance cf Card
eight category sorting times
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Appendix 2; 11 Analysis of Manual Dex"teiri"ty
data
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Please make a mark on the line to indicate how well or how badly you feel you slept
last night. A mark in the centre would mean an average, normal night, a mark to the
left a poor night, a mark to the right a better night.
Please make a mark on the line to show how bright, fresh and alert you feel this
morning.
A normal, average sort of feeling should mean a mark in the centre. If you feel
unusually bright and full of zest your mark should be to the left of centre, if unusually


















Please indicate, by a mark on the line, how calm or anxious you have felt mentally






Please indicate, by a mark on the line, how well you have felt able to concentrate









Appendix 4:1 (over). Census Returns used in Surveys 1 and 2
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Appendix 4:1
HYPNOTIC DRUG CENSUS RETURN FOR MIDNIGHT, TUESDAY, 31st MARCH, 1981
HOME:
This information is being collected by the Social Work Department for all
residents in its OPHs at the above date, to coincide with the SWSG collection
of data on resident handicap and infirmity. Please list residents in the
same order as the SWSG return.
Complete where hypnotic drug used
Line
No.
Date of Birth HYPNOTIC/SEDATIVE DRUG
Give name if such a drug

















































Appendix 4:2. Drug glossary used in hypnotic drug surveys (1980-81)
Hypnotic Drug Census
Trade names are given in the left hand column, pharmaceutical
names appear in brackets. This list is not exhaustive. If you
























































































A1) Digital event recorder for target A
B1) " " " " " B
C1) " " " " fascia
D) 6v power source
e) Hand-Held Stylus
Contact between the stylus (e) and either of the targets (A,B) is recorded
as a 'hit' on A1 and B1 respectively. Contact between the stylus and the
fascia is recorded as an 'error' on C1 .
Dimensions
Tapping Board (i.e. Fascia): 20.5cm x L5.5cm
Targets: from 1.5cm to 6cm in diameter
Distance between targets: 25cm centre to centre
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Appendix 5:2 (over)
Visual Analogue rating scales used in Experiment 2
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A mark in the centre of the line will scan 1 no ch-.njc1. if you have
trouble arriving at a conclusion, consult other Care Workers, and come to
a group decision.
1. Considering the time taken to get to sleep, the number of awakenings













3. Throughout the day has the resident been?
Extremely ( j Generally
bright if lethargic and
and alert drowsy













NAME OE RESIDENT. DATE.
COMMENTS (Continence, untypical events)
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Appendix 6:1 Visual Analogue rating
scales used in Experiment 3
^LACE A MARK ON THE LINE AT A POINT WHICH CORRESPONDS WITH YOUR ANSWER
A MARK IN THE CENTRE OF THE LINE MEANS "NO CHANGE"
LAST NIGHT, DID YOU SLEEP
Place a mark on the line at a point which corresponds with
your answer, A mark in the centre of the line means "no
change". If you have trouble arriving at a conclusion,
consult other Care Workers, and come to a group decision.
During the early part of the morning was the residents-














Appendix 6:2 (over) Typical page of prose used for the letter
cancellation task.
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"They were very cunning, though. They must have thought
that there was some chance of their being followed, for they
would never go out alone, and never after nightfall. During
two weeks I drove behind them every day, and never once saw
them separate. Drebber himself was drunk half the time, but
Stangerson was not to be caught napping. I watched them late
and early, but never saw the ghost of a chance; but I was not
discouraged, for something told me that the hour had almost
come. My only fear was that this thing in my chest might burst
a little too soon and leave my work undone.
"At last, one evening I was driving up and down Torquay
Terrace, as the street was called in which they boarded, when
I saw a cab drive up to their door. Presently some luggage was
brought out and after a time Drebber and Stangerson followed
it, and drove off. I whipped up my horse and kept within sight
of them, feeling very ill at ease, for I feared that they were going
to shift their quarters. At Euston Station they got out, and I left
a boy to hold my horse and followed them on to the platform. I
heard them ask for the Liverpool train, and the guard answer
that one had just gone, and there would not be another for some
hours. Stangerson seemed to be put out at that, but Drebber
was rather pleased than otherwise. I got so close to them in the
bustle that I could hear every word that passed between them.
Drebber said that he had a little business of his own to do, and
that if the other would wait for him he would soon rejoin him.
His companion remonstrated with him, and reminded him that
they had resolved to stick together. Drebber answered that the
matter was a delicate one, and that he must go alone. I could
not catch what Stangerson said to that, but the other burst out
swearing, and reminded him that he was nothing more than his
paid servant, and that he must not presume to dictate to him.
On that the secretary gave it up as a bad job, and simply
bargained with him that if he missed the last train he should
rejoin him at Halliday's Private Hotel; to which Drebber
answered that he would be back on the platform before eleven,
and made his way out of the station.
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